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Abstract 
Rho GTPases play a key role in regulating the migration of many cell types including 
astrocytes. Astrocytcs are relatively poor migrating cells, whereas, gliomas, can be highly 
invasive, infiltrating the surrounding tissue and spreading difftisely in the brain due, in 
part, to their highly motile behaviour. This thesis investigates the aberrant migration of 
three human glioma cell lines (U373, U138, U87) and, using microinjection techniques, it 
is shown that the small GTPase Rac is essential for the migration of astrocytes as well as 
for the three glioma cell lines. In agreement with a higher rate of migration, it was 
demonstrated that the level of active Rac (Rac-GTP) is higher in U373 than in astrocytes. 
Surprisingly, however, the levels of Rac-GTP in the more motile cell lines, U138 and 
U87, are much lower than U373 cells. 
Rac activity in cells can be stimulated through increases in the levels of PI(3,4,5)P3 
generated by the enzyme PI 3- kinase. PI(3,4,5)P3 levels are negatively controlled by the 
dual specificity phosphatase PTEN, which dephosphorylates PI(3,4,5)P3- In in vitro 
assays, PTEN has also been shown to have protein phosphatase activity. All three glioma 
cell lines lack PTEN. This work demonstrates that re-expression of wtPTEN inhibits the 
migration of all three glioma cell lines, without affecting the migration of astrocytes. 
Moreover, data is presented showing that the protein, not the lipid, phosphatase activity 
of PTEN, is essential for inhibiting migration. Most unexpectedly, however, additional 
mutagenesis studies reveal that it is the C2 domain of PTEN that mediates the inhibitory 
effect on the migration of these tumour cell lines, and that in the full-length protein, the 
phosphorylation of residue Tbr383 controls the anti-migratory activity of the C2 domain. 
Finally, using the carboxy terminus of PTEN as bait to screen a brain yeast two-hybrid 
library, new potential binding partners of PTEN are identified. 
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Chapter 1 
Introduction 
1.1 Summary 
Tumour cells possess a plethora of mechanisms to escape from their site of origin and 
invade normal neighbouring tissue or metastasize to distant organs. This property of 
turnour cells is the major cause of the ineffectiveness of the current treatment therapies. 
Cancers of the central nervous system (CNS) in particular, are considered to be some of 
the most invasive tumours, and although they lack the ability to use the lymphatic system 
to metastasize to sites outside the CNS, they acquire properties that allow them to 
infiltrate normal brain tissue very effectively (Le et al., 2003). The most common brain 
tumours originate from glial cells and are termed gliomas. Glial cells are subdivided into 
microglia (cells that function as circulating leukocytes of the brain) and into macroglia. 
Macroglia cells include astrocytes, oligodendrocytes and ependymal cells. Gliomas can 
arise from all glial cell types, but the most common and aggressive are thought to derive 
from astrocytes (Kleihues et al., 1995). 
Tumour cells, regardless of their tissue of origin, share a variety of signal transduction 
pathways and biochemical properties that enable them to migrate and disseminate within 
or across tissues and organs. Migrating cells need to break the extracellular matrix, which 
provides the first physical barrier for the advancing cell. Gliomas possess a unique set of 
proteolytic enzymes that makes them particularly successful in spreading diffusely in the 
CNS. In addition, unlike other cancers, gliomas exhibit a mesenchymal type movement, 
which enables them to infiltrate the brain with greater ease (Friedl and Wolf, 2003). For a 
14 
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cell to migrate, it needs to elongate a protrusion (spread) towards the direction of 
movement, form new adhesion sites with the substratum at the front, contract the cell 
body, and move the rear by dissolving the extracellular -matrix adhesions at the back. 
Signaling cascades are activated to coordinate cell spreading and migration, most notably, 
pathways that regulate actin cytoskeleton remodeling. At the centre of the actin 
rearrangement lies the Rho family of small GTPases that regulate many cellular processes 
involved in cell movement (Ridley, 200 1 a). 
Rho GTPases are tightly regulated and can be activated by a variety of upstream 
signals, including growth factors binding to tyrosine kinase receptors, agonists binding to 
seven-pass membrane receptors, or integrin-matrix interactions. Although there is little 
evidence to implicate Rho GTPase dysregulation directly with cellular transformation, 
aberrant upstream signaling to Rho GTPases may play an important role in human cancer 
formation, particularly with respect to cell invasion and metastasis (Jaffe and Hall, 2002; 
Malliri and Collard, 2003). Gliomas, for example, upregulate EGF and PDGF tyrosine 
kinase receptor signaling, which can lead to Rac activation (Ridley et al., Cell 1992, 
Nobes et al., Cell 1995). Phosphatidylinositol 3-kinase (PI 3-kinase) is also regulated 
downstream of receptor tyrosine kinases and the PI 3-kinase signaling pathway is 
frequently a target in tumors, as it confers a cell growth and proliferative advantage. 
PTEN, the primary antagonist to PI 3-kinase signaling, is mutated in many primary 
human cancers, including gliomas. It plays a role in the insulin signaling pathway and has 
been shown to regulate cell growth, apoptosis, migration and invasion (Knobbe et al., 
2002). PTEN inactivation lies therefore at the heart of human tumour formation. 
This thesis addresses the aberrant signaling pathways of glioma cells that affect cell 
migration, with particular emphasis on the roles played by the Rho family of GTPases 
and PTEN. 
1.2 Gliomas 
1.2.1 Classification and general characteristics 
Gliomas, and in particular astrocytomas, are the most common primary glial-derived 
brain tumours in humans. They rarely metastasize outside the CNS and are therefore 
defined by their clinical grade classification. Grade I tumours are biologically benign, 
cystic astrocytomas, grade JI tumours are low-malignancy tumours, histologically 
15 
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characterised by nuclear atypia and cellular pleomorphism. Grade III tumours are known 
as anaplastic astrocytomas and exhibit a high mitotic rate. Finally, grade IV tumours are 
highly malignant and are referred to as glioblastoma multiforme (GBM). GBMs have a 
high proliferation rate and are accompanied by increased angiogenesis and tissue necrosis 
(Figure 1.1) (Maher et al., 2001; Rao, 2003). Malignant gliomas are highly invasive and 
are termed diffuse gliomas because of their property to infiltrate normal brain tissue and 
quickly spread in the CNS. This makes them incurable by surgery and glioblastomas are 
invariably fatal. 
FIGURE 1.1 
Two examples of GBMs with different clinical history. Reproduced from Maher et al., 2001. 
(A) Grade 11 astrocytoma from a young woman whose tumour progressed to GBM 5 years 
after diagnosis. Arrows indicate neoplastic astrocytes with hyperchromatic nuclei. (B) GBM 
from an older man with a short clinical history. N: necrosis, P: palisading nuclei, MVP: 
microvasculature proliferation. 
The heterogeneity of glioblastoma morphology makes it difficult to trace the cell of 
origin. They are grossly subdivided according to their histological characteristics into 
astrocytomas, oligodendrogliomas and oligoastrocytomas (Dai and Holland, 2003). Most 
GBMs, however, display astrocytic differentiation markers, e. g. glial fibrillary acid 
16 
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protein (GFAP) and astrocytes are therefore regarded as the most common cell of origin. 
Astrocytes perform a variety of functions in the CNS, including the regulation of 
neuronal homeostasis, growth and survival, guidance of neuronal axonal migration and 
formation of synapses. They are also involved in immune responses and in repair of tissue 
after injury, in a process known as gliogenesis. Some astrocyte precursor cells retain the 
ability to proliferate well after CNS development, a property that may make them more 
prone to transformation compared to other cells of the CNS (Wechsler-Reya and Scott, 
2001). 
Astrocytes are produced from multipotent neural stem cells (NCSs) that have the 
capacity to self renew and generate neurons, astrocytes and oligodendrocytes. As 
differentiation progresses along the cell lineages, more restrictive precursor cells are 
generated. First, NCSs produce neural precursor cells that only give rise to neurons, and 
glial precursor cells that can only give rise to astrocytes and oligodendrocytes (Rao and 
Mayer-Proschel, 1997; Rao et al., 1998). Glial-precursor cells then generate astrocyte or 
oligodendrocyte progenitor cells that produce astrocytes or oligodendrocytes respectively. 
The proliferation and differentiation of these progenitor cells are tightly controlled by 
extracellular stimuli. Astrocyte differentiation, for example, is promoted by EGF (Bachoo 
et al., 2002) and EGF receptor (EGFR) knockout mice exhibit a delay in astrocyte 
differentiation and have a fewer number of astrocytes in several parts of the brain 
(Komblurn et al., 1998). Other astrocyte differentiation factors include the cytokines of 
the ciliary neurotrophic factor (CNTF) and leukemia inhibitory factor (LIF) that use the 
Jak/Stat signaling pathway, and bone morphogenetic proteins (BMPs) that can promote 
astrocyte differentiation on their own or in combination with LIF (Wechsler-Reya and 
Scott, 2001). 
Gliomagenesis is a process likely to involve a combination of events leading to the 
formation of the highly malignant phenotype of GBM. A popular hypothesis is that 
genetic mutations cause mature astrocytes or oligodendrocytes to dedifferentiate to an 
earlier glial cell type, for example a precursor cell, and thus acquire all the migratory and 
proliferative properties that this cell possessed during CNS development (Maher et al., 
2001). The acquisition of further mutations either in a progenitor cell or in a cell that has 
undergone dediferrentiation in signal transduction pathways that control growth, 
proliferation and apoptosis, would then result in the formation of increasingly aggressive 
tumours with a high invasive capacity (Zhou et al., 2003). 
17 
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1.2.2 Glioma mutations in signaling pathways 
Gliomas arise either de novo (primary) or as low-grade tumours that progress to a 
more malignant phenotype (secondary). It is thought that they develop along different 
genetic pathways and are thus clinically distinct. Gliomas exhibit losses of parts of 
chromosomes or amplification of genes and most of the genetic mutations identified 
target either cell cycle arrest and apoptotic pathways or signal transduction cascades 
downstream of receptor tyrosine kinases. 
1.2.2.1 Cell cycle dysregulation 
Alterations in genes encoding Rb, cyclins, CDKs or CDK inhibitors (CKIs) are 
frequent in gliomas. The transition of low-grade to intermediate-grade in gliomas is 
usually characterised by an increase in proliferation rate and is accompanied by losses of 
parts of chromosomes 9 and 13 that encode for key components of the Rb signaling 
pathway. Mutations in Rb have been described in about 25% of malignant astrocytomas. 
Mutations have also been described in the cyclin-dependent Icinases CDK4 and CDK6. It 
has been reported that the CDK4 gene is amplified 10- to 100-fold in 15% of 
glioblastornas and overexpression of CDK4 in cultured astrocytes results in 
immortalization (Holland et al., 1998). The most common mutation that disrupts the cell 
cycle pathway in gliomas is in the M4A-ARF gene, which encodes for the proteins 
pI 6'NK4' and p 14 ARF (or pl9ARF in mice) (Arap et al., 1997). CKIs prevent the binding of 
D-type cyclins to CDK4/6 and displace the inhibitor p27KIP', which in turn inhibits CDK2 
(Figure 1.2). This prevents CDK2-dependent hyperphosphorylation of Rb and subsequent 
progression into S phase. Loss of pI 6'NK4" promotes the activation of CDK4/6 and results 
in the phosphorylation of Rb and entry into S phase. Mutation of p16 INK4' occurs in 
around 60% of high-grade gliomas (Maher et al., 200 1). 
18 
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FicURE 1.2 
Cell cycle components mutated in gliomas. Proteins involved in the regulation of GI to S 
phase transition are depicted. INK4 family CKIs inhibit cyclinD/CDK4/6 complexes, whereas 
Cip/Kip CKIs act on both CyclinD/CDK4/6 and Cyclin E/CDK2 complexes. This prevents 
phosphorylation of Rb and subsequent release of E2F and entry into S phase. pl4/pl9ARF 
negatively regulates the p53 inhibitor MDM2, and promotes apoptosis. A red asterisk 
indicates the proteins frequently mutated in gliomas. 
The p 14/p I 9ARF gene is a tumour suppressor that acts on the MDM2-p53 signaling 
pathway. Expression ofplqARF inhibits the growth of human gliomas in culture (Arap et 
al., 1997) probably by binding directly to MDM-2 and inhibiting the degradation of p53 
(Figure 1.3). It also promotes p53-dependent apoptosis and induces GI cell cycle arrest. 
The p53 gene is another common target of inactivating mutations in human gliomas 
(Evans et al., 2003; Fei and El-Deiry, 2003). It is primarily an early event in 
gliomagenesis and mutations mostly affect residues required for DNA binding. It has 
been reported that around 25% of glioblastomas have inactivating mutations or deletions 
in the p53 gene and around 5%-12% have amplification of the gene that encodes the p53 
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regulator MDM-2. MDM-2 promotes the proteosomal degradation of p53 by directly 
binding to p53 and acting as an E3 ubiquitin ligase (Kubbutat et al., 1997; Lohrum. et al., 
2000). 
1.2.2.2 Growth factor upregulation 
Growth factors and their receptors play an important role in glial development and are 
often targets in gliomagenesis. Amplification of the EGFR occurs in 40-50% of 
glioblastomas resulting in abnormally elevated levels of EGFF' and is an event more 
frequently associated with high-grade glioblastomas (Fenstermaker and CiesielsId, 2000). 
Studies in mice suggest a critical role for EGFR during CNS development and although 
EGFR has been shown to be involved in astrocyte differentiation, it also appears to be 
necessary for sustained proliferation of the neural stem cell pool (Maher et al., 2001). 
Several EGFR ligands, including EGF and TGF-(x, have been shown to promote 
proliferation of astrocytes in culture and growth of astrocyte precursor cells (Wechsler- 
Reya and Scott, 200 1). 
There is evidence to suggest that glioblastomas express EGF and TGF-a together with 
EGFR and thus growth of these turnours can be sustained through both paracrine and 
autocrine stimulatory loops of the EGFR (Figure 1.3). Another consequence of receptor 
amplification (which occurs in 40-60% of GBMs) is that often this results in the 
expression of mutated forms of the receptor. Approximately 60% of glioblastomas 
express truncated EGFF, which lacks part of the extracellular domain and can no longer 
bind ligand, but is constitutively tyrosine phosphorylated and is thus always active 
(Ekstrand et al., 1994; Nagane et al., 2001; Nishikawa et al., 1994). The constitutively 
active EGFR is not efficiently downregulated, unlike the wild-type form, and introduction 
of the truncated active EGFR into glioma cells, dramatically enhances their 
turnourigenicity (Ciesielski and Fenstermaker, 2000), proliferative capacity and resistance 
to apoptosis (Nagane et al., 1996). In addition, mice expressing the viral oncogene 
derived from the EGFR, v-erbB, have been shown to develop oligodendrogliornas (Weiss 
et al., 2003). 
A second growth factor suggested to be involved in an autocrine stimulatory loop with 
its receptor is PDGF (Figure 1.3). Increased expression levels of both PDGF and PDGFR 
have been reported in low-grade astrocytomas, and turnours that express both ligand and 
receptor have also been identified (Lokker et al., 2002). Transgenic mice expressing 
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PDGF in neural progenitors and astrocytes developed oligodendrogliomas and 
oligoastrocytomas respectively (Dai et al., 2001). In addition, the pattern of PDGF 
expression closely correlates with p53 mutations in low-grade tumours, suggesting a 
possible genetic interaction (Hen-nanson et al., 1996). 
+vefeedback 
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FIGURE 1.3 
Growth factor receptor upregulation in gliomas. A few of the signaling pathways downstream 
of EGFR and PDGFR are depicted. EGFR amplification results in EGF upregulation and the 
subsequent autocrine and paracrine loop of receptor activation (similarly for PDGF/PDGFR). 
A truncated EGFR (denoted by a red cross) is constitutively active. The Ras/MAPK and PI 3- 
kinase/PKB are two of the many pathways activated downstream of the PDGF and EGF 
receptors. PKC and MYC are also targets of the tyrosine kinase receptor signaling. 
Constitutive activation or amplification of EGF/EGFR and PDGF/PDGFR leads to the 
activation of downstream signaling pathways including the P13-kinase/Akt pathway, the 
RAS/MAPK pathway, the protein kinase C pathway and the C-MYC pathway (Figure 
1.3). Consistent with this, elevated levels of Ras and Akt have been reported in human 
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gliomas. Studies with transgenic mice showed that expression of active Ras or v-Src in 
astrocytes induced the formation of glioblastomas and astrocytomas respectively. Mice 
with germline genetic mutations, however, resulting in active Ras and Src, develop 
normally and any gliomas formed are due to secondary mutations (Guha et al., 1997). In 
addition, although the combined activation of Ras and Akt signaling pathways have been 
reported to induce glioblastomas, no activating mutations in either protein have been 
identified in human gliomas (Dai and Holland, 2001). It is likely that the abnormal 
activation of the receptor tyrosine kinase receptors EGFP, PDGFR and FGF results in the 
simultaneous activation of several downstream pathways that together lead to the 
formation of glioblastomas or increase the tumourigenicity of low-grade tumours. 
1.2.2.3 Mutations on chromosome 10q 
A large number of gliomas (75-90%) have part of the long arm of chromosome 10 
missing. This region is also often deleted in other tumours, including breast, prostate and 
endometrial carcinoma. PTEN was identified as one of the tumour suppressor genes 
frequently lost or inactivated in this region. Approximately 40% of high-grade gliomas 
exhibit PTEN mutations and PTEN inactivation occurs in both primary and secondary 
gliomas, suggesting that it may be interacting with the Rb or EGFR pathways. The 
induction of tumour growth by the combined activation of active Ras and Akt can be 
blocked by overexpression of PTEN (Cheney et al., 1998; Furnari et al., 1997). PTEN 
induces growth suppression by causing a GI cell-cycle block in these glioblastomas 
(discussed in detail later) (Myers et al., 1998). 
Another important turnour suppressor candidate in this region is the antagonist of the 
MYC oncoprotein, Mxil (Max interactor 1) (Meroni et al., 2000). Mxil is a cell growth 
regulator and is mutated in prostate carcinomas and in 15% of high-grade glioblastomas. 
Re-introduction of Mxil in glioblastoma cells inhibits proliferation and induces cell cycle 
arrest at the G2 to M phase transition (Manni et al., 2002). Mice lacking Mxil develop 
prostatic tumours but do not develop any gliomas, suggesting that Mxil is not an 
important target in gliomagenesis. DMBT1 (deleted in malignant brain tumours) is 
another gene frequently mutated on chromosome 10q and is deleted in 50-80% of 
glioblastomas and anaplastic astrocytomas. DMBTI is an extracellular matrix protein that 
belongs to the scavenger-receptor cysteine-rich superfamily with a role in epithelial cell 
differentiation and in immune responses and polarity. Its function in the CNS, however, is 
unknown. 
22 
1. INTRODUCTION 
1.2.3 Turnour invasion 
1.2.3.1 Migratory phenotype 
The migratory behaviour of gliomas and their ability to invade normal tissue and 
spread diffusely is a key component of their malignant phenotype. Invasion is a property 
of both low-grade astrocytomas and high-grade glioblastomas and resembles the 
migratory phenotype of glial cells during CNS development. It is possible that glioma 
invasion follows the same mechanisms of early glial migration during embryogenesis 
through the reactivation of the same signaling pathways. In the adult, neurons, 
oligodendrocytes and astrocytes do not migrate. However, it has been shown that in 
response to injury, nestin-positive cells, most probably neural stem cells and glial 
progenitors, migrate to the site of injury and there undergo terminal differentiation into 
astrocytes. It is not clear whether these pathways can be disrupted during tumourigenesis, 
but they provide a likely source for malignant transformation. It was demonstrated that 
neural stem cells and glioma cells co-cluster following in vivo injection, suggesting that 
they might use the same routes when migrating in the CNS (Johansson et al., 1999; 
Magavi et al., 2000). Migration and invasion of gliomas is very different to other tumours 
that do not spread locally to the extent that gliomas do, but rather use the lymphatic 
system and the blood vessels to metastasize to distant sites. Gliomas lack the ability to 
cross the blood brain barrier, but rather have acquired properties that enable them to 
spread in the surrounding normal tissue (Rao, 2003). 
Tumour cells infiltrate neighbouring tissue in diverse patterns that usually reflect their 
differentiation stage (Figure 1.4). They can migrate as individual cells or as clusters, 
strands or sheets, known as 'collective migration'. Collective cell invasion is 
predominantly a feature of highly differentiated tumours such as prostate and large-cell 
lung carcinomas. Cells either protrude as sheets that still remain in contact with the 
primary site and disseminate only locally, or clusters of cells detach from their site of 
origin and enter tissue gaps or metastasize via the lymphatic system. Single cell migration 
can be subdivided into mesenchymal, amoeboid and fon-nation of cell chains. Myoblasts 
and melanomas move in a chain-like manner, still maintaining cell-cell contacts and 
forming junctions at the tip of the cell (Friedl and Wolf, 2003). Amoeboid migration is 
characteristic of the amoeba, Diclyostelium discoideum. In higher eukaryotes, this type of 
movement is retained by leukocytes and some tumour cells, such as lymphoma and 
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myeloid leukemia cells (Farina et al., 1998). Leukocytes and Dictyosteliufn use a type of 
movement that is generated by cortical filamentous actin and is based on short-lived 
interactions with the substratum. Small-cell lung and prostate carcinomas use this type of 
movement to undergo early detachment and spread from a small primary tumour. 
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FIGURE 1.4 
The different types of tumour cell migration. Individual cells display either an amoeboid type 
of migration (Dictyostelium, leukemia or lymphoma cells) or a mesenchymal migration 
(gliomas, fibrosarcomas). Collective migration is subdivided into chain-like movement 
(melanoma cells, epithelial tumours) and migration as sheets (epithelia] tumours, vascular 
tumours). 
Gliomas show an elongated, spindle-like morphology and exhibit a mesenchymal -type 
movement that is dependent on integrin attachments to the substratum to produce the high 
traction forces necessary to propel the cell forward. Mesenchymal migration is slower 
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than amoeboid migration and one of the reasons is that focal adhesion turnover is 
relatively slow (Webb et al., 2002). 
1.2.3.2 Factors promoting invasion 
The extracellular matrix is the main component being destroyed in a tissue during 
tumour cell invasion and differs for each cell type within an organ. Tumour cells of the 
CNS possess a unique set of proteolytic enzymes that enables them to infiltrate normal 
brain tissue (Lakka et al., 2003). Anaplastic astrocytomas and glioblastoma cells express 
higher levels of the receptor for the serine protease urokinase-type plasminogen activator 
(uPA), uPAR, than do normal cells or low-grade gliomas (Yamamoto et al., 1994). 
Transfection of low-grade gliomas with uPAR was shown to increase their invasive 
capacity in a matrigel assay, compared to parental cells, in a uPA-dependent manner 
(Mohanam et al., 2002; Mohanam. et al., 1998; Mohanarn et al., 1999). Furthermore, 
studies with antisense-uPA, showed that the increased cell motility conferred by 
uPA/uPAR signaling is dependent on the PI 3-kinase/Akt pathway (Chandrasekar et al., 
2003). In glioblastoma cells, uPAR colocalises at focal contacts with the (xvP3 integrin, 
and downregulation of uPAR increases the expression of a3PI integrin, induces changes 
in cell morphology and disorganization of the cytoskeleton (Gladson et al., 1995; Rao, 
2003). Studies in nude mice demonstrated that stably transfected glioblastoma cells with 
antisense uPAR undergo apoptosis when injected in the mouse brain (Adachi et al., 2002; 
Mohanarn et al., 2001). The observed cell death correlates with an increase in BAX, 
release of cytochrome c and activation of caspase-9. 
A second key factor in glioma invasiveness is the production of MMPs(Le et al., 
2003). MMPs are a family of secretory-independent endopeptidases with proteolytic 
activity against ECM components. Expression of MMPs is regulated by a variety of 
factors including growth factors, cytokines, cell-matrix and cell-cell interactions. MMPs 
are kept in inactive state by their specific tissue inhibitors (TIMPs) (Nuttall et al., 2003). 
In addition to degrading the ECM, which also leads to the release of matrix-bound growth 
factors, they activate signal transduction pathways that promote migration and 
proliferation. Human glioma cells express MMP-2 and MMP-9 and the expression levels 
of these MMPs closely correlate with tumour progression (Hu et al., 2003; Lakka et al., 
2003; Wang et al., 2003). In gliomas, the PI 3-kinase signaling pathway is often 
constitutively activated due to the loss of the PI 3-kinase antagonist PTEN or due to 
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EGFR overexpression. EGFR signaling was shown to induce MMP-9 activation, an effect 
dependent on PI 3-kinase, and hyaluronic acid-mediated secretion of MMP-9 and 
subsequent activation of the MAPK pathway in human gliomas, was inhibited by re- 
introduction of PTEN (Choe et al., 2002; Park et al., 2002). 
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FIGURE 1.5 
The uPA/uPAR and MMP pathways. Pro-uPA bound to its receptor is cleaved more 
efficiently by plasmin to produce uPA. uPA, in turn, cleaves plasminogen into plasmin in a 
positive feedback loop. The tail of uPAR can activate transcription via the Jak/Stat pathway. 
uPAR colocalises with integrins at focal contacts and is involved in the activation of several 
pathways downstream of integrins, like the Ras/MAPK pathway. MMPs are released as 
inactive pro-MMPs and are cleaved into active MMPs by a variety of components, including 
growth factors and plasmin. ECM: extracellular matrix. 
A multitude of environmental factors promote, regulate and direct tumour cell 
migration and consequently tumour invasion. In addition to MMPs and other proteases 
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that facilitate movement within the tissue, growth factors, such as EGF, PDGF and IGF I 
also promote cell migration and invasion through the activation of several signal 
transduction pathways (Lakka et al., 2002)). EGF induces migration and process 
extension of both normal astrocytes and astrocytic turnour cells, whereas IGF-1 promotes 
chernotaxis of breast cancer cells in an integrin-dependent mechanism (Hu et al., 2003; 
Wang et al., 2003). PDGF, on the other hand, has been shown to be important in low- 
grade glioma migration through activation of PI 3-kinase and PLC-y pathways. A 
common mediator of growth factor and integrin stimulated migration and tumour cell 
invasion is the family of Rho GT? ases. Gliomas and tumour cells in general, display 
many common features of normal migrating cells, when migrating during development. 
To gain a better insight in the mechanisms of glioma invasion, it is important, therefore, 
to examine cell migration more closely. 
1.3 Cell migration and Rho GTPases 
Cell migration is an essential process in all multi-cellular organisms and is important 
not only during development, but also throughout life for responses such as wound repair 
and angiogenesis and during immune surveillance. In the animal, cell migration is 
directed by extra-cellular cues acting either as attractants or repellants. These may be 
soluble factors that can act at a distance, or local signals received from neighboring cells 
or extra-cellular matrix. They elicit a large variety of intracellular responses that include 
changes in the organization of the actin and microtubule cytoskeletons, vesicular 
transport pathways and gene transcription (Figure 1.6). 
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FIGURE 1.6 
Regulation of cell migration. The main pathways that regulate cell migration are shown. 
These include PKCs, PLC, PI 3-kinase, MAPK and Rho GTPases. 
The process of cell migration has been extensively studied in tissue culture, where the 
environment can be controlled and easily manipulated. However, the genetic analysis of 
whole organisms is making sigmificant and novel contributions (Lehmann, 2001). It Is 
now widely accepted that the central mechanism driving cell migration is the extension of 
a leading edge protrusion or lamellipodium, the establishment of new adhesion sites at the 
front, cell body contraction, and detachment of adhesions at the cell rear (Figure 1.7). All 
these steps involve the assembly, the disassembly or the reorganization of the actin 
cytoskeleton and each must be coordinated both in space and time to generate productive, 
net forward movement. 
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FIGURE 1.7 
Schematic representation of the key steps of cell migration (seen from the top and the side). A 
migrating cell polarises in the direction of movement in a Cdc42 dependent manner and 
polymerises actin to form filopodia and Rac-depenclent lamellipodia. The cell also spreads 
and makes new adhesions with the substratum (focal contacts). Finally, it contracts in a Rho- 
dependent way, and the tail retracts following the dissolution of the adhesions at the rear. 
Multiple intracellular signaling molecules have been implicated in cell migration, 
MAPK cascades, lipid kinases, phospholipases, Ser/Thr kinases (such as protein kinase 
Cs [PKC] and p65PAK) and tyrosine kinases (such as AbI and Src). However, one 
particular family of proteins seems to play a pivotal role in regulating the biochemical 
pathways most relevant to cell migration; Rho GTPases (Figure 1.7) (Ridley, 2001 a). 
1.3.1 The Rho GTPase cycle 
Rho GTPases are ubiquitously expressed and approximately 20 members have been 
identified in mammals, seven in Drosophila melanogaster, five in Caenorhabditis 
elegans and 15 in Dictyostelium discoideum (Schultz et aL, 1998). They act as molecular 
switches to control signal transduction pathways by cycling between a GDP-bound, 
inactive forin and a GTP-bound, active form (Figure 1.8). The RhoGTPases cycle is 
tightly regulated by three groups of proteins. Guanine nucleotide exchange factors 
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(GEFs), promote the exchange of GDP for GTP to activate the GTPase, GTPase- 
activating proteins (GAPs) negatively regulate the switch by enhancing the intrinsic 
GTPase activity and guanine nucleotide dissociation inhibitors (GDls) are thought to 
block the GTPase cycle by sequestering and solubilizing the GDP-bound form (Schmidt 
and Hall, 2002). 
I Upstream 
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FIGURE 1.8 
The Rho GTPase cycle. Rho GTPascs cycle between an inactive GDP-bound form and an 
active GTP-bound form. The cycle is tightly regulated mainly by guanine nucleotide 
exchange factors (GEFs), GTPase activating proteins (GAPs) and guanine nucleotide 
dissociation inhibitors (GDIs). In their active form, Rho GTPases can bind to effector 
molecules and mediate their effect, for example, on the actin cytoskelton. 
In their GTP-bound state, the Rho GTPases interact with a variety of downstream 
targets (effectors), to elicit a variety of intracellular responses. The signaling specificity is 
thought to be established through the binding of scaffold proteins (Buchsbaum et al., 
2002; Buchsbaum et al., 2003). The best-characterised function of Rho GTPases is in the 
regulation of actin dynamics. Tissue culture studies (carried out originally in fibroblasts, 
GEF 
Pi 
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but later in many other cell types) using constitutively active and dominant negative, 
interfering forms, have shown that Rho regulates the assembly of contractile, 
actin: myosin filaments, while Rae and Cdc42 regulate the polymerisation of actin to form 
peripheral lamellipodial and filopodial protrusions, respectively (Hall, 1998). In addition, 
all three GTPases promote the assembly of integrin-based, matrix adhesion complexes 
(Nobes and Hall, 1995; Ridley and Hall, 1992). It is perhaps not surprising, therefore, that 
these three regulatory proteins play such an important part in controlling cell migration. 
Furthermore, and in addition to their effects on actin, Rho, Rac and Cdc42 can influence a 
wide range of other biochemical activities. Most notably, Cdc42 is required for the 
establishment of cell polarity in all eukaryotic cells, including yeast, while all three can, 
in distinct ways, affect the microtubule cytoskeleton and gene transcription (Van Aelst 
and D'Souza-Schorey, 1997). 
1.3.2 Rho GTPase signaling to the actin cytoskeleton 
1.3.2.1 Rac and Cdc42 
Rac and Cdc42 are both required at the front of migrating cells. Rac is required to 
generate protrusive force at the front, while Cdc42 is required to recognize external 
directional cues and polarise protrusive activity accordingly. Cdc42 also induces 
filopodia. Their role is not entirely clear, but they have been suggested to probe the 
extracellular milieu. The cellular targets of Rac and Cdc42 that promote changes to the 
actin cytoskeleton have been the subject of intense investigation. The Ser/Ibr kinase 
p65PAK is commonly activated upon either Rac or Cdc42 activation and is believed to 
play an important r6le in regulating actin dynamics during cell adhesion and migration. 
p65PAK regulates focal adhesion turnover with the help of PIX and GIT1 (GRK 
interactor 1) but how it does so is not known (Manabe Ri et al., 2002; Obermeier et al., 
1998). In addition, p65PAK1 phosphorylates and activates LIM kinase (LIMK), which in 
turn phosphorylates and inactivates cofilin (Figure 1.9) (Arber et al., 1998; Edwards et 
al., 1999). Cofilin, which facilitates depolymerisation at the pointed end of actin 
filaments, cycles between an active and inactive form, and this is essential for promoting 
filament treadmilling at the front of migrating cells (Bamburg, 1999). 
Members of the WASp/SCARIWAVE family of scaffold proteins are key regulators 
of actin polymerisation and WASp interacts directly with the GTP-bound form of Cdc42 
(Takenawa and Miki, 2001). In their activated state, the WASp/SCARAVAVE proteins 
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are able to activate the Arp2/3 complex, which can initiate actin polymerisation, either de 
novo or at the tips or sides of pre-exisiting filaments. In this way the dendritic 
morphology of lamellipodial actin is thought to be generated (Amann and Pollard, 2001; 
Weaver et al., 2003). WASp/WAVE can also bind to profilin, which acts synergistically 
with Arp2/3 to speed-up actin polymerisation (Blanchoin et al., 2000; Yang et al., 2000). 
Rac and Cdc42 are thought to activate members of this family directly (Eden et al., 2002; 
Rohatgi et al., 2000), although activation could also be indirect through the Rac and 
Cdc42 effector IRSp53 (Figure 1.9) (Krugmann et al., 2001; Miki and Takenawa, 2002; 
Miki et al., 2000). 
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Schematic representation of some of the main components that mediate the effects of Rho 
GTPases on the actin cytoskeleton. Rae and Cdc42 both induce actin polymerisation through 
the activation of IRSp53 and WASp/WAVE/Scar family members that subsequently activate 
Arp2/3 to initiate actin nucleation. Alternatively, they bind and activate the kinase p65PAK 
that inhibits cofilin downstream of LIMK. Rho, on the other hand, activates IRSp53 through 
its effector mDia. Rho also leads to actin: myosin crosslinking by inhibiting myosin light chain 
(MLC) phosphatase through pl60ROCK. There is substantial cross-talk between the GTPases 
in order to coordinate the responses on the actin cytoskeleton. 
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13.2.2 Rho 
Rho activity in migrating cells is associated with focal adhesion assembly and cell 
contractility. One important Rho target involved in stimulating actin: myosin filament 
assembly and therefore contractility is the SerfFhr kinase p160ROCK. In migrating 
leukocytes, for example, Rho and p160ROCK are required for proper rear cell 
detachment (Alblas et al., 2001). ROCK plays an essential role during migration of P 
cells in the larval development of C. elegans and during dorsal closure and gastrulation in 
Drosophila (Barrett et al., 1997; Magie et al., 1999; Spencer et al., 2001). In its active 
state, p160ROCK, like p65PAK, can phosphorylate and activate LIMK, which in turn 
phosphorylates and inactivates cofilin leading to stabilization of actin filaments within the 
actin: myosin filament bundles (Maekawa et al., 1999; Sumi et al., 2001). p160ROCK 
interacts with and phosphorylates the myosin binding subunit (MBS) of myosin light 
chain phosphatase and thereby inactivates it (Kawano et al., 1999). This leads to 
increased levels of myosin phosphorylation which then can cross-link actin filaments and 
generate contractile force. At the rear of a migrating cell, this can promote movement of 
the cell body and detachment of the cell rear (Mitchison and Cramer, 1996). Clearly, 
however, this activity is incompatible with membrane protrusion and hence mechanisms 
must be in play to inhibit this activity at the leading edge. One way this might occur is 
through the Rac/p65PAK pathway - p65PAK can phosphorylate and inactivate myosin 
light chain kinase (MLCK), leading to decreased levels of myosin phosphorylation 
(Kaback et al., 1984; Mosses et al., 1999). Conflicting results have shown that p65PAK 
can phosphorylate and activate MLC thus enhancing cell contractility (Sells et al., 1999). 
Another important downstream target of Rho is mDia, the mammalian orthologue of 
Drosophild Diaphanous (Geneste et al., 2002). mDia belongs to the formin-homology 
containing family of proteins, which have been linked to actin filament assembly in both 
Drosophild and yeast (Castrillon and Wasserman, 1994; Pruyne et al., 2002; Sagot et al., 
2002). The binding of RhoGTP to mDia opens up and activates this scaffold protein. It 
cooperates with p160ROCK in the assembly of actin: myosin filaments, but its 
biocheincial contribution is unclear (Uehata et al., 1997; Watanabe et al., 1999). 
Interestingly, mDia can also bind to the Rae and Cdc42 effector IRSp53 in a Rho- 
dependent manner and this could provide yet another way for Rho GTPase cross-talk 
(Fujiwara et al., 2000). 
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1.3.3 Rho GTPases and microtubules 
Although the effects of Rho GTPases on the actin cytoskeleton have received most 
attention to date, it is now clear that they can also modulate the microtubule cytsokeleton 
and this may play an important role during the migration of at least some cell types 
(Wittmann and Waterman-Storer, 2001). The first clue for a link was the observation that 
disruption of microtubules with nocodazole activates Rho, but when washed out of cells it 
leads to Rac activation (Liu et al., 1998). Later Rho was shown to promote the 
stabilization of microtubules through its target niDia that directly interacts with 
microtubules and promotes their capping (Figure 1.10) (Ishizaki et al., 2001). Another 
possible pathway to regulate microtubule dynamics in mammalian cells could well be the 
one that is known to operate in yeast (Gundersen, 2002). It has been shown, by direct 
imaging studies of the budding cortex, that yeast regulate capture and shrinkage of 
microtubules by a mechanism that involves the formin Bnil, Kar9 and Biml/Yebl, a 
homologue of the mammalian microtubule tip protein EB1 (Adames and Cooper, 2000; 
Schuyler and Pellman, 2001). Rac, on the other hand, has been shown to modify 
microtubule dynamics through p65PAK-dependent phosphorylation and inactivation of 
the microtubule destabilising protein stathmin (Figure 1.10) (Daub et al., 2001; Kuntziger 
et al., 2001). 
Cdc42 plays a crucial role in defining cell polarity with respect to the external 
environment. Inhibition of Cdc42 in macrophage cells, for example, blocks their ability to 
undergo chemotaxis towards a gradient of CSF-1, although it does not inhibit their ability 
to move (which is Rac dependent) (Ridley, 2001b). The mechanism by which Cdc42 
regulates chemotaxis is not known. However, work with neutrophils, suggests that there 
exists a positive feedback loop between the Rho GTPases and PI(3,4,5)P3 in order to 
establish cellular asymmetry and polarity (discussed later) (Weiner et al., 2002). Polarised 
cell migration is often reflected in the organization of the microtubule cytoskeleton and 
the centrosome, which ususally face the direction of migration. In migrating astrocytes 
and fibroblasts, Cdc42 regulates this reorientation of the microtubules and centrosome 
and recent work has revealed some of the mechanisms involved (Nobes and Hall, 1999). 
In its GTP-bound state, Cdc42 activates a target complex of Par6 (a scaffold protein) and 
the atypical protein Idnase C, PKCý (Figure 1.10) (Etienne-Manneville and Hall, 2001). 
The specific activation of this complex at the leading edge of the migrating cells is 
essential for determining the polarity and direction of migration. Recently it has been 
shown that Cdc42-dependent phosphorylation of GSK3 releases APC to bind to plus ends 
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of microtubules and contribute to the regulation of cell polarisation (Etienne-Manneville 
and Hall, 2003). 
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FIGURE 1.10 
Simplified representation of the effects of Rho GTPases on microtubules. Cdc42 regulates 
microtubule dynamics by becoming recruited to a Par6/ PKC', complex. Formation of the 
complex leads to the inhibition of GSK-3 and the release of APC, which can associate with 
the plus-end of microtubules at the leading edge. Rac also regulates microtubules by 
activating p65PAK to phosphorylate and inactivate stathmin, a microtubule-destabilising 
protein. Little is known on how Rho activation stabilises microtubules, other than it involves 
its effector mDia. 
Interestingly APC has recently been shown to interact with ASEF, a Rac-specifc GEF, 
again pointing to cooperation between Rac and Cdc42 at the leading edge (Kawasaki et 
aL, 2000). APC, however, has also been shown to promote microtubule polymerisation 
in vitro and in cultured mammalian fibroblasts and in Xenopus epithelia] cells, there is 
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evidence to indicate that APC can bind to microtubules and move along them probably 
through binding to the microtubule-associated protein EBI and the kinesin KAP3, thus 
playing a similar role to the yeast protein Kar9 (Gundersen, 2002; Jimbo et al., 2002; 
Nakamura et al., 2001). The movement of APC towards the plus ends of microtubules in 
migrating cells could serve to localise ASEF to sites of actin-rearrangement, where Rac 
could be recruited in a similar way and be activated only locally (Bienz, 2002; Jimbo et 
al., 2002). GEFH I, a GEF that has been shown to induce GTP loading on both Rac and 
Rho, could be acting in an analogous way to ASEF, as there is evidence to suggest that it 
localises to microtubules too (Ren et al., 1998). 
1.3.4 Extracellular Control 
A variety of extracellular signals have been implicated in the initiation or regulation of 
cell migration and broadly fall into two categories: soluble components, and extracellular 
matrix. These mediate signaling cascades that drive the Rho GTPase cycle by modifying 
any of the GTPase regulatory proteins. 
1.3.4.1 Integrin-matrix interactions 
Cell-matrix interactions are mediated mainly through integrins that form clusters, 
called focal adhesions or focal contacts, in the plasma membrane and bridge the outside 
world to the intracellular milieu particularly the actin cytoskeleton (Figure 1.11) (DeMali 
et al., 2003; Hynes, 2002). In Drosophild for example, position-specific (PS) integrins, 
which are most similar to the 01 vertebrate integrins, are needed for proper migration of 
the endodermal cells during midgut development (Martin-Bermudo et al., 1999). Real 
time imaging by a number of groups has revealed the assembly of small, Rac-dependent 
focal contacts associated with the protruding front of a migrating cell, followed by their 
Rho-dependent maturation into larger focal adhesions in the cell body and eventually 
disassembly at the rear (Rottner et al., 1999; Webb et al., 2002). It is clear, therefore, that 
Rho GTPases must be activated precisely in space. In migrating endothelial cells, for 
example, Rac induces the localisation of integrin avP3 to lamellipodia as visualized with 
an antibody specific to the high-affinity state of the integrin (Kiosses et al., 2001). In 
addition to promoting integrin clustering, Rho GTPases are themselves activated by 
integrin engagement with matrix, maldng this a particularly intimate relationship (Nguyen 
36 
1. INTRODUCTION 
et al., 2001). Thus during spreading of fibroblasts on fibronectin, which has some 
similarities to migration, Cdc42 and Rae are activated upon engagement of the integrins 
to the substratum (as observed by looking at the phosphorylation of several downstream 
kinases like FAK or Src), leading to actin polymerisation at the periphery and protrusion 
of the membrane (Berrier et al., 2002; Clark et al., 1998; O'Connor and Mercurio, 2001). 
At later times, these two GTPases are downregulated and Rho activity is increased, as the 
cells stabilize their morphology and put down firm focal adhesions (Arthur and Burridge, 
2001; Ren et al., 1999). Activation of Rae and transient inhibition of Rho seem to be 
critical events at the front of migrating cells, whereas activation of Rho is required in the 
cell body and at the rear. 
The mechanisms by which these two GTPases are differentially activated within a 
single cell are not clear, however recent studies have given us some insights (Sander et 
al., 1999). Integrin 001 engagement by laminin (10/11) preferentially activates Rac 
through phosphorylation of pl30Cas and activation of the CrkII / DOCK180 pathwaybut 
engagement of the integrin cc5pl to fibronectin seems to activate Rho (Gu et al., 2001). 
Elegant FRET studies by the Schwartz lab have shown that integrins control the 
translocation of Rac to the plasma membrane at the front of the migrating cell and 
enhance its association with effectors by causing its dissociation from Rho-GDI (Del 
Pozo et al., 2002). Finally, activation of integrin cc6P4 by laminin has been shown to play 
a role in cell migration of carcinoma cells by inducing the activation and translocation of 
Rho (rather than Rac) to ruffles, in a cAMP dependent way, presumably for the formation 
of new adhesions (O'Connor et al., 2000). 
1.3.4.2 Soluble factors 
A huge range of proteins and lipids have been found to affect the migratory behaviour 
of cells (Figure 1.11). Growth factors acting on tyrosine kinase receptors are important 
regulators of cell migration. They have been studied extensively in tissue culture assays 
and in genetically tractable organisms such as Drosophila and C elegans, particularly 
during development (Forbes and Lehmann, 1999; Lehmann, 2001). Studies first carried 
out in mammalian cells showed that many growth factors capable of promoting cell 
migration are strong activators of Rac (Nobes and Hall, 1995; Ridley et al., 1992). 
Addition of PDGF to fibroblasts, for example, stimulates Rac-dependent lamellipodia 
formation and membrane ruffling reflecting the induction of actin polymerisation at the 
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cell periphery. Recently a new technique for visualizing activated Rac in living cells, 
FLAIR (fluorescence activation indicator for Rho proteins), has been used with cells 
induced to migrate along a gradient of PDGF. In this case, PDGF induces an intracellular 
gradient of active Rac, the highest levels being at the leading edge and the lowest at the 
rear of the migrating cell (Kraynov et al., 2000). 
Interestingly, PDGF also leads to the activation of Rho, apparently through the 
inactivation of pl90RhoGAP, a negative regulator of Rho GTP levels (Chiarugi et al., 
2000). It is expected that active Rho will be excluded from the leading edge of migrating 
cells, but this has not yet been shown directly. PDGF signaling provides a nice example 
of how the same stimulus activates different GTPases to produce a coordinated response; 
the mechanisms by which the two GTPase are differently localised is, however, 
completely unknown. 
Two peptide factors acting through tyrosine Icinase receptors, EGF and PvfI 
(homologous to VEGF and PDGF) are thought to act as chemoattractants directing border 
cell migration during oocyte maturation in Drosophila. The PVR (the receptor for PvfI) 
is thought to control F-actin accumulation in the border cells by signaling to Rac via mbc 
(myoblast city), the fly orthologue of mammalian DOCK 180 (Duchek and Rorth, 2001; 
Duchek et al., 2001). 
Lipids, acting externally through seven-pass trans-membrane receptors, can also 
influence cell migration through the modulation of GTPase pathways. In fibroblasts, 
lysophosphatidic acid (LPA) is a strong activator of Rho and might be expected to inhibit 
cell migration (Nobes and Hall, 1995; Ridley and Hall, 1992). However, in vascular 
smooth muscle cells, LPA acting through a different receptor leads to the rapid activation 
of the Ser/*Ibr kinase p65PAK, a target of Rac. It appears that this is mediated by 
activation of the Tiam-1 (a Rac GEF) in a God and PI 3-kinase dependent mechanism and 
this leads not only to the activation of Rac but also to the inhibition of Rho signaling 
(Sander et al., 1999; Schmitz et al., 2002; Van Leeuwen et al., 2003). A recent paper has 
shown that Rho can activate Rac and when pl60Rho kinase is inhibited, this leads to 
lamellipodia formation rather than stress fibers (Tsuji et al., 2002). This cross-talk 
between Rho GTPases is clearly an important feature of their ability to act coordinately. 
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Simplified representation of some of the upstream regulatory pathways of Rho GTPases. 
Ligand binding to either tyrosine kinase receptors or G-protein coupled receptors or integrins 
results in the activation of signaling components like FAK, Src, She, Fyn, PI 3-kinase that 
ultimately lead to the activation or inactivation of GEFs and GAPs respectively. Activation of 
PH-domain GEFs (e. g. TIAM-1, pREX, Vav) leads to the activation of Rae and Cdc42. 
In vivo experiments have pointed to the importance of another lipid, sphingosin-1- 
phosphate (SI-P), in migration processes. In zebrafish, SI-P is required for embryonic 
myocardial precursor cell migration, while a gene knockout for the SIP receptor 
EDGI/SIPI in mice is embryonic lethal due to a vascular maturation defect because the 
mural cells, vascular smooth muscle cells and pericytes fail to migrate to the arteries and 
capillaries (Liu et a]., 2000; Pyne and Pyne, 2000). The SIP receptor is a G-protein 
coupled receptor and in response to SIP, Rac is most likely activated via the 
heterotrimeric G protein, Gi leading to phosphorylation of p1 30Cas by the Src-I ike kinase 
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Fyn. pl30Cas translocates to the plasma membrane and activates Rac (Okamoto et al., 
2000a; Okamoto et al., 2000b; Vouret-Craviari et al., 2002). It has also been reported that 
SIP stimulates endothelial cell migration and cortical actin assembly through activation 
of PI 3-kinase and subsequently protein kinase B (PKB/Akt), which in turn 
phosphorylates the SIP receptor EDGI and promotes Rae activation (Lee et al., 2001). 
In addition to attractive cues, there is growing evidence that repulsive cues also play 
an important role in directing cell migration. This has been studied best in the context of 
neuronal axon extension and growth cone guidance, which shows many similarities to the 
protrusive front of a migrating cell, although in this case the cell body does not move. 
Studies in C elegans, Drosophila and Xenopus have clearly identified a crucial role for 
Rho GTPases in these aspects of neuronal behavior, as well as in neuronal cell migration 
itself (Luo, 2000). Work carried out by many groups has come to the conclusion that Rho 
acts antagonistically to Rac/Cdc42, the former causing growth cone and axon retraction 
and the latter causing extension (Kozma et al., 1997). As an example, the ephrins are 
membrane-bound repulsive ligands for dorsal root ganglion-derived neuronal growth 
cones that act through the family of Eph tyrosine kinase receptors (Schmucker and 
Zipursky, 2001). Upon ligand binding, EphA activates Rho through the GEF ephexin and 
promotes growth cone collapse, in part through activation of its downstream Ser/Thr 
kinase target, pI 60ROCK (Figure 1.12) (Shamah et al., 200 1; Wahl et al., 2000). 
Another family of repulsive growth cone guidance molecules, the semaphorins act 
through the plexin family of receptors. Here too, activation of Rho appears to be essential 
for repulsion, though in this case Rac activity is also required (Driessens et al., 2001; Hu 
et al., 2001). Further analysis has revealed a complicated relationship between the plexin 
B receptor and GTPases; the cytoplarnsic tail of the receptor can interact directly with 
RacGTP (suggesting it might be a Rac target) and with PDZ-RhoGEF, a Rho-specific 
GEF (Figure 1.12) (Driessens et al., 2002; Perrot et al., 2002). 
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Rho GTPases are regulators of growth cone migration. Rho is activated downstream of the 
repulsive growth cone cues, ephrins and sernaphorins. Ephrins bind to their receptor EphR to 
activate the Rho-GEF ephexin, whereas sernaphorins bind to plexins to activate PDZ-Rho 
GEF Rac-GTP is also known to bind to the cytoplasmic tail of plexin. 
1.3.5 PI 3-kinase signaling in cell migration 
1.3.5.1 PI(3,4,5)P3, a signal for polarised chemotaxis 
PI 3-kinases (PI 3-kinases) have been widely implicated in controlling cell migration 
and polarity [Stephens, 2002 #3198]. During leukocyte chemotaxis, type IA PI 3- 
kinases are required for lamellipodium extension and migration towards colony- 
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I (CSF-1), whereas type IB PI 3-kinases are required for neutrophil chernotaxis to a 
variety of inflammatory mediators that signal via G-protein coupled receptors (Hirsch et 
al., 2000; Li et al., 2000; Sasaki et al., 2000; Vanhaesebroeck et al., 1999). PI 3-kinases 
are heterodimers of a regulatory and a catalytic subunit. The p85 regulatory subunit is a 
target for phosphorylation by a variety of cytoplasmic and receptor tyrosine kinases and 
binds constitutively to the plIO catalytic subunit. Type I PI 3-kinases phosphorylate 
phosphatidylinositol phospholipids at position 3 of the inositol ring (Vivanco and 
Sawyers, 2002). Their main product is PI(3,4,5)P3, which is believed to primarily act as a 
ligand to recruit PH domain containing proteins to the plasma membrane. The property of 
certain PH domains to specifically translocate to localised pools of PI(3,4,5)P3 was 
exploited by several groups to visualize bursts of PI(3,4,5)P3 on the plasma membrane, 
using pleckstrin homology (PH) domains fused to GFP (GFP-PH). Studies in 
Dictyostelium, neutrophils and fibroblasts demonstrated co-localisation of the GFP-PH 
construct with centers of actin polymerisation at the front of the migrating cell (Haugh et 
al., 2000; Parent et al., 1998; Servant et al., 1999). 
The role of PI 3-kinase in chernotaxis has also been examined through PI 3-kinase 
knock-out studies in mice and Dictyostelium. Mouse PI 3-kinasey 4- neutrophils 
demonstrated an impaired ability to chernotax towards a gradient of fMLP, C5a or 
interleukin-8 and fail to activate PKB, the main downstream target of PI(3,4,5)P3 (Hirsch 
et al., 2000; Li et al., 2000; Sasaki et al., 2000). Close examination of these neutrophils 
revealed that they were unable to efficiently sustain a pseudopod extension exclusively 
towards the chernotactic gradient. Similarly, Dictyostelium cells that had the PI 3-kinasel 
and PI 3-kinasO genes inactivated, showed an impaired directionality, migrated more 
slowly and in a less polarised manner towards a gradient of either cAMP or folate, 
compared to parent cells (Funarnoto et al., 2002; Funamoto et al., 2001). The importance 
of PI 3-kinases was supported further by studies in macrophages using antibodies raised 
specifically against class IA PI 3-kinasep and PI 3-kinase8 isoforms and several studies 
using the PI 3-kinase inhibitors wortmannin and LY294002 (Chung et al., 2001; Sadhu et 
al., 2003; Vanhaesebroeck et al., 1999). 
Recent studies in Dictyostelium demonstrated that PI 3-kinases are responsible for the 
establishment and maintenance of the response to a chernotactic gradient through the 
localised production of PI(3,4,5)P3 (Funamoto et al., 2002; Iijima. and Devreotes, 2002). 
Funamoto et al., showed that PI 3-kinases rapidly translocate to the plasma membrane in 
response to the global application of a chemoattractant, and that their localisation is 
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restricted to the leading edge of migrating cells during chernotaxis. The kinetics of 
relocalisation of PI 3-kinases closely resembles the relocalisation kinetics of PH domain 
proteins (Funamoto et al., 2002). Importantly, the same group demonstrated that 
relocalisation of PI 3-kinases to the plasma membrane is independent of their activation. 
These results suggest that although PI 3-kinases are key regulators of cell polarity, 
additional mechanisms that lie upstream of P13-kinases must be responsible for 
establishing the initial cell asymmetry, in response to a chernotactic gradient. 
13.5.2 Downstream targets of PI(3,4,5)P3 signaling 
The production of PI(3,4,5)P3 leads to an increase in GTP-bound Rac in many cell 
types. Expression of a constitutively activated PI 3-kinase in fibroblasts, for example, 
generates extensive lamellipodia and membrane ruffling through Rac activation, though 
interestingly not other Rac-mediated signals such as JNK activation (Reif et al., 1996). 
The mechanism by which this lipid promotes GTP loading on Rac is thought to be 
through a direct interaction with Rac GEFs. All members of the Dbl family of GEFs 
contain a PH domain and at least some of these can bind phospholipids. In Vav, for 
example, PI(3,4,5)P3 binding relieves an interaction between the PH and DH (catalytic) 
domains to stimulate activity, though this is unlikely to be the whole story since tyrosine 
phosphorylation also occurs (Abe et al., 2000; Han et al., 1998; Liu and Burridge, 2000; 
Sachdev et al., 2002). Deletion of the PH domain in the GEFs Dbs and Lfc, on the other 
hand, results in a loss of activity, but this can be restored by addition of a CAAX motif to 
target the protein to the plasma membrane (Whitehead et al., 1995; Whitehead et al., 
1999). In this case, a major role of PI(3,4,5)P3 is thought to be in inducing membrane 
translocation. Tiam-1, a Rac specific GEF, provides another example where the PH 
domain regulates targeting to the plasma membrane as it can be functionally replaced by 
a myristoylation signal (Michiels et al., 1997). PIX has been shown to be regulated by 
PI(3,4,5)P3- When localised at the front of a migrating cell, PIX activates Rac and 
promotes actin polymerisation, but it also interacts with the Rac target p65PAK and is 
thought to regulate focal adhesion turnover (Bagrodia et al., 1999; Koh et al., 2001; 
Manser et al., 1998; Yoshii et al., 1999). Finally, members of a new class of 
unconventional GEFs, including the Rac specific GEF, DOCK180/DOCK2, and the 
Cdc42 specific GEF, DOCK9/zizimin, also contain domains that would allow their 
regulation through binding to PI(3,4,5)P3 (Brugnera et al., 2002; Cote and Vuori, 2002). 
DOCK180 contains a basic domain that has been shown to bind PI(3,4, S)P3 and zizimin 
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contains a PH domain (Cote and Vuori, 2002; Meller et al., 2002). Studies in Drosophila 
and lymphocytes have revealed a role for DOCK180 in cell migration and chernotaxis 
and these effects might be modulated through PI(3,4,5)P3 targeting and subsequent 
activation of Rac (Duchek and Rorth, 200 1; Duchek et al., 200 1). 
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FIGURE 1.13 
PI(3,4,5)P3 is a key regulator of polarised cheinotaxis and cell migration. Activation of PI 3- 
kinase leads to increased levels of cellular PI(3,4,5)P3- PI(3,4,5)P3 regulates the spatial 
recruitment of PH domain containing proteins involved in cell polarity and chemotaxis. It also 
activates Rae to induce actin polymerisation required for cell migration, by recruiting and 
activating DbI farnily GEFs and unconventional GEFs like DOCK180. PTEN is a negative 
relulator of PI(3,4,5)P3 and hence cell polarity and migration. 
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The relationship between Rac and PI 3-kinase during cell migration may be more 
interesting, since the two are able to interact directly with each other and Rac activation 
stimulates PI 3-kinase leading to the production of PI(3,4,5)P3 (Benard et al., 1999; 
Bokoch et al., 1996; Genot et al., 2000; Hawkins et al., 1995; Servant et al., 2000). This 
would provide an opportunity for a positive feedback loop. To explore this possibility, 
Boume and co-workers made use of neutrophils expressing the PH domain of Akt 
coupled to fluorescent green protein (PH-Akt-GFP) as a probe for the spatial distribution 
of PI(3,4,5)P3 (Wang et al., 2002; Weiner et al., 2002). They found that in response to a 
chemoattractant or an exogenously delivered bolus of PI(3,4,5)P3, neutrophils 
asymmetrically accumulate PI(3,4,5)P3 and filamentous actin at the leading edge and this 
involves a positive feedback loop operating between PI 3-kinase and Rac. Disruption of 
this feedback loop results in a jerky, non-polarised cell response to chemoattractants. The 
exchange factors regulating Rac during neutrophil chemotaxis are not known, although 
the RacGEF PREX-1, has recently been shown to be activated by PI(3,4,5)P3 in 
neutrophils leading to Rac-dependent stimulation of the NADPH oxidase (Welch et al., 
2002). 
1.3.5.3 PTEN in directional sensing 
Elegant studies in Dictyosteliurn by the Firtel and Devreotes laboratories have 
provided important evidence for a role of the PI(3,4,5)P3 phosphatase PTEN in cell 
chernotaxis. The two laboratories have used complementary approaches to show that 
chemotaxis of Dictyostelium cells is dependent upon the interplay of PTEN and PI 3- 
kinases. These studies revealed that PTEN null cells exhibit chernotactic defects 
reciprocal to those of PI 3-kinase I/PI 3-kinase 2 null cells or to wild type cells treated 
with PI 3-kinase inhibitors. PTEN null cells have numerous filopodia and pseudopodia, 
move more rapidly and appear to have multiple polarity axes thus exhibiting a slower 
overall response to the chemoattractant compared to wild type cells (Iijima and 
Devreotes, 2002). On the other hand, PI 3-kinase I/PI 3-kinase 2 null cells have a reduced 
number of pseudopodia compared to wild type cells and had chernotactic defects due to 
an overall loss in polarity (Funamoto et al., 2002). In addition, PTEN knock-in cells 
displayed a slower rate of chernotaxis and a decrease in cell polarity. 
Both groups observed that PH domain proteins were still able to broadly localise at the 
front of the migrating cells and the tips of membrane protrusions, suggesting that 
although polarity is impaired, it is not completely lost. PTEN knock-out cells, however, 
45 
1. INTRODUCTION 
although polarity is impaired, it is not completely lost. PTEN knock-out cells, however, 
had a more sustained accumulation of PH domains at the plasma membrane upon 
chemoattractant stimulation (Iijima and Devreotes, 2002). Funamoto et al., observed that 
PTEN had a reciprocal localisation to PI 3-kinase. PTEN transiently translocates from the 
plasma membrane to the cytosol with kinetics that mirror those of PI 3-kinase 
relocalisation. In chemotaxing cells, PTEN is localised mostly at the edges and the 
posterior part of the cells, whereas PI 3-kinase accumulates at the leading edge of the 
migrating cell, towards the chemotactic gradient (Funamoto et al., 2002). In addition, 
PTEN null cells, displayed a prolonged accumulation of F-actin relative to wild type 
cells, suggesting that actin polymerisation is a direct downstream event in PI 3-kinase 
signaling. Overall these observations demonstrate that PI 3-kinases and PTEN through 
their antagonistic effects on PI(3,4,5)P3 are key players in the maintenance, and also 
possibly in the establishment of cell polarity. 
1.4 PTEN 
1.4.1 Discovery of PTEN 
PTEN is a tumour suppressor protein that was independently identified by three 
groups in 1997 (Li and Sun, 1997; Li et al., 1997a; Steck et al., 1997). It maps to the 
chromosomal region 10q, which had previously been described as the most frequently 
mutated region in prostate and endometrial cancers and glioblastomas. Two groups, Li et 
al. and Steck et al. used positional cloning approaches to map the PTEN gene to region 
lOq23 (Li et al., 1997a; Steck et al., 1997). Sequence analysis revealed a region that was 
homologous to tensin and auxillin and that coded for a tyrosine-phosphatase domain, 
hence the name PTEN (phosphatase and tensin homologue deleted on chromosome 10), 
also known as MMAC I -for mutated in multiple advanced cancers. A third group, Li and 
Sun was searching for novel protein phosphatases when they identified TEPI, for 
transforming growth factor (TGF) - regulated and epithelial cell-enriched phosphatase, 
which proved to be identical to PTEN. TEP1 was shown to dephosphorylate 
phosphotyrosyl-RCML, a substrate frequently used to test for in vitro tyrosine 
phosphatase activity. Furthermore, when the critical cysteine residue in the active site was 
mutated to a serine residue (C124S), a mutation present in Cowden's disease patients, the 
ability of PTEN to act as a phosphatase was abolished (Li and Sun, 1997). The major 
physiological substrate of PTEN, however, was later shown to be PI(3,4,5)P3, and several 
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groups demonstrated the ability of PTEN to dephosphorylate position D3 of 
phosphoinosityl. phospholipids, with highest affinity for PI(3,4,5)P3 (Maehama and 
Dixon, 1998; Myers et al., 1998). 
1.4.2 PTEN homologues 
The PTEN gene is ubiquitously expressed in all eukaryotic cells, and the mammalian 
gene encodes for a 403 amino acid protein comprised of a phosphatase and a C2 domain 
(Lee et al., 1999). PTEN orthologues in Saccharomyces cerevisiae and 
Schizosacharomycespombe, however, lack the C2 domain (Figure 1.15) (Heymont et al., 
2000; Li et al., 1997b; Sulis and Parsons, 2003). Although a single PTEN gene has been 
identified in Xenopus laevi, Caenorhabditis elegans and Drosophila melanogaster, 
several mammalian homologues of PTEN have now been characterised, and these are 
TPTE, PTEN2 and TPIP (Figure 1.14) (Chen et al., 1999; Marfatia et al., 2000; Walker et 
al., 200 1; Wu et al., 200 1). The expression patterns of PTEN2 and TPTE are restricted to 
the testis, whereas TPIP is expressed in the testis, stomach and brain. In addition to the 
phosphatase and C2 domains, these PTEN homologues have multiple transmembrane 
(TM) domains in their amino termini and differ in their subcellular distribution and 
phosphatase activities with respect to PTEN. In contrast to the cytosolic distribution of 
PTEN, TPTE is localised to the plasma membrane but lacks any detectable phosphatase 
activity (Walker et al., 2001). The murine homologue PTEN2 and the human homologue 
TPIP display similar phosphoinositide-3-phosphate activity to PTEN in vitro, but are 
localised to the Golgi apparatus and the endoplasmic reticulum, respectively (Walker et 
al., 2001; Wu et al., 2001). It seems, therefore, that there is no functional redundancy of 
PTEN in the downregulation of cellular PI(3,4,5)P3 levels, at least at the plasma 
membrane, which might explain its importance as a tumour suppressor and why it is a 
key target in tumourigenesis. 
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FIGURE 1.14 
Domain structure of the mammalian PTEN homologues PTEN2, TPIP, TPTE. The domain 
predictions were performed using the SMART (Simple Modular Architectural Tool) website 
and modified according to Walker et al., 2001. Phosphatase domain: pink, C2 domain: green, 
TM domain: blue, PDZ binding motif. - purple. 
1.4.2 PTEN: a tumour suppressor 
1.4.3.1 PTEN is the major susceptibility gene in two human hamartoma 
syndromes 
Deletions of the whole or parts of chromosome I Oq23 were shown to be associated, at 
a high frequency with various human sporadic turnours and at least two hamartoma 
syndromes. PTEN is the major susceptibility gene in Cowden disease (CD) and for 
Bannayan-Riley-Ruvalcaba syndrome (BRRS). Cowden disease is an autosomal 
dominant familial cancer syndrome with an estimated incidence of more than I in 
200,000. It is characterised by the development of malignant carcinomas of the breast and 
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epithelial thyroid glands, as well as the presence of hamartomas of the skin, oral mucosa, 
intestinal and endometrial epithelium (Liaw et al., 1997; Marsh et al., 1998a; Marsh et al., 
1997a; Marsh et al., 1997b). 
Around 80% of Cowden disease cases have been found to harbor germline PTEN 
mutations, two thirds of which have been mapped to exons 5,7 and 8 (Marsh et al., 
1998a). Mutations of the PTEN gene include deletions and insertions, resulting in 
nonsense or missense events, and occur over the entire length of PTEN, with 43% 
mapping to the phosphatase domain (exon 5). When patients with Cowden disease were 
examined for the importance of PTEN in the development of the various hamartomas, it 
was found that loss of heterozygosity (LOH) had occurred in 25% of thyroid and breast 
cancers (Gimm. et al., 2000a; Simpson and Parsons, 2001). 
Germline PTEN mutations have also been described in families with BRRS. The 
disease is characterised by polyposis, lipomatosis, hemangiomatosis, macrocephaly and 
high birth weight (Marsh et al., 1998b). PTEN germline mutations have been identified in 
60% of patient cases with BRRS. These include loss of region lOq23 and mutations 
resulting from chromosome rearrangements. BRRS, unlike CD, is not associated with an 
increased risk in malignant carcinomas, although breast tumours, lipomas and 
fibroadenomas have all been associated with the disease. The clinical manifestations of 
CD and BRRS are very similar and their mutational patterns seem to overlap. They are 
therefore believed to represent variable penetrance of the same disorder. Thus, the 
syndromes that harbor PTEN mutations have all been grouped together and referred to as 
the PTEN Hamartoma Tumour Syndrome (PHTS), and these also include Proteus 
syndrome (PS) and Lhermitte-Duclos syndrome (LDS) (Gimm et al., 2000a; Waite and 
Eng, 2002). 
1.4.3.2 PTEN is mutated in many sporadic cancers 
The importance of PTEN's tumour suppressor function has been highlighted in a 
range of human sporadic malignancies, including glioblastoma, melanoma, and cancers of 
the thyroid, breast, endometrium, prostate and ovary (Li et al., 1997a; Steck et al., 1997). 
The frequency of PTEN mutations and the most likely cause of PTEN loss are 
summarized in Table LL Interestingly, PTEN inactivation can affect very different stages 
of turnour progression. In endometrial carcinomas, loss of PTEN expression can occur 
very early on, even in the prernalignant stages of the disease, and appears at highest 
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frequency in those adenocarcinomas that exhibit a non-aggressive phenotype (Mutter, 
2001). The same is also true in some ovarian cancers (Sato et al., 2000). Endometriod 
endometrial carcinomas display PTEN mutations in 45% of the cases, of which 61% 
show complete loss of PTEN expression and more than 90% show reduced protein 
expression, whereas endometrioid ovarian turnours exhibit PTEN mutations at a 
frequency of 21%. 
Tissue Tumor type 
Frequency of 
PTEN Inactivation 
Average/ Range 
Primary cause 
Brain Glioblastoma 48% (17-70%) Mostly LOH 
Breast Ductal carcinoma 37% (15-48%) Mostly LOH 
Endometrium Endometriold 42% (34-83%) LOH and mutation 
carcinoma 
Prostate Adenocarcinoma 33% (17-41%) Mostly LOH 
Ovary Cyst 33%(6-45%) LOH and mutation 
adenocarcinorna 
Skin Melanoma 33% (32-33%) Mostly LOH 
Thyroid Carcinoma 37% Mosity LOH 
TABLE 1.1 
PTEN mutations and deletions in sporadic human cancers. Adapted from Mutter, AJP 2001. 
In contrast, melanoma, prostate carcinoma and glioblastorna show loss of PTEN 
expression in more advanced stages of the disease, usually associated with the metastatic 
forms of these tumours. PTEN loss most likely occurs before metastasis, however, since 
in most prostate tumours that have metastasized, PTEN expression is also absent in the 
primary site. It was found that, in 50% of the prostate turnours studied the region lost was 
lOq23 and in 10-15% of the cases, PTEN had been inactivated by homozygous deletion. 
Furthermore, studies examining PTEN expression revealed that the mRNA and protein 
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levels of PTEN were reduced in 50% of the cases, and that this occurred predominantly in 
advanced cancers. Similarly, in melanomas, the frequency of PTEN mutations in the 
primary tumour is much lower than that in which the cancer has metastasized. 
Examination of 4 primary and 30 metastatic melanomas revealed very low or no 
expression of PTEN in 65% of the cases (Zhou et al., 2000). Therefore, it is likely that 
loss of PTEN is associated with progression of these turnours to a more malignant 
phenotype. 
Gliomas that have lost PTEN are primarily the aggressive glioblastomas, and it has 
been shown that PTEN deletion is not a frequent occurrence among tumours that undergo 
a progressive increase in malignancy grade, but is rather a characteristic of primary 
glioblastomas. Indeed, the mutation rate of PTEN in glioblastomas was found to be 44%, 
whereas in low grade gliomas and astrocytomas PTEN mutations are rare (Duerr et at., 
1998). It seems, therefore, that PTEN loss plays an important role in the progression of 
this and other tumours to a more aggressive phenotype. 
1.4.3.3 PTEN controls cell growth, cell cycle arrest and apoptosis 
In order to examine the role of PTEN in development and turnour progression, mice 
were generated that were homozygous or heterozygous deficient for PTEN. These 
experiments demonstrated an important role for PTEN during development. Homozygous 
PTEN deficient mice were not viable and died within embryonic days 6.5 and 9.5, and the 
embryos appeared disorganised. One group targeted exons 3 to 5 of the PTEN gene, 
another group targeted exons 4 to 6, whereas a third group targeted exon 5, which coded 
for the phosphatase domain of PTEN. In all cases the mutant mice showed abnormal 
patterning with expanded cephalic and caudal regions, and developed a variety of 
turnours, including prostate endometrium. and thyroid carcinomas (Di Cristofano et al., 
1998; Podsypanina et al., 1999; Suzuki et al., 1998). Some of the observed neoplasias and 
hamartomas resembled those observed for CD and BRRS, but these mice also developed 
a variety of other turnours that were not characteristic of human hamartoma syndromes 
(Podsypanina et al., 1999). 
Recently, several groups have used tissue-specific promoters to express Cre 
recombinase, and conditionally mutate both alleles of PTEN by incorporating lox 
recombination sites that flank specific PTEN exons. Cre recombination was used to target 
functionally inactive PTEN in mouse T and B cells, cardiac myocytes, mammary 
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epithelium cells, primordial germ cells, keratinocytes and neurons (Backman et al., 2001; 
Crackower et al., 2002; Kwon et al., 2001; Suzuki et al., 2001). Surprisingly, loss of 
PTEN in these cell types did not induce carcinomas immediately, but after a long follow- 
up, a subpopulation of PTEYý* cells was observed to transform into malignancies. When 
Cre-LoxP was used to inactivate PTEN in the mouse brain, mice developed enlarged 
brains, and in particular, the cerebellum and neuronal cell bodies were almost double the 
size of their wild type counterparts, thus contributing to the observed brain phenotype. 
However, no tumours were observed, and depending on which promoter was used to 
inactivate PTEN, there were significant differences in the observed phenotypes 
(Morrison, 2002). Groszner et al., used the nestin promoter to delete PTEN throughout 
the brain, which resulted in an increase in proliferation of neural stem cells and a decrease 
in cell death of PTEN-ý neurons (Groszer et al., 2001). However, when Kwon et al., and 
Backman et al., used the glial fibrillary acidic protein (GFAP) promoter to induce a more 
restricted deletion of PTEN and avoid targeting of neuronal stem cells, the levels of 
proliferation and apoptosis appeared normal (Backman et al., 2001; Kwon et al., 2001). 
These groups did, however, observe a progressive increase in neuronal soma cell size. 
To analyse the role of PTEN more closely in cellular processes such as cell growth 
and proliferation, mouse embryonic stem cells and fibroblasts lacking PTEN expression 
were generated. PTEN-1- cells exhibited elevated levels of PI(3,4,5)P3, phosphorylated- 
PKB and P70 S6 kinase (S6K). Furthermore, an increased rate in proliferation and a 
reduced sensitivity to apoptotic stimuli was also observed for PTEN4- T and B cells, 
neurons, keratinocytes and mammary epithelium. An increase in cell size was also 
observed in T cells, neurons and cardiac myocytes, which also exhibited defects in 
contractility (Backman et al., 2001; Crackower et al., 2002). Reintroduction of PTEN in 
PTEN-1- fibroblasts or carcinoma cells restored the cells' ability to respond to apoptotic 
stimuli and inhibited cell cycle progression in PTEN-"' glioblastoma cells (Cheney et al., 
1998; Furnari et al., 1997; Li et al., 1998; Stambolic et al., 1998). Most of the effects 
associated with loss of PTEN appear to be due to the high levels of cellular PI(3,4,5)P3 
generated by these cells. PTEN+1- T and B cells were impaired in their ability to undergo 
Fas-dependent apoptosis, because of the abnormally high levels of phosphorylated active 
Akt/PKB generated by the elevated levels of cellular PI(3,4,5)P3. Accordingly, treatment 
of these cells with wortmannin restored the ability of these cells to degrade Akt in a 
caspase-dependent way and to respond to Fas-induced apoptosis (Di Cristofano et al., 
1999). 
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The effect of PTEN has also been examined in several model organisms, including 
Drosophila and C elegans. The Drosophila PTEN orthologue, dPTEN shares 44% 
overall amino acid identity with the mammalian PTEN, with most of sequence 
similarities lying in the amino terminal half of the protein (Figure 1.15a). Similar to mice, 
Drosophila dPTEN mutants die during embryogenesis. Tissue specific inactivation of 
dPTEN in the wing and eye revealed PTEN4- clones to be larger that wild type clones, 
and this was found to be cell autonomous, whereas overexpression of OTEN during 
development results in inhibition of cell proliferation (Gao et al., 2000; Huang et al., 
1999). Interestingly, overexpression of PTEN in differentiated cells in the eye induces 
apoptosis, suggesting different roles of PTEN according to the developmental stages 
(Huang et al., 1999). Finally, a distant C elegans homologue of PTEN, DAF-18, has 
been shown to control lifespan, and to be an important component of the insulin signaling 
pathway (Figure 1.15). Deletion of the daf-18 gene dramatically reduces lifespan and 
rescues the daf-2 (the worm PI 3-Idnase orthologue) phenotype, which normally promotes 
longevity (Mihaylova et al., 1999). 
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PTEN orthologues. (a) Homology tree. Numbers refer to the proportion of differences 
between sequences. (b) Domain structure predicted using the SMART websitc. The catalyfic 
domain is depicted with a pink pentagon. Regions of low compositional complexity are 
depicted as dark pink. 
1.4.4 An antagonist to PI 3-kinase 
Shortly after the discovery of PTEN and its characterization as an important tumour 
suppressor belonging to the family of tyrosine phosphatases, work by several groups led 
to the significant finding that PTEN dephosphorylates PI(3,4,5)P3 both in vitro and in 
vivo (Li and Sun, 1997; Maehama and Dixon, 1998; Myers et al., 1998). The isolation of 
another PTEN mutant (G129E) from tumor and Cowden disease samples that abolished 
PTEN's phospholipid phosphatase activity, but retained activity against phospho-peptide 
substrates, strengthened the link between PTEN's tumour suppression function and its 
lipid phosphatase activity. 
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1.4.4.1 Downregulation of Akt/PKB 
Much attention has focused on the regulation of protein kinase B (otherwise known as 
Akt) activity by PTEN. This is mainly due to the fact that it has been well established that 
Akt is a major downstream target of PI 3-kinase. Upon an increase in the cellular levels of 
PI(3,4,5)P3. the serine/threonine kinase Akt, by binding PI(3,4,5)P3 on its PH domain, 
translocates to the plasma membrane, where it becomes phosphorylated by the protein 
kinases PDKI and PDK2 (Alessi et al., 1998; Anderson et al., 1998; Cohen et al., 1997). 
Phosphorylation of Akt is required for the protein to become active and function as an 
important regulator of proliferative and cell survival processes (Figure 1.16) (Ahmed et 
al., 1997; Toker and Newton, 2000). 
Studies in Drosophila and C elegans revealed a critical role in the regulation of Akt 
activity by PTEN. Stocker et al., showed that selective expression of a constitutively 
active form of Akt in the Drosophila eye results in a very similar phenotype to that of 
PTEN mutant cells, whereas overexpression of a hypomorphic allele of Akt rescues 
PTEN4- fly embryos from lethality (Stocker et al., 2002). In C elegans, some of the 
PTEN4- phenotypes are rescued by double stranded RNA interference of Akt1 and Akt2 
(Ogg and Ruvkun, 1998). Similarly, studies in mammalian cells have shown that deletion 
of PTEN results in elevated levels in phospho-Akt. In addition, tumour cell lines that lack 
PTEN and PTEN null mouse fibroblasts have higher levels of phospho-Akt than PTEN 
positive cells. Pre-treatment of serum-starved PTEN4- and PTEN-"ý cells with the PI 3- 
kinase inhibitor wortmannin abolished the basal and PDGF-induced increase in Akt 
phosphorylation. Finally, reintroduction of PTEN in these cells lowered the levels of 
phosphorylated Akt (Davies et al., 1998; Li et al., 1998; Li and Smithgall, 1998; 
Ramaswamy et al., 1999). 
1.4.4.2 Control of cell cycle 
Several groups have now shown that PTEN controls the cell cycle by inducing GI 
arrest in glioblastoma cells and thyroid carcinoma cells. This correlated with an 
upregulation in the cell cycle inhibitor p27K'P1 and a concomitant downregulation in the 
activities of the GI-dependent cyclin kinases, such as CDK2, cyclin-A and cyclin-E 
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(Bruni et al., 2000; Cheney et al., 1998; Li et al., 1998). The D cyclins are key regulators 
of the GI to S transition, whereas p27 is an inhibitor of the GI cyclin-dependent kinases. 
It was later shown that PTEN controls the ubiquitin-dependent degradation of p27 
through the ubiquitin E3 ligase SCF SKP2 complex (Mamillapalli et al., 2001). For PTEN to 
induce cell cycle arrest, a functional phosphatase activity is required, though using two 
phosphatase mutants (C124S and G129E), Weng et al. showed that it is the protein 
phosphatase activity that mediates regulation of cyclin DI expression. In contrast, the 
levels of the cyclin-dependent inhibitors p27, p2l and p57 were upregulated downstream 
of PTEN's lipid-phosphatase activity following a decrease in the levels of active Akt 
(Weng et al., 2001). More recently, PTEN has been reported to prevent cyclin DI from 
localizing to the nucleus during the G1 to S phase transition and this could be rescued by 
expression of a constitutively active form of Akt (Radu et al., 2003). An interesting 
mechanism by which PTEN might also control cyclin DI levels is through the regulation 
of 0-catenin. Recently, a study by Persad et al., revealed that in prostate cancer cells that 
lack PTEN expression, there is a constitutively high accumulation of P-catenin in the 
nucleus. The authors propose that PTEN negatively regulates GSK-3 activity by 
downregulating integrin-linked kinase (ELK) activity, which would stabilize P-catenin to 
translocate to the nucleus and activate gene transcription (Persad et al., 2000; Persad et 
al., 2001; Stambolic, 2002). 
Another way, however, by which PTEN might control cell cycle arrest is through the 
inhibition of the retinoblastoma protein Rb (Paramio et al., 1999). Paramio et al., showed 
that PTEN is unable to mediate cell cycle arrest in Rb-dcflcicnt cells, an effect rescued by 
reintroduction of Rb. Moreover, PTEN overexprcssion inhibits the hyperphosphorylation 
of Rb and reduces cyclin D1 protein expression, which is restored by coexpression of a 
constitutively active form of PI 3-kinase. Finally, mice in which Rb had been selectively 
deleted under the GFAP promoter displayed aberrant proliferation of astrocytes and the 
development of astrocytomas, a process that was accelerated in a PTEN"'- background 
(Xiao et al., 2002). 
1.4.4.3 Regulation of apoptosis 
The PI 3-ldnase/Akt pathway is an important regulator of apoptosis. Akt has been 
shown to phosphorylate the proapoptotic protein Bad, a Bcl-2 family member, and the 
protease Caspase-9. Dephosphorylated Bad inactivates pro-survival signals, such as Bcl- 
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XL, and promotes apoptosis. HEW' ES cells exhibit increased levels of phosphorylated 
Akt and phosphorylated Bad (Sun et al., 1999). Reintroduction of PTEN in PTEN4- 
glioma cells or mouse embryonic fibroblasts (MEFs) resulted in a reduction in the levels 
of phosphorylated Akt and in the inhibition of Bad phosphorylation. Interestingly, 
however, the cells were not induced to undergo apoptosis, but instead they underwent 
PTEN-dependent anoikis (Davies et al., 1998). Finally, several studies have demonstrated 
that the PI 3-kinase/Akt pathway provides cell survival signals through the activation of 
the transcription factor NF-KB. NF-KB is sequestered in the cytosol as an inactive 
complex bound by its inhibitor IKB. Degradation of IKB allows the translocation of NF- 
KB to the nucleus where it initiates transcription of target genes. Activation of NF-KB is 
also regulated by phosphorylation, which upregulates its transactivation potential of the 
NF-KB subunits (Ghosh et al., 1998; Zandi et al., 1998; Zandi et al., 1997). Recently, 
PTEN was shown to block the transcriptional activity of NF-KB (Koul et al., 2001b; 
Mayo et al., 2002). Reintroduction of PTEN in prostate cells inhibited the TNF- 
stimulated NF-KB-dependent transcription, without affecting IKB degradation, DNA 
binding or nuclear translocation, but by down-modulating the transactivation potential of 
NF-KB (Mayo et al., 2002). Another study, however, showed that PTEN blocks TNF or 
IL-1 induced NF-KB transcriptional activity by affecting its DNA binding (Koul et al., 
2001b). These conflicting results might be explained by the differences in the assays or 
the cells used. 
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PTEN regulates apoptosis and cell growth by downmodulating phospho-Akt levels. Akt 
promotes cell growth through the activation of mTOR and the inactivation of p53 by MDM-2. 
It inhibits apoptosis by negatively regulating apoptotic mediators such as Bad, Capsase-9 and 
FKHRLI. Concomitantly, it causes the release of NFK-B from its inhibitor IK-B to inhibit 
apoptosis. 
Another important substrate for the kinase Akt is the Forkhead family of transcription 
factors. Dephosphorylated FKHRLI can translocate to the nucleus and induce 
transcription of target genes, such as Fas ligand, and trigger apoptosis. Several studies 
have now shown that Akt promotes cell survival by phosphorylating and inactivating 
FKHRLI (Brunet et al., 1999; Tang et al., 1999; Tang et al., 2002). AFX, another 
forkhead transctiption factor family member, is also a target of Akt/PKB phosphorylation 
(Kops and Burgering, 1999). AFX has been shown to mediate cell cycle arrest by 
transcriptionally inactivationg the cyclin-dependent kinase inhibitor p27 K'P I (Medema et 
al., 2000). PTEN, by controlling the levels of active Akt in a cell, could thus regulate both 
cell cycle arrest and apoptosis (Figure 1.16). Indeed, reintroduction of PTEN into PTEN- 
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null cells induces the nuclear localisation and transcriptional activity of FKHR, and 
expression of a Forkhead protein, modified so that it cannot be phosphorylated by Akt, is 
able to trigger cell cycle arrest and apoptosis to an extent similar to overexpression of 
PTEN (Nakamura et al., 2000). 
1.4.4.4 Additional roles for the lipid phosphatase activity of PTEN 
Studies in Drosophila and C elegans have placed PTEN in the insulin signaling 
pathway (Figure 1.17). During Drosophila development, activation of DAkt1 by insulin 
and Dp I 10, the PI 3 -kinase orthologue, causes cell growth. This process is antagonized 
by OTEN, since overexpression of OTEN suppresses the growth-promoting phenotype 
of cells overexpressing DpllO (Goberdhan et al., 1999). The recent characterization of 
ch ico, the Drosophila orthologue of IRS 1-4 showed that ch ico, Dp 110 and the insulin 
receptor Inr are all positive regulators in the insulin signaling pathway controlling cell 
growth and proliferation (Figure 1.17). Removal of chico from cells in the eye generated 
a phenotype opposite to that seen for PTEN4- cells, whereas removal of chico in PTEN4- 
cells resulted in a PTEN phenotype, suggesting that PTEN acts to antagonize chico and 
thus confirmed PTEN's role as a negative regulator of the insulin pathway. 
Overexpression of Inr in the eye induces overproliferation and results in lethality. 
Cooverexpression of OTEN, however, completely rescued lethality and the 
overproliferation phenotype (Huang et al., 1999). C elegans studies revealed that DAF- 
18 (the C elegans PTEN homologue) acts as a negative regulator of the DAF-2 (insulin) 
and AGE-I (PI 3-kinase) signaling pathways (Ogg and Ruvkun, 1998; Rouault et al., 
1999). DAF-2 and AGE-I are key regulators of lifespan and dauer formation (a state of 
hibernation in unfavourable growth conditions) in C elegans (Gil et al., 1999). Deletion 
of the daf-2 or age-] genes induces dauer formation and dramatically increases lifespan. 
Deletion of daf-18, however, completely suppresses the daf-2 or age-] phenotype 
(Mihaylova et al., 1999; Paradis et al., 1999). 
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PTEN's role in the insulin pathway is evolutionarily conserved. In mammals, the insulin 
pathway regulates growth and apoptosis through the activation of Akt, which activates mTOR 
to promote growth, and inhibits mediators of apoptosis, like Bad and FKHR. In Drosophila, 
the insulin pathway controls growth and cell proliferation through the activation of chico and 
dAkt. In C. elegans, the insulin pathway homologues Daf-2 and Age-I regulate longevity and 
dauer formation. They activate Akt that normally antagonizes the function of Daf-16, a 
forkhead transcription factor. In mammals, Drosophila and C. elegans, PTEN acts as 
negative regulator of the insulin signaling pathway. 
Mammalian studies have reinforced the role of PTEN in the insulin pathway (Figure 
1.17). IRS-1, IRS-2, IRS-3 and IRS-4 are cellular insulin signaling substrates that become 
phosphorylated when insulin binds to its receptor (Figure 1.17). Upon tyrosine 
phosphorylation, these proteins can bind substrates that contain Src homology 2 domains, 
including PI 3-kinase. Upon activation, PI 3-kinase increases the levels of PI(3,4,5)P3 in 
the cell and activates Akt that induces the translocation of the membrane transporter 
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GLUT4 to the plasma membrane and results in higher glucose uptake. Expression of 
PTEN in 3T3-LI adipocytes inhibited the insulin-stimulated production of 2- 
deoxyglucose and translocation of GLUT-4 (Nakashima et al., 2000). However, 
expression of PTEN in PTEYý" breast cancer cells caused upregulation of IRS-2, 
suggesting that PTEN can elicit a positive feedback loop of PI 3-kinase signaling 
(Simpson et al., 2001). 
PTEN's established role as a PI 3-kinase antagonist led to studies examining the role 
of PTEN during angiogenesis, since insulin, hypoxia and IGF-1 induce expression of 
several angiogenic genes, which may be regulated by the PI 3-kinase/Akt pathway. In 
glioblastoma cell lines that lack PTEN, reintroduction of PTEN significantly reduced 
hypoxia and IGF-l- dependent induction of HIF-l-regulated genes, such as the vascular 
endothelial growth factor (VEGF). HIF-1-dependent gene transcription is ablated by 
expression of dominant negative Akt or PI 3-kinase, and by wild type PTEN (Zhong et 
al., 2000). Akt activation leads to the stabilization of HIF-1, which in turn leads to the 
upregulation of VEGF. In contrast, PTEN suppresses the hypoxia-induced stabilization of 
HIF-1 and decreases VEGF mRNA expression and VEGF promoter activity (Pore et al., 
2003; Zundel et al., 2000). Thus, loss of PTEN in advanced tumours, such as 
glioblastomas, may contribute to the progression of the turnour to a more malignant 
phenotype through the upregulation of HIF-1 gene expression and the induction of 
angiogenesis. 
When PTEN's effect on the regulation of Akt was examined in cells of the immune 
system, it was shown that it regulates proliferation and activation of T cells, and also 
plays a role in FCy-receptor phagocytosis. PTEN expression in Jurkat T cells induced 
apoptosis. This effect could be rescued by coexpression of a membrane-bound 
constitutively active form of Akt. Similar to the effects seen by inhibiting PI 3-kinase, 
PTEN expression decreased TCR-activation of the extracellular signal-related kinase 2 
(ERK2) (Wang et al., 2000). The T-cell specific PH-domain containing kinase Itk is 
found constitutively associated with the plasma membrane. PTEN expression, however, 
resulted in the redistribution of Itk to the cytosol. In addition, PTEN null cells were found 
to be hyper-responsive to TCR stimulation as they displayed an increased Itk activation 
and phosphorylation of phospholipoase C-y, as well as an increased activation of ERK 
(Shan et al., 2000). Finally, a study by Kim et al., showed that expression of PTEN 
completely abrogates phagocytosis of IgG-sensitized red blood cells, and this is 
dependent on PTEN's lipid phosphatase activity (Kim et al., 2002). These studies indicate 
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that PTEN, in addition to regulating the insulin pasthway and angiogeneses, plays an 
important role in phagocytosis and in TCR signaling in T cells. 
1.4.5 A role for PTEN in cell spreading, migration and invasion 
1.4.5.1 PTEN and cell spreading 
PTEN's role as a tumour suppressor is thought to be due to its ability to act as a lipid 
phosphatase and dephosphorylate PI(3,4,5)P3 and thus antagonize the PI 3-kinase 
signaling pathway. PTEN, however, has also been shown, at least in vitro, to 
dephosphorylate protein substrates, and this may also contribute to PTEN's tumour 
suppressor role (Myers et al., 1997). Indeed, several groups have made use of two 
naturally occurring mutants of PTEN isolated from turnours, to show that PTEN's protein 
phosphatase activity contributes to a role for PTEN in cell spreading, migration and 
tumour invasion. Tamura et al., showed that restoring PTEN expression in PTEN-" 
fibroblasts or glioma cells delays or inhibits integrin-dependent spreading of these cells. 
This effect seems to be associated with a downregulation in the phosphorylation of the 
integrin-signaling molecules, focal adhesion kinase (FAK), pl30Cas and Shc (Tamura et 
al., 1998). Using a mutant of PTEN (G129E) that was inactive in its ability to 
dephosphorylate lipid substrates but still retained activity towards protein substrates and a 
mutant of PTEN (C124S) that displayed no catalytic activity towards lipid or protein 
substrates, they showed that the effects on cell spreading were dependent on protein 
phosphatase activity, perhaps acting through FAK, pl30Cas or Shc. In support of this, 
PTEN directly interacts with and reduces adhesion-dependent tyrosine phosphorylation of 
FAK (Haier and Nicolson, 2002; Tamura et al., 1998). 
Further investigation by Gu et al., led to the finding that PTEN can downregulate Shc 
phosphorylation, which inhibits the recruitment of the Grb2/Sos complex, and 
downregulates the EGF-stimulated activation of the MAPK pathway (Gu et al., 1999). 
This group proposed two pathways by which ITEN might lead to the inhibition of cell 
spreading and growth, both dependent on PTEN's protein phosphatase activity. In the 
first pathway, PTEN downregulates integrin-mediated activation of FAK and Shc and 
thus inhibits Ras activation and the formation of focal contacts. Dephosphorylation of 
FAK by PTEN, however does not seem to be universal since it was shown that the 
phosphorylation status of FAK in PTEN"- ES cells is not higher than that in PTEN"' ES 
cells (Sun et al., 1999). The second pathway involves the inhibition of EGF or PDGF- 
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stimulated Shc phosphorylation and recruitment of the Grb2/Sos complex by PTEN, 
which in turn inhibits activation of Ras and the MAPK signaling pathway. It is likely, 
however, that the lipid phosphatase activity of PTEN also plays a role in the inhibition of 
the MAPK pathway since PTEN, by downmodulating the levels of cellular PI(3,4,5)P3 
can inhibit the translocation of Gabl to the plasma membrane. Gabl is an adaptor 
molecule that has been shown to move to the plasma membrane through the binding of 
PI(3,4,5)P3 on its pleckstrin homology domain (PH), recruit Ras, and hence activate the 
MAPK pathway (Liu and Rohrschneider, 2002). 
1.4.5.2 PTEN and cell migration 
Several studies have reported an important role for PTEN in cell migration particularly 
neuronal and glial cell migration (Marino et al., 2002). Furthermore, reexpression of 
PTEN in PTEN-deficient fibroblast or human glioma cells significantly inhibits their 
ability to migrate in an in vitro wound-healing assay, while inactivation of PTEN by 
expression of antisense enhances fibroblast cell migration (Tamura et al., 1998). It seems, 
however, that PTEN can potentially control cell migration through different mechanisms. 
In PTEN"- fibroblasts, neither the C124S or G129E mutants could reduce cell motility, 
suggesting that migration is affected through lipid phosphatase activity. This effect of 
PTEN seemed to depend on the downregulation of the GTPases Rac and Cdc42, as 
PTEN4- cells were found to have increased levels of active Rac and Cdc42 compared to 
PTEN+'+ cells (Figure 1.18) (Liliental et al., 2000). Interestingly, it has been reported that 
Rac and Cdc42 can activate Akt and colocalise with Akt at the leading edge of fibroblasts 
(Higuchi et al., 2001). Expression of a constitutively active form of Akt increased cell 
motility of fibroblasts, whereas a dominant negative form suppressed cell motility 
mediated by active Rac and Cdc42. Finally, dominant negative Akt was shown to reduce 
the enhanced cell motility of PTEN4' mouse embryonic fibroblasts (Higuchi et al., 200 1). 
Thus, it seems that PTEN can also regulate cell motility by downinodulating the levels of 
cellular phospho-Akt. 
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PTEN controls cell spreading and migration. PTEN directly dephosphorylates and inactivates 
FAK and Shc, key mediators of cell spreading and migration. By clowntrodulating PI(3,4,5)P3 
levels, PTEN also inhibits activation of Rac and Cdc42 by PKB and blocks recruitment of 
Gab I to the plasma membrane, where it can activate Ras. 
Another mechanism by which PTEN may be regulating cell migration is by regulating 
the phospho-tyrosine activation of FAK, Shc and p1 30Cas (Figure 1.18) (Tamura et aL, 
1999). Work by Gu et al., proposes a mechanism by which PTEN can inhibit both a 
pathway regulating random cell migration promoted by Shc, MEK and ERK MAP kinase 
signaling, and a pathway regulating a more persistent, directed cell motility, which 
depends on FAK and P1 30Cas and involves extensive cytoskeletal rearrangements and an 
increase in focal adhesions (Gu et al., 1999). 
1.4.5.3 PTEN and cell invasion 
Importantly, PTEN also exerts its tumour suppressor function by regulating cell 
invasion. Interestingly, the protein phosphatase activity of PTEN was shown to be 
required for inhibition of cell invasion of glioblastoma cells, as measured by in vitro 
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invasion assays across a membrane filter barrier (Park et al., 2002; Tamura et al., 1999). 
This effect of PTEN was found to correlate with a decrease in the phosphorylation state 
of FAK and pl30Cas and coexpression of FAK or pl30Cas with PTEN rescued the 
PTEN inhibition on cell invasion and migration (Tamura et al., 1999). Recently, a study 
by Park et al., showed that a mechanism by which PTEN inhibits cell invasion is through 
the downregulation of matrix metalloproteinases (MMPs). Expression of PTEN in PTEN- 
deficient glioma cells significantly reduced the hyaluronic acid-induced secretion of 
MMP-9 and MMP-2 and inhibited invasion, and this correlated with a reduction in FAK 
phosphorylation and was dependent on a functional protein-phosphatase activity of PTEN 
(Koul et al., 2001a; Park et al., 2002). Conflicting studies, however, showed that even 
though PTEN could rescue invasion of the same glioblastoma cells, this was independent 
of its catalytic activity, since the phosphatase-inactive mutant of PTEN (C124S) could 
also inhibit invasion (Maier et al., 1999). Moreover, this group did not observe a decrease 
in the level of FAK phosphorylation when PTEN was reintroduced into the glioblastoma, 
cells. Finally, another mechanism by which PTEN may regulate cell invasion was 
proposed recently, which involves the stabilization of intercellular junctions. Kotelevets 
et al., showed that expression of PTEN in Src-transformed MDCK cells reverts the 
morphological transformation of these cells, forces them to aggregate and inhibits cell 
scattering. PTEN inhibits the invasive phenotype of these cells in an E-cadherin, lipid- 
phosphatase activity-dependent manner (Kotelevets et al., 200 1). 
1.4.6 Linking structure to function 
PTEN contains a signature motif HCY. XGY-XR present in the active site of dual 
specificity and protein tyrosine phosphatases, but aside from this motif, has little 
sequence homology to these phosphatases. Instead, its amino terminal half was shown to 
have some similarity to tensin and auxillin. Nevertheless, PTEN was shown to exhibit 
phosphatase activity in vitro against highly acidic phospho-tyrosine, phospho-serine and 
phospho-threonine containing peptide substrates (Myers et al., 1997). As a result of 
PTEN needing acidic substrates, Maehama and Dixon were prompted to test 
phospholipids as potential substrates and found that the protein could dephosphorylate 
phosphoinositol substrates at the D3 position both in vitro and in cells (Maehama and 
Dixon, 1998; Maehama and Dixon, 1999). This was later confirmed by Myers et al., who 
linked the ability of PTEN to act on phospholipids with its turnour suppressor function 
(Myers et al., 1998). 
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Little was known about the carboxy-ten-ninal half of PTEN until the crystal structure 
was solved in 1999 (Lee et al., 1999) (Figure 1.19). This revealed that PTEN contained a 
170 amino acid C2 domain. C2 domains are independently folding structural modules of 
about 130 residues, believed to serve a membrane-targeting role (Murray and Honig, 
2002; Rizo and Sudhof, 1998). They were first identified in protein kinase C, hence the 
name C2 for PKC conserved-2, and were shown to bind Ca 2- and pbosphollpids. Most 
C2 domains identified belong to proteins involved in signal transduction (e. g., cytosolic 
phospholipase A, (cPLA-, ), phospholipase C (PLC), protein kinase C (PKC), and PI 3- 
kinase) or in vesicle trafficking (e. g., synaptotagmin and rabphilin-3). C2 domains share 
little sequence identity, which may explain their functional diversity. They primarily bind 
membranes in a Ca 2--dependent way (e. g., PLC, PI 3-kinase), although there are many C2 
domains that bind membranes in a Ca 2--independent way (e. g., PKC6, E) or are involved 
in protein-protein interactions (e. g., synaptotagmin) (Rizo and Sudhof, 1998). 
FIGURE 1.19 
Crystal structure of PTEN. Reproduced from Lee et a]., 1999. PTEN is composed of an N- 
terminal catalytic domain and a C-terminal C2 domain. The first 6 residues and the last 50 
residues are missing from the crystal structure. 
66 
Image removed due to third party copyright
1. INTROOUCTION 
The C2 domain of PTEN is a Ca 2 '-Independent domain that binds phospholipids in 
vitro, initially thought to function as a membrane-targeting domain for PTEN (Lee et al., 
1999) but in fact, it seems that the catalytic domain of PTEN is more directly involved 
with membrane binding. The C2 domain is most likely required for a higher affinity 
interaction with the plasma membrane, possibly to stabilize PTEN and to productively 
position the catalytic domain (Das et al., 2003; Georgescu et al., 2000). A variety of 
human turnours have been described with mutations that map to the C2 domain or C- 
terminus of PTEN and these either completely or partially abrogate PTEN's ability to 
dephosphorylate inositol-1,3,4,5-tetraphosphate in vitro, or have no effect on its catalytic 
activity (Table 1.2) (Waite and Eng, 2002). Since there are several missense mutations 
that do not directly target PTEN's phosphatase activity, although they might affect it, this 
suggests that PTEN's tumour suppressor function is not always dependent on its ability to 
reduce the levels of cellular PI(3,4,5)P3. 
Mutation Phosphatase activity 
S227F 20% 
G251C <5% 
K289E 60% 
D331G 30% 
F341V <5% 
K342N 50% 
V343E <5% 
L345Q <5% 
F347L 10% 
V369G 90% 
T4011 130% 
TABLE 1.2 
PTEN mutations that map to the C2 domain. Adapted from Han et al., 2000. Phosphatase 
activity of PTEN measured against Ins(1,3,4,5)P4 and results were normalized to wild type 
PTEN (100%). 
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In addition to the C2 domain, PTEN contains a PDZ binding motif at its extreme C- 
terminus. PDZ-binding motifs are short consensus sequence motifs (ITKV) present at 
carboxy termini of proteins. They bind to PDZ-domains, so named for first being 
identified in the junctional proteins PSD-95, DLG and ZO- I (Hung and Sheng, 2002). 
Yeast-two hybrid studies isolated several potential PTEN binding partners that mapped to 
the PDZ binding motif of PTEN. These include MAGI-2 (membrane associated guanylate 
kinase inverted-2) and hDLG (human Disc-large), which belong to the membrane- 
associated guanylate kinase (MAGUK) family of proteins, and MAST205 (microtubule- 
associated serine-threonine kinase) (Adey et al., 2000; Wu et al., 2000a; Wu et al., 
2000b). MAGI-2 is the only protein so far to have been shown to interact with 
endogenous PTEN. MAGI-2 enhances PITEN's ability to suppress phospho-Akt levels in 
a cell, whereas deletion of the PDZ binding motif from PTEN, reduces its ability to do so 
(Wu et al., 2000a). On the contrary, deleting the PDZ binding motif, by introducing a stop 
codon, did not abrogate PTEN's ability to act as a lipid phosphatase and lower the levels 
of cellular phospho-Akt and FKHRL1, nor did it reduce its ability to inhibit anchorage- 
independent cell growth (Koul et al., 2002; Leslie et al., 2000). It did, however, abolish 
PTEN's ability to inhibit PDGF-stimulated ruffling of fibroblasts (Leslie et al., 2000). 
Interestingly, Drosophila and C elegans PTEN does not contain a PDZ binding motif but 
this sequence is highly conserved among the mammalian orthologues. It is likely that 
PTEN has evolved to control additional signaling pathways that might or might not 
include PI(3,4,5)P3 regulation. In several proteins, it has been suggested that 
phosphorylation of a threonine or serine residue in the PDZ binding motif, regulates its 
association with PDZ domain-containing proteins. It was shown, with the use of peptides, 
that phosphorylation of Thr401 in the carboxy terminus of PTEN regulates its interaction 
with PDZ domain proteins (Adey et al., 2000). Phosphorylation of PTEN on Thr4O I, 
however, has not yet been reported. A variety of human turnours have been identified that 
contain missense mutations in the PDZ binding sequence, including Thr401, and it is 
therefore likely that the PDZ motif enhances PTEN activity, possibly by more efflcient 
targeting through the binding of PDZ domain proteins. Recently, a PI(4,5)P2 binding 
motif was also identified at the extreme N-terminus of PTEN. Studies in Dictyostelium 
showed that it was important for PTEN localisation to the membrane during cell 
chernotaxis (Iijima and Devreotes, 2002; Iijima et al., 2002). 
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FIGURE 1.20 
Schematic representation of the PTEN protein structure. In addition to a catalytic domain and 
a C2 domain, PTEN contains a PDZ binding motif at its extreme C-ten-ninus and a PI(4,5)P, 
binding motif at its extreme N-terminus. Both these motifs are thought to have a targeting 
role. 
1.4.7 Regulation of PTEN 
1.4.7.1 Phosphorylation 
PTEN is extensively phosphorylated on a cluster of five residues (three serine and two 
threonine residues) in its carboxy tenTimal tail, after the C2 domain (Figure 1.21) (Birle et 
al., 2002; Tolkacheva et al., 2001; Torres and Pulido, 2001; Vazquez et al., 2000). 
Radiolabelling experiments of overexpressed or endogenous PTEN with [32p] in cells 
have revealed that PTEN becomes phosphorylated on both serine and threonine residues. 
Although the extent of phosphorylation of PTEN at individual residues is not yet clear, it 
appears that PTEN is constitutively phosphorylated in cells. The kinase responsible for 
phosphorylating each site is unknown, although there has been some in vitro evidence to 
suggest that CK2 phosphorylates PTEN on at least two of the five sites (Torres and 
Pulido, 2001; Vazquez et al., 2000). 
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FIGURE 1.21 
PTEN is extensively phosphorylated on its carboxy terminus. PTEN is primarily 
phosphorylated on residues S370, S380, T382, T383 and S385. Some of these residues are 
substrates for casein kinase 2 (CK2). When phosphorylated, PTEN is inactive, as measured by 
its ability to dephosphorylate phospholipids. 
Mutational and deletional analysis has shown that phosphorylation regulates PTEN 
activity and stability. Mutation of the phosphorylation sites to alanine residues or deletion 
of the last 50 residues of PTEN seems to make the protein more unstable and prone to 
degradation, possibly through a proteasome-dependent mechanism (Birle et aL, 2002; 
Tolkacheva et al., 2001; Torres and Pulido, 2001; Vazquez et al., 2000). This agrees with 
early studies showing that PTEN contains two PEST sequences, which have been known 
to target proteins for proteolytic degradation, and with studies showing that C-tenninally 
truncated PTEN mutants have reduced expression levels compared to full-length PTEN 
(Georgescu et al., 1999). On the other hand, substitution of the phosphorylation sites to 
aspartic or glutamic acid residues (to mimic phosphorylation), reduced phosphatase 
activity as measured by their ability to induce GI arrest and transcription of FKHR, but 
had a higher half-life compared to the wild type protein (Tolkacheva et al., 2001; 
Vazquez et al., 2000). 
Phosphorylation, therefore, seems to stabilize PTEN in an inactive conformation, 
whereas dephosphorylation activates it. To date the phosphatase responsible for 
dephosphorylating PTEN remains unknown and until recently, there was no data to 
suggest any conditions under which the phosphorylation levels of endogenous PTEN 
would be regulated. Studies by Birle et al., however, have shown that, following 
polyclonal activation of human blood T lymphocytes, PTEN expression increases and 
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PTEN becomes phosphorylated on at least one residue. In addition, [ 32p] metabolic 
labeling data suggest that PTEN phosphorylation is positively regulated by increasing 
amounts of cellular PI(3,4,5)P3, as treatment with wortmannin reduced PTEN 
phosphorylation, whereas transfection of an active form of Akt/PKB (myrPKB) increased 
phosphorylation of PTEN (Birle et al., 2002). It is likely, therefore, that PTEN regulates 
its own phosphorylation by decreasing the levels of PI(3,4,5)P3 in a cell and inactivating 
the kinase, or one of the kinases, responsible for phosphorylating it. 
1.4.7.2 Localisation 
PTEN predominantly localises to the cytosol. Since PTEN has been shown to 
dephosphorylate PI(3,4,5)P3 levels at the plasma membrane, it must somehow translocate 
to the site of PI(3,4,5)P3 production, in response to stimuli . Recent studies 
by Das et al., 
using a PTEN mutant that lacks the last 52 amino acids fused to green fluorescent protein 
(GFP), demonstrated that PTEN relocalises to the plasma membrane and that 
phosphorylation of the PTEN tail seems to negatively regulate membrane association 
(Das et al., 2003). In addition, in Dictyostelium, expression of GFP-PTEN has been 
shown to localise uniformly on the plasma membrane and relocalise in response to cell 
chernotaxis (Funamoto et al., 2002). Changes in the subcellular localisation of PTEN 
have also been identified in several human turnours. In normal follicular thyroid cells, 
PTEN is mostly found in the nucleus, whereas in thyroid carcinomas, PTEN cytoplasmic 
staining was stronger than nuclear staining (Gimm et al., 2000b). Similarly, in normal 
pancreatic islets, PTEN is predominantly nuclear, but in 19 of 23 endocrine pancreatic 
tumours, it was shown to relocalise to the cytoplasm (Perren et al., 2000). 
Immunohistochernical studies have demonstrated that PTEN localisation varies among 
tissues. In neurons, fibroblasts and cells of the thyroid and adrenal medulla, PTEN is 
predominantly in the nucleus, whereas in epithelial cells of the skin, colon, prostate and 
breast, most of PTEN is cytoplasmic. It is not yet clear what controls the subcellular 
distribution of PTEN. Work by Ginn-Pease and Eng in breast cancer cells showed that the 
level of PTEN in the nucleus varies with the cell cycle. An increased accumulation of 
PTEN was found associated with the GO-G, phase, which was significantly reduced in S 
phase (Ginn-Pease and Eng, 2003). PTEN does not contain any nuclear localisation 
signals and the mechanism of PTEN accumulation in the nucleus is unknown. 
Localisation of PTEN in the cytoplasm or the plasma membrane may, however, be 
regulated by its C-terminus. In polarised MDCK cells, PTEN was shown to localise at 
71 
1. INTRODUCTION 
tight junctions, possibly through the binding of the protein MAGI-2 through its PDZ 
binding motif (Wu et al., 2000a). Whether the specific cellular distribution of PTEN 
closely correlates with its differing roles as a turnour suppressor, remains to be seen. 
1.4.7.3 Expression 
Although the study of PTEN function has been intense since its discovery in 1997, 
little is known about the regulation of its expression. PTEN is a ubiquitously expressed 
gene but its expression pattern varies during development (Gimm et al., 2000a). It has 
been proposed that one of the causes of PTEN inactivation is promoter methylation and 
the timing in loss of I'TEN expression might correlate with the frequency in the 
occurrence of certain carcinomas (Baeza et al., 2003; Podsypanina et al., 1999). PTEN 
has been linked to suppression of tumour growth and loss of PTEN in ES cells results in 
the gain-of-function for anchorage-independent growth (Di Cristofano et al., 1998). In 
human glioma and breast cancer cells, expression of PTEN leads to anoikis (cell death 
due to loss of adhesion) and recently it was shown that loss of cell-matrix interactions 
increased the expression levels of endogenous FITEN (Koul et al., 2001a; Lu et al., 1999; 
Tamura et al., 1999; Wu et al., 2002). 
Three groups have recently identified key regulators of PTEN transcriptional 
activation. Virolle et al., demonstrated that PTEN and Eg-I (early growth response-1) 
transcription factor expression are upregulated during ultraviolet irradiation. Egr-I 
directly binds and transactivates expression of the PTEN gene in response to irradiation or 
etoposide treatment, both in vitro and in vivo and is required for PTEN-induced apoptosis 
(Virolle et al., 2001). Mouse embryonic fibroblasts (MEFs) that have either null for 
PTEN or Egr-1 are resistance to radiation-stimulated apoptosis. Reintroduction of Egr-1 
into egr-1-1- MEFs restored PTEN mRNA transcription and abolished resistance to 
apoptosis (Virolle et al., 200 1). 
PPARy (peroxisome proliferator-activator receptor 7), is a turnour suppressor gene 
involved in the regulation of cell growth and proliferation and in anti-inflammatory 
responses (Kersten et al., 2000; Sarraf et al., 1999). Activation of PPARy was shown to 
lead to upregulation in PTEN expression in macrophages, colorectal cancer cells (Caco2) 
and in breast cancer cells (MCF7). Similarly to Egr-1, PPARy can directly bind to a 
genomic sequence upstream of the PTEN promoter and thus activate PTEN transcription. 
Conversely, disruption of PPARy-mediated PTEN expression using an antisense 
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oligonucleotide, reduced the extent of monocyte differentiation into macrophages and 
decreased the number of macrophages undergoing apoptosis (Patel et al., 2001). 
Finally, Stambolic et al., have shown that the tumour suppressor p53 is also 
responsible, at least in part, in activating PTEN transcription during cell death. p53 
directly induces the transactivation of the PTEN gene and, in turn, PTEN expression is 
required to mediate p53-dependent apoptosis, possibly by shutting down the cell survival 
machinery (Stambolic et al., 2001). The same group, in addition to identifying the p53 
DNA binding sequence, uncovered a positive regulatory element upstream of the PTEN 
promoter that drives constitutive activation of the PTEN gene. Very recently, Freeman et 
al., showed that PTEN also regulates transcription of p53, suggesting that there exists a 
positive feedback loop between these two very important tumour suppressors (Freeman et 
al., 2003). 
1.5 Conclusions 
It is clear that PTEN controls many critical cellular functions and therefore merits the 
attention it has had so far. Significant advances have been made in delineating the PTEN 
signaling pathways both as a lipid and a protein phosphatase. Several pressing questions, 
however, still remain. For example, how are the lipid and protein phosphatase activities 
regulated and under which conditions, if any, does PTEN act as a protein phosphatase in 
vivo? Regulation of PTEN through phosphorylation is a compeling possibility, but little is 
known about the extent of PTEN phosphorylation in vivo, and although CK2 has been 
proposed as the kinase, no antagonizing phosphatase has been discovered so far. Even 
though the basic concepts of PTEN structure and function have been established, it is not 
entirely clear what the role of the C2 domain is. In addition, mammalian PTEN contains a 
PDZ binding motif that has been shown to bind to several PDZ-domain containing 
proteins, but the significance of this is not known. 
This thesis addresses PTEN's function in glioma cell migration and spreading and 
identifies a new role for its C2 domain. 
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Material and Methods 
2.1 Molecular Biology 
2.1.1 Polymerase chain reactions 
PCR reactions were carried out in a reaction volume of 100ýd with 100ng of DNA 
template, 50pmol of each primer, lOmM dNTPs and with Iýd of High fidelity PCR 
reaction system (3.5U/gI, ROCHE), in the provided Mg+- containing buffer. Cycling 
conditions were as follows: I cycle at 94'C for 3 min, followed by 30 cycles at [94'C for 
1 min, 52'C for 2 min and 72'C for 3 min] and I cycle at 721C for 10 min. All primers 
were ordered from MWG-Biotech, unless otherwise indicated. 
2.1.2 DNA constructs 
cDNA constructs used in this study are described in table 2.1. Where necessary, 
constructs were verified by sequencing (CYTOMYX). 
Plasmids Characteristics and Source 
pRK5myc:: N17Rac Encodes for dominant negative Rac, Hall lab. 
pRK5myc:: L61Rac Encodes for constitutively active Rac, Hall lab. 
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pRK5myc:: N I 7Cdc42 Encodes for dominant negative Cdc42, Hall lab. 
pRK5myc:: L6ICdc42 Encodes for constitutively active Cdc42, Hall lab. 
pCGN-HA:: PTENwi Encodes for full-length wt PTEN, a gift from N. Tonks (Myers et al., 
PNAS 1998). 
pCGN-H A:: PTEN (C I 24S) Encodes for full-length PTEN (C I 24S), a gift from N. Tonks (Myers et 
al., PNAS 1998). 
pCGN-HA:: PTEN (G129E) Encodes for full-length PTEN (G129E), a gift from N. Tonks (Myers et 
al., PNAS 1998) 
pRK5myc:: PTENwt Encodes for full-length wt PTEN. Made by PCR and subcloned as a 
BamHl/EcoRl fragment into pRK5myc. Template: pCGN- 
HA:: PTENwt 
Primer 1: 5'GCAGGA'I'('('ACAGCCATCATCAAAGAGATC 3' 
Primer 2: 5' GCCGAATI'('TCAGACTMGTAATTTGTG 3' 
pRK5myc:: PTEN (C I 24S) Encodes for full-length PTEN, with a point mutation in the catalytic 
domain at C124. Made by PCR and subcloned as a BamHl/EcoRI 
fragment into pRK5myc. Template: pCGN-HA:: PTEN (C124S) 
Primer 1: 5'GCAGGA"I'('('ACAGCCATCATCAAAGAGATC 3' 
'AA-1"1'('TCAGACTMGTAAMGTG 3' Primer 2: 5' GCCG 
pR K5 myc:: PTEN (G 129 E) Encodes for full-length PTEN, with a point mutation in the catalytic 
domain at G129. Made by PCR and subcloned as a BamHl/EcoRl 
fragment into pRK5myc. Template: pCGN-HA:: PTEN (G I 29E) 
Primer 1: 5'GCA(jCiA'I'('('ACAGCCATCATCAAAGAGATC 3' 
Primer 2: 5' GCCG A A'l "f"('TCAGACTTTTGTAAT-FTGTG 3' 
pRK5 flag:: PTENAC Encodes for the N-terminal domain of PTEN (residues 1- 179). Made 
by PCR and subcloned as a BamHI/EcoRl fragment into pRK5fIag. 
Primer 1: 5'GCAGGA'I'('('ACAGCCATCATCAAAGAGATC 3' 
Primer 2: 5'GCGAATT('TCAGCTATAATAATACACATAGCG 3' 
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pRK5 flag:: PTENAN Encodes for the C-terminus of PTEN lacking the PI(4,5)P2 binding 
motif (residues 86-403). Made by PCR and subcloned as a 
BamHI/EcoRl fragment into pRK5fIag. 
Primer 1: 5'GCA(-iCiA'I'('('GCACAATATCCTTTTGAAGAC 3' 
Primer 2: 5' GCCGAATTCTCAGACTTTTGTAAMGTG 3' 
pRK5myc:: PTENACAT Encodes for the C-terminal domain of PTEN (residues 179-403). Made 
by PCR and subcloned as a BamHI/EcoRl fragment into pRK5myc. 
Primer 1: 5'GCGGGA I ('('AGCTACCTGTTAAAGAATCAT 3' 
Primer 2: 5' GCCGAATTCTCAGACT=GTAATTTGTG 3' 
pRK5myc:: PTENAPDZBM Encodes for full-length wt PTEN lacking the PDZ binding motif 
(residues 1- 394). Made by PCR and subcloned as a BamIlI/EcoRI 
fragment into pRK5myc. 
Primer 1: 5'GCAGGAT('CACAGCCATCATCAAAGAGATC 3' 
Primer 2: 5'GCGAAT'l'('TCATTCATCAAA 3' 
pRK5myc:: PTENATAIL Encodes for full-length wt PTEN lacking the last 50 amino acids 
(residues 1- 354). Made by PCR and subcloned as a BamF[I/EcoRI 
fragment into pRK5myc. 
Primer 1: 5'GCAGGAT('('ACAGCCATCATCAAAGAGATC 3' 
Primer 2: 5' GCG AAT'I'('TCATGACGGCTC 3' 
pRK5myc:: PTENACATA Encodes for PTENACAT minus the PDZ binding motif (residues 179- 
PDZBM 394). Made by PCR and subcloned as a BamF[FEcoRl fragment into 
pRK5myc. 
Primer 1: 5'GCG(jCiAT('C'AGCTACCTGTTAAAGAATCAT 3' 
Primer 2: 5' GCG AATTCTCATIFCATCAAA 3' 
pRK5myc:: PTEN-C2 Encodes for the C2 domain of PTEN (residues 179 - 353). Made by 
PCR and subcloned as a Ban-tHI/EcoRl fragment into pRK5myc. 
Primer 1: 5'GCG(J(iA'I'('('AGCTACCTGTTAAAGAATCAT 3' 
Primer 2: 5' GCGAAT'F('TCATGACGGCTC 3' 
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pRK5myc:: Syt-C2A Encodes for the C2A domain of Synaptotagmin (a gift from Dr. Dan 
Cutler) (residues 80-182). Made by PCR and subcloned as a 
BamHI/EcoRl fragment into pRK5myc. Primers were purchased from 
SIGMA Genosys. 
Primer 1: 5'GC(IGATC'CCTGGATTATGATTTCCAGAATAAC 3' 
Primer 2: 5'GC(JAATTCTCACTCT-FCCTTCTCTGCACTTT 
GCAG 3' 
PRK5myc:: Syt-C2B Encodes for the C213 domain of Synaptotagmin (a gift from Dr. Dan 
Cutler) (residues 211-325). Made by PCR and subcloned as a 
BamHI/EcoRI fragment into pRK5myc. 
Primer 1: 5'GC(jGA']'('C'CTTCGCTATGTACCTACTGCTGGC 3' 
Primer 2: 5'GCGAATTCTCACTCCTCTACCTGCAGGGTGT 
GCCA 3' 
pRK5 flag:: PTEN (C I 24S)AC Encodes for PTENAC with a point mutation in the catalytic domain at 
C124 (residues 1- 179). Made by PCR and subcloned as a 
BamHI/EcoRI fragment into pRK5flag. 
Primer 1: 5'GCAGGA'I'('('ACAGCCATCATCAAAGAGATC 3' 
Primer 2: 5'GCGAA'F'I'('TCAGCTATAATAATACACATAGCG 3' 
pRK5flag:: PTEN (C I 24S)- Encodes for the active site of PTEN with a point mutation at C124 
(86-147) 
(residues 86 - 147). Made by PCR and subcloned as a BamHI/EcoRI 
fragment into pRK5flag. 
Primer 1: 5'GCAGGA'I-CC'GCACAATATCCTTTTGAAGAC 3' 
Primer 2: 5'GCG(iAA'I"F('TCACMAAAAATTTGCCCCGATG 3' 
pRK5myc:: PTEN (C124S)- Encodes for PTEN (C124S) with point mutations at S380, T382, T383, 
A4 
S385 to alanine residues. Made by PCR and subcloned as a 
Bam1II/EcoRI fragment into pRK5myc. 
Primer 1: 5'GCA(](-iA'I'('('ACAGCCATCATCAAAGAGATC 3' 
Primer 2: 5'GCG AAI'T('TCAGACTTTTGTAATTTGTGTATGCTG 
ATCTTCATCAAAAGGTTCAT-FCTCTGGATCAGCGTCAGCG(i('(i 
TCAGCATATCTATAATG3' 
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pRK5myc:: PTEN (C124S)- Encodes for PTEN (C124S) with a point mutation at S380 to an alanine 
S380A 
residue. Made by PCR and subcloned as a BamHI/EcoRl fragment into 
pRK5myc. 
Primer 1: 5'GCAGGA'FCCACAGCCATCATCAAAGAGATC 3' 
Primer 2: 5'GCG AAT'F('TCAGACTTTTGTAATTTGTGTATGCTG 
ATCTTCATCAAAAGGTTCATTCTCTGGATCAGAGTCAGTGGTG 
TCAGCATATCTATAATG3' 
pRK5myc:: PTEN (C124S)- Encodes for PTEN (C I 24S) with a point mutation at T382 to an alanine 
T382A 
residue. Made by PCR and subcloned as a BamHl/EcoRl fragment into 
pRK5myc. 
Primer 1: 5'GCAGGA'I'('CACAGCCATCATCAAAGAGATC 3' 
Primer 2: 5'GC(IAATTCTCAGACTTTTGTAATTTGTGTATGCTG 
ATCTTCATCAAAAGGTTCATTCTCTGGATCAGAGTCAGTGGCG 
TCAGAATATCTATAATG 3' 
pRK5myc:: PTEN (C124S)- Encodes for PTEN (C124S) with a point mutation at T383 to an alanine 
T383A 
residue. Made by PCR and subcloned as a BamHl/EcoRl fragment into 
pRK5myc. 
Primer 1: 5'GCA(iGAT('CACAGCCATCATCAAAGAGATC 3' 
Primer 2: 5'GCG AATT('TCAGACTTTTGTAATTTGTGTATGCTG 
ATCTTCATCAAAAGGTTCATTCTCTGGATCAGAGTCAGCGGTG 
TCAGAATATCTATAATG3' 
pRK5 myc:: PTEN (C I 24S)- Encodes for PTEN (C124S) with a point mutation at S385 to an alanine 
S385A 
residue. Made by PCR and subcloned as a BamHl/EcoRl fragment into 
pRK5myc. 
Primer 1: 5'GCAGGAT('('ACAGCCATCATCAAAGAGATC 3' 
Primer 2: 5'GCGAA I"1'('TCAGACTTTTGTAATTTGTGTATGCTG 
ATCTTCATCAAAAGGTTCATTCTCTGGATCAGCGTCAGTGGTG 
TCAGAATATCTATAATG3' 
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pRK5myc:: PTENACAT-A4 Encodes for PTENACAT with point mutations at S380, T382, T383, 
S385 to alanine residues. Made by PCR and subcloned as a 
BamHFEcoRI fragment into pRK5myc. 
Primer 1: 5'GCG(j(jA I ('('AGCTACCTGTTAAAGAATCAT 3' 
Primer 2: 5'GCG AATT('TCAGACTTTTGTAATTTGTGTATGCTG 
ATCTTCATCAAAAGGTrCAT-FCTCTGGATCAGCGTCAGCGGCG 
TCAGCATATCTATAATG3' 
pRK5myc:: PTENACAT- Encodes PTENACAT with point mutations at S380, T382, S385 to 
DDTD 
aspartic acid residues. Made by PCR and subcloned as a BamHI/EcoRI 
fragment into pRK5myc. 
Primer 1: 5'GCG(iGAT('('AGCTACCTGTTAAAGAATCAT 3' 
Primer 2: 5' GCGAA"I"1'('TCAGACTTTTGTAATTTGTGTATGCT 
GATCTTCATCAAAAGGTTCATTCTCTGGATCATCGTCAGTG 
TCGTCATCATATCTATAATG3' 
pRK5 myc:: PTEN wt-T3 83 D Encodes for full-length wt PTEN with a point mutation at T383 to an 
aspartic acid residue. Made by PCR and subcloned as a Bam. HI/EcoRI 
fragment into pRK5myc. A gift from Annette Self. Primer 2 purchased 
from SIGMA Genosys. 
Primer 1: 5'GCA(jGA']'('('ACAGCCATCATCAAAGAGATC 3' 
Primer 2: 5'GCG A A'FT('TCAGACTT-FTGTAATTTGTGTATGCTG 
ATCTTCATCAAAAGGTTCATTCTCTGGATCAGAGTCATCGGTG 
TCAGAATA3' 
pRK5myc:: PTENACAT- Encodes PTENACAT with a point mutation at T383 to an aspartic acid 
T383D 
residue. Made by PCR and subcloned as a Ban-LHI/EcoRl fragment into 
pRK5myc. A gift from Annette Self. Primer 2 purchased from SIGMA 
Genosys. 
Primer 1: 5'GCGGGATCCAGCTACCTGTTAAAGAATCAT 3' 
Primer 2: 5'GCGAATTCTCAGACTTTTGTAATTTGTGTATGCTG 
ATCT-FCATCAAAAGGT-FCATTCTCTGGATCAGAGTCATCGGI'G 
TCAGAATAY 
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pRK5myc:: PTENwt-D4 Encodes for full-length wt PTEN with point mutations at S370, S380, 
T382, S385 to aspartic acid residues. Made by overlapping PCR using 
as template pRK5myc:: PTENwt-D3, and subcloned as a Bam1ll/EcoRI 
fragment into pRK5myc. A gift from Sarah Nicholls. Primers 2,4 and 6 
purchased from SIGMA Genosys. 
PCRI: 
Primer 1: 5'GCAGGA FCCACAGCCATCATCAAAGAGATC 3' 
Primer 2: 5' CAGGTTCATTGTCAGAAACATCTGGTGTTAC 3' 
PCR2: 
Primer 3: 5' GTAACACCAGATGTTGATGACAATGAACCTG 3' 
Primer 4: 5' GCCTCAGAAGGTACCTAAC 3' 
PCR3: Template; products of PCRI and PCR2. 
Primer 5: 5'GCAG 6A 1'('('ACAGCCATCATCAAAGAGATC 3' 
Primer 6: 5' GCCTCAGAAGGTACCTAAC 3' 
pRK5myc:: PTEN (C124S)- Encodes for PTEN (C124S) with point mutations at S370, S380, T382, 
D4 
S385 to aspartic acid residues. Made by overlapping PCR using as 
template pRK5myc:: PTEN(Cl 24S)-D3, and subcloned as a 
BamHI/EcoRl fragment into pRK5myc. A gift from Sarah Nicholls. 
Primers 2,4 and 6 purchased from SIGMA Genosys. 
PCRI: 
Primer 1: 5'GCA(i(IA'I-('('ACAGCCATCATCAAAGAGATC 3' 
Primer 2: 5' CAGGTTCATTGTCAGAAACATCTGGTGTTAC 3' 
PCR2: 
Primer 3: 5' GTAACACCAGATGTTGATGACAATGAACCTG 3' 
Primer 4: 5' GCCTCAGAAGGTACCTAAC 3' 
PCR3: Template; products of PCR I and PCR2. 
Primer 5: 5'GCA(I(IAT('('ACAGCCATCATCAAAGAGATC 3' 
Primer 6: 5' GCCTCAGAAGGTACCTAAC 3' 
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pR K5myc:: PTENwt-S3 70D- Encodes for full-length wt PTEN with point mutations at S370 to an 
A4 
aspartic acid residue and S380, T382, T383, S385 to alanine residues. 
Made by overlapping PCR using as template pRK5myc:: PTENwt (for 
PCRI) and pRK5:: PTEN(CI24S)-A4 (for PCR2), and subcloned as a 
BamHI/EcoRI fragment into pRK5myc. A gift from Sarah Nicholls. 
Primers 2,4 and 6 purchased from SIGMA Genosys. 
PCRI: 
Primer 1: 5'GCAGGAT('('ACAGCCATCATCAAAGAGATC 3' 
Primer 2: 5' CAGGT-FCAT-FGTCAGAAACATCTGGTGTTAC 3' 
PCR2: 
Primer 3: 5' GTAACACCAGATGTTGATGACAATGAACCTG 3' 
Primer 4: 5' GCCTCAGAAGGTACCTAAC 3' 
PCR3: Template; products of PCR I and PCR2. 
Primer 5: 5'GCA(](-iA'I'C('ACAGCCATCATCAAAGAGATC 3' 
Primer 6: 5' GCCTCAGAAGGTACCTAAC 3' 
pRK5myc:: PTEN (C I 24S)- Encodes for PTEN (C124S) with point mutations at S370 to an aspartic 
S370D-A4 
acid residue and S380, T382, T383, S385 to alarime residues. Made by 
overlapping PCR using as template pPK5:: PTEN(CI24S)-A4 and 
subcloned as a BamHI/EcoRI fragment into pRK5myc. A gift from 
Sarah Nicholls. Primers 2,4 and 6 purchased from SIGMA Genosys. 
PCR 1: 
Primer 1: 5'GCA(j(iA]'('('ACAGCCATCATCAAAGAGATC 3' 
Primer 2: 5' CAGGTTCATTGTCAGAAACATCTGGTGTTAC 3' 
PCR2: 
Primer 3: 5' GTAACACCAGATGTTGATGACAATGAACCTG 3' 
Primer 4: 5' GCCTCAGAAGGTACCTAAC 3' 
PCR3: Template; products of PCRI and PCR2. 
Primer 5: 5'GCA(I(IA-I'('('ACAGCCATCATCAAAGAGATC 3' 
Primer 6: 5' GCCTCAGAAGGTACCTAAC 3' 
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pYTH9-HA:: Encodes for PTENACAT minus the PDZ binding motif (residues 179- 
PTENANAPDZBM 394). Made by PCR and subcloned as an NCOI/EcoRl fragment into 
pYTH9-HA. Primer I purchased from SIGMA Genosys 
Primer 1: 5'TACCGG('('ATG(iTAAGCTACCTGTTAAA 3' 
Primer 2: 5' GCGAA"I"FCTCATTCATCAAA 3' 
TABLE 2.1 
Cloning strategy and list of primers. Restriction sites are indicated in red. Templates used 
were pRK5myc: PTENwt or pRK5myc:: PTEN(C] 24S) accordingly, unless otherwise stated. 
2.1.3 Restriction digests and purification of DNA fragments 
PCR products were purified prior to digestion using phenol: chloroform extraction or 
the Quiagen PCR Extraction method according to the manufacturer's instructions. 
Plasmid DNA (2-5ýtg) and PCR products were normally digested in a volume of 40ýtl 
with IgI of each restriction enzyme (New England Biolabs) in New England Biolabs 
buffers, for lh at 37T. The resulting digest products were added to Ix loading buffer 
[6x: 30% glycerol (v/v), 0.25% bromophenol blue (w/v), 0.25% xylene cyanol FF (w/v)] 
and routinely run on 1% TAE agarose gels (10 x TAE: OAM Tris acetate, I OmM EDTA) 
containing 0.8ýtg/ml ethidium bromide. Bands of interest were excised and purified using 
the Quiagen Purification method according to the manufacturer's instructions. 
2.1.4 Ligations 
Ligation reactions were carried out using a molar ratio of vector: insert of 1: 6 or 1: 8 in 
a final volume of I Oul containing I ul of T4 DNA ligase (I U/ ld, Invitrogen) and 2jul of 
the 5x DNA ligase buffer supplied with the ligase by Invitrogen. Reactions were 
incubated at room temperature for 34hrs and the entire ligation mix used to transform 
CaC12 competent E. Coh. 
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2.1.5 Preparation of CaC12 competent E. Coli 
Competent E. Coli were prepared by inoculating 25mls of L-Broth with a single colony 
of DH5(x and incubating overnight at 37'C with vigorous shaking. The overnight culture 
was diluted into 500mls of L-Broth and incubated at 37'C with vigorous shaking until an 
OD6oO of 0.6 was reached. The cells were chilled on ice for 5 min and centrifuged for 15 
min at 4000rprn at 4"C. The pellet was resuspended into 250mls of OAM CaC12 and left 
on ice for 30 min prior to centrifugation at 40OOrpm for 10 min at 4"C. The pellet was 
then resuspended into 25mls of cold buffer composed of 15% glycerol and 50MM CaC12 
in ddH20 and aliquoted into 200gl aliquots that were snap frozen in liquid nitrogen and 
stored at -801C. 
2.1.6 Transformation of competent E. Coli 
Competent E. Coli (100gl/DNA sample) were thawed on ice, mixed gently with the 
DNA and incubated for 30 min on ice. The E. Coli were induced to take up the DNA by 
'heat shocking' the transformation mix for 2 min at 421C, followed by immediate 
addition of Iml of L-Broth. Each E. Coli transformation mix was then incubated for 45 
min at 37C with vigorous shaking. Typically, 200gl of each sample was plated onto L- 
Broth/ Agar plates containing the required antibiotic (100gl/ml ampicillin or 50PLI/ml 
kanamycin) for selection of growth of the transformed E. Coli, and the plates incubated 
overnight at 370C to allow colony growth. 
2.1.7 Purification of DNA 
Minipreps of DNA were prepared by inoculating 2mls of L-Broth, containing the 
appropriate antibiotic (100gg/ml ampicillin or 50gg/ml kanamycin), with a single colony 
of E. Coli and incubating overnight at 371 with vigorous shaking to allow growth. 1.5 mls 
of each culture were transferred to an eppendorf tube and centrifuged at 130OOrpm for 3 
min at room temperature. The supernatant was discarded, except for 50gl, and the pellet 
resuspended by vortexing. The cells were lysed by adding 300gI of STET buffer (8% 
sucrose, 5% TritonX-100,50mM EDTA pH 8.0,50mM TrisHCI pH8.0, -Img/ml 
lysozyme) and boiling for 1 min at 1001C. The samples were centrifuged at 130OOrpm for 
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15 min at 4'C. The resulting pellet was removed using a sterile Gilson pipette tip and 
discarded. DNA was precipitated by addition of 300ýd of cold isopropanol and 
centrifugation at 13000rpm for 10 min at room temperature. The pellet containing the 
DNA was washed with 70% ethanol, air dried and resuspended in 50gl TE pH 8.0. Each 
DNA sample (5ýd) was digested and run on an agarose gel to check for purity and the size 
of the insert. 
Maxipreps of DNA were prepared by growing overnight cultures in 250mls of L- 
Broth at 37'C with vigorous shaking. The DNA was purified using the QIAFilter Plasmid 
Maxi kit (Quiagen) purification method, according to the manufacturer's instructions. 
2.2 Cell Biology 
2.2.1 Cell lines and culture conditions 
2.2.1.1 COS-7 and MDA-MB435 cells 
The monkey fibroblast cell line COS-7 and the human mammary epithelial cell line 
MDA-MB435 (received from Michael O'Hare) were maintained in Dulbecco's Modified 
Eagle's Medium (DMEM, Gibco) supplemented with a penicillin/streptomycin solution 
mix (penicillin 100U/ml, streptomycin 100gg/ml, Gibco) and 10% of fetal calf serum 
(PAA laboratories) that had been heat inactivated by incubating for 45 min at 52*C (hi- 
FCS). Both cell lines were grown in a 10% C02 and 370C temperature controlled 
incubator. 
2.2.1.2 U373, U138 and U87 
The human glioma cell lines U373, U138 and U87 were maintained in Modified 
Eagle's Medium [MEM (Eagle)] with Glutamax (Gibco) supplemented with a 
penicillin/streptomycin solution mix (penicillin IOOU/ml, streptomycin 100pg/ml, 
Gibco), 5mls of MEM 100x non-essential amino acids (Gibco), 20mM HEPES [pII 7.5] 
(Gibco) and 10% of heat-inactivated fetal calf serum (PAA laboratories). All three cell 
0 lines were grown in a5 /0 C02 and 371C temperature controlled incubator and were kept 
in culture until passage 20 (P20) had been reached, at which point they were discarded 
and a new vial of low-passage cells was thawed. 
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2.2.1.3 Astrocytes 
Primary cultures of astrocytes were obtained as follows: Striata were dissected out 
from the brains of E17 CD rat embryos and mechanically dissociated in serum-free 
medium. The resulting cells were plated on (poly)-L-omithine (1.5ýtg/ml) coated dishes 
(60 mrn diameter) in DMEM containing 1 g/l glucose, lOmM HEPES [pH 7.5] (Gibco) 
and 10% FCS (The dissection was performed by Dr. Sandrine Etienne-Manneville). The 
cells were grown in a 5% C02 and 37'C temperature controlled incubator. After 21 days 
in culture, more than 95% of the cells were routinely positive for glial fibrillary acidic 
protein (AMERSHAM). Cultures were fin-ther enriched for astrocyte cells by washing 
once in calcium- and magnesium-free PBS-A, trypsinisation (0.25% trypsin, 0.02% 
EDTA) and subsequent plating on new (poly)-L-omithine coated dishes or on (poly)-L- 
ornithine coated glass coverslips. Cells were used 10-15 days later for experimental 
manipulations. 
2.2.2 The wound-healing assay 
Astrocytes, U373, U138 and U87 cells were plated on glass coverslips and allowed to 
grow in a 5% C02 and 371C temperature controlled incubator until they formed a 
monolayer or reached -90% confluency in the case of the U138 and U87 cells. A sterile 
glass pipette or a Gilson tip was used to scratch the monolayer (wound) in the shape of a 
cross and the coverslip was moved to a dish containing fresh medium. The cells were 
allowed -Ih to recover from wounding prior to manipulation by microinjection or 
analysis by time-lapse microscopy (see below). Microinjected cells on coverslips were 
typically allowed to migrate for 8h or l6h (for U373, U138, U87) or 24h (astrocytes) 
before washing once with PBS-A and fixing with 4% (w/v) paraformaldehyde (SIGMA) 
for 15 min. 
2.2.3 Microinjection of U373, U138, U87 and astrocytes 
Just prior to microinjection, cells on coverslips were transferred to a 6cm culture dish, 
containing 5mls of the corresponding culture medium that had been allowed to equilibrate 
for 30 min in a 5% C02 and PIC temperature controlled incubator. Cells were 
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microinjected using an Eppendorf micromanipulator 5171 and transjector 5240 system on 
a Zeiss Axiovert 135M microscope in a 5% C02 and 37*C controlled chamber. 
Maxiprep-prepared DNA was diluted into PBS-A at a final concentration of O. Img/ml 
and microinjected direcly in the nuclei of 100 cells for each coverslip. The cells were 
returned to the incubator to allow for expression and completion of the wound-healing 
assay. 
2.2.4 Transfection of COS-7 cells 
Small-scale transfection of COS-7 cells was performed using the GeneJuice 
(Novagen) method according to the manufacturer's instructions. Typically, cells were 
seeded on 6-well culture plates at a density Of IX105 cells/ well or 2xI 05 cells/ well in 2ml 
culture medium (DMEM containing 10 % FCS and penicillin/streptomycin), 16h to 18h 
prior to transfection. Cells in each well were transfected with a total of lAg of maxiprep 
DNA diluted in 100gl DMEM containing 3ýd of GeneJuice reagent. Cells were then 
incubated for 24h or 48h in 5% C02 at PIC a to allow for expression of the DNA, before 
being harvested for biochemistry. 
2.2.5 Immunofluorescence staining 
Cells on coverslips were fixed in 4% (w/v) paraformaldehyde for 15 min at room 
temperature prior to permeabilisation with 0.2% Triton X-100 (TX-100)/ PBS-A for 10 
min and quenching in sodium borohydride/ PBS-A (0.2mg/ml) for 15 min. 
Immunostaining was performed by incubating cells with primary antibodies diluted in 
PBS-A for Ih at room temperature, followed by 9 washes in PBS-A and incubating with 
fluorescent-conjugated antibodies for 45 min at room temperature. Cells were washed 6 
times in PBS-A and 2 times in ddH20 prior to mounting on slides using 7ýd of Mowiol 
mountant (Calbiochem). Images were captured using a Hammamatsu C5985 CCD camera 
and processed with OpenLab software. 
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2.2.6 Reagents 
2.2.6.1 Antibodies used for immunofluorescence staining 
Myc-epitope tagged constructs were visualised with mouse anti-Myc 91310 antibody 
(prepared in the lab by Dr. Annette Self) used at a dilution of 1: 100 in PBS-A followed 
by TRITC or FITC - conjugated anti-mouse IgG (Jackson Labs). Flag-epitope tagged 
constructs were visualised with Mouse anti-Flag M2 IgG (SIGMA) used at I Ogg/ml in 
PBS-A followed by TRITC or FITC - con ugated anti-mouse IgG (Jackson Labs) and j 
HA-epitope tagged constructs were visualized with rat anti-HA IgG (Roche, clone 31710) 
used at 1: 150 dilution (100ptg/ptl) followed by FITC - conjugated anti-rat IgG (Jackson 
Labs). 
2.2.6.2 Inhibitors 
Cytochalasin. D (SIGMA) was used at a concentration of 500nM or 2pM. 
Wortmannin (SIGMA) was used at a concentration of I OOnM or 500nM. 
2.2.7 Video time-lapse microscopy 
Time-lapse movie recordings were captured using a CCD camera (SONY SSC- 
M370CE) and time-lapse controller (Openlab Software), attached directly to a Zeiss 
Axiovert 135M microscope. Cells were maintained in sealed flask in a temperature - 
controlled chamber (37"C). Images were captured under phase-contrast, at I frame/ 5 min 
directly by Openlab Software. 
2.3 Protein Biochemistry 
2.3.1 Preparation of GST fusion proteins 
2.3.1.1 Purification of recombinant Rac/ Rho/ Cdc42 for GEF assays 
GST-Rac, GST-RhoA and GST-Cdc42 (pGEX-2T-Rac, pGEX-2T-RhoA, pGEX-2T- 
Cdc42 in B121 E-Coli) were prepared by inoculating 100ml of L-Broth (containing 
100ýtg/rnl ampicillin) and incubating overnight at 37*C with vigorous shaking. The 
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overnight culture was diluted into 900ml of L-Broth/ ampicillin and incubated for a 
further 2h at 37'C with vigorous shaking. Expression of the fusion protein was induced 
by adding isopropyl-p-D-thiogalactopyranoside (IPTG) to a final concentration of 0.1 mM 
for 3h followed by vigorous shaking at 37'C. Cells were collected by centrifugation at 
40OOrpm for 10min at 4'C and resuspended in 3ml of cold lysis buffer [50mM TrisHCl 
pH7.6,50mM NaCl, 5mM M902, ImM dithiotreitol (DTT), 1mm phenylmethylsulfonyl 
fluoride (PMSF)]. Cells were lysed by sonicating on ice (3 bursts of 1 min with 30sec 
intrervals, using small probe on an MSE Soniprep 150 sonicator at an amplitude of 
14ýtm) and the lysates cleared by centrifugation at 40OOrpm for 10 min at 41C. The 
supernatant was transferred to a clean 15ml Falcon tube and incubated with Iml of 
Glutathione-agarose beads (prepared by prewashing 5 times with an equal volume of lysis 
buffer and kept as a 1: 1 suspension) on a rotating wheel for Ih at 4C. The beads were 
pelleted by centrifugation at 40OOrpm for 1 min and washed 6 times with 5ml of cold 
Buffer A (5OmM TrisHCl pH7.6,50mM NaCl, 5mM MgCl2) to remove any unbound 
protein. The GST-fusion proteins were eluted from the beads by adding an equal volume 
of freshly prepared release buffer (5OmM TrisHCl pH8,150mM NaCl, 51171M MgCl2, 
IMM DTT, 5mM reduced glutathione) and incubated for 2 min at 4'C on a rotating 
wheel. The beads were pelleted and the supernatant kept in a separate clean tube. The 
elution step was repeated and the two supernatants pooled. Alternatively, the protein was 
released from the beads through cleavage of the GST tag by incubating the beads with 
1 OU of human thrombin in digestion buffer (5OmM TrisHCl pH7.6,150mM NaCl, 5mM 
M902,2.5mM CaC12. I mM DTT) overnight, on a rotating wheel at 4'C. After thrombin 
digestion, the beads were pelleted by centrifugation at 130OOrpm for I min and the 
supernatant removed to a clean microfuge tube. The beads were incubated with a further 
0.5 ml of high salt buffer (5OmM TrisHCl pH7.6,150mM NaCl, 5mM MgC129 IMM 
DTT) for 2 min on a rotating wheel at 41C. The beads were pelleted once again and the 
two supernatants were pooled. In both cases (elution or thrombin digestion), the protein 
was concentrated to a volume of -150ýd (using an Amicon Centricon 10 filter device) by 
centrifugation in a fixed angle rotor at 70OOrpm (-2h), aliquoted in 10ý11 samples and 
snap frozen in liquid nitrogen and stored at -80'C. 
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2.3.1.2 Purification of GST-PAK CRIB and GST-Rhotekin for pull-down assays 
GST-PAK CRIB (pGEX-2T-PAK CRIB in B121 E. Coli) was prepared by inoculating 
100ml of L-Broth (containing 50gg/ml ampicillin and 25ptg/ml chloramphenicol) and 
allowing growth overnight at 37'C with vigorous shaking. The overnight culture was 
diluted into 900ml of L-Broth/ampicillin/chloramphenicoI and incubated for 2h at 30"C 
with vigorous shaking. Protein expression was induced by adding IPTG to a final 
concentration of 0.5mM and allowing growth for a further 5h at 30"C with vigorous 
shaking. The cells were collected by centrifugation at 40001pin for 20 min at 4C and the 
pellet resuspended in 20ml of cold sucrose buffer [50mM TrisHCI pH8,40MM EDTA, 
25% (w/v) sucrose, 5mM DTT, ImM PMSF, 1 complete inhibitor tablet/50mls of buffer 
(Boehringer)] and incubated for 20 min on a rotating wheel at 4'C. The cells were lysed 
by addition of 8ml of cold lysis buffer (50mM TrisHCI pH8, I OOMM MgC129 0.2% (w/v) 
Triton X-100,5mM DTT, ImM PMSF, 1 complete inhibitor tablet/50mls of buffer) and 
rotating for a further 10 min at 4"C prior to sonication (as described previously). The 
suspension was cleared by centrifugation at 10000rpin for 45 min and the supernatant 
transferred to a 15ml Falcon tube prior to the addition of lml of a 50% Glutathione- 
agarose bead slurry (kept as a 1: 1 suspension in lysis buffer). The GST-fusion protein was 
allowed to bind the beads on a rotating wheel at 41C for lh. The beads were pelleted by 
centrifugation (at 2500rpm for 30 sec) and washed 6 times with 5mls of cold wash buffer 
(50mM TrisHCI pH 7.6,5OmM NaCl, 5mM MgCl2). Finally, the beads were resuspended 
in 500gI of wash buffer containing 25% glycerol and aliquoted in 50gl aliquots, snap 
frozen in liquid nitrogen and stored at -80'C. 
GST-Rhotekin was prepared in the same way as GST. PAK CREB with the following 
modifications: pGEX-2T-PAK CREB E. Coli (B121) were grown for 2h at 22' prior to 
induction with IPTG. 
2.3.2 GTPase Pull-down assays 
U373, U138 and U87 cells were each grown to confluency in 9mrn dishes in culture 
medium (as described in 2.2.1). Each dish was washed twice with cold TBS (5OmM 
TrisHCI pH8,150mM NaCl) prior to lysing the cells with 200ýd / dish of cold lysis buffer 
(50mM TrisHCl pH 7.5,1% Triton X-100,500mM NaCl, 50mM M902,0.5% sodium 
deoxycholate, ImM PMSF, 20jig/ml aprotinin, 20gg/ml leupeptin, 5gg/ml pepstatin) on 
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ice. The cells were scraped off the dish immediately and the lysates cleared by 
centrifugation at 13000rprn for 10 min at 4*C. 20ýd of the supernatant were transferred to 
a clean eppendorf and boiled for 5 min in 2x Laemli sample buffer. The rest of the 
supernatant was added to 50ýfl of GST-PAK CRIB coupled to Glutathione agarose beads 
(see 2.3.1) in order to precipitate the active forms of Rac (Rac-GTP) and Cdc42 (Cdc42- 
GTP). The samples were incubated on a rotating wheel at 4'C for lh. As a positive 
control, one of the samples was incubated with GTPyS (which binds to Rac and Cdc42 
and mimics the activated state) and 50ptl of GST-PAK CRIB beads and placed on a 
rotating wheel for 30 min at room temperature and 30 min at 4'C. The beads were then 
precipitated by centrifugation at 130OOrpm for l5sec at 4"C and washed 4 times with cold 
wash buffer (50mM TrisHcl pH 7.5,150niM NaCl, I%Triton X-100,10MM M9029 0.2 
mM PMSF). The samples were split in half and analysed by SDS-PAGE followed by 
immunoblotting using either mouse monoclonal anti-Cdc42 IgG or mouse monoclonal 
anti-Rac IgG (clone 23A8). The relative levels of Rac and Cdc42 were analysed for each 
cell line relative to the corresponding levels of Rac and Cdc42 in total cell lysates by 
quantification using Quantity One software (Biorad). 
2.3.3 GEF assays (ON-Rates) 
The different GTPases (2 gg) were incubated at 30'C for 15 min in 320 Al loading 
buffer (20 mM Tris-HCl [pH 7.5], 100 mM NaCl, 100pM AMP-PNP, 0.2 MM DTT, 2 
n-LM EDTA) containing IOPM [3 H]-GDP (AMERSHAM), then placed on ice, followed 
by addition of 5gl Of 0- IM M902 was added. Exchange reactions were allowed to take 
place at 301C in the presence of ImM cold GTP and 0.5mg/ml BSA, and in the presence 
or absence (control buffer) of 20ýtg of each of the cell lysates. At the indicated times, 
40ýd aliquots of the reaction were removed and diluted into 1 ml of cold Buffer A (50 
mM Tris-HCI [pH 7.5], 50 mM NaCl, and 5 MM MgC12) and passed through pre-soaked 
nitrocellulose filters (NC45 Schleicher & Schuell 0.4ýtm). Filters were washed once with 
10 ml cold Buffer A, transferred to vials, left to dry and counted in a scintillation counter 
following addition of 8 ml of scintillation fluid per vial. 
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2.3.4 Immunoprecipitation assays 
Cells were rinsed on ice with cold PBS-A containing ImM orthovanadate (SIGMA) 
and lysed on ice with RIPA buffer (10 mM Tris/HCI [pH 7.5], 140 mM NaCl, I MM 
orthovanadate, 1% Nonidet P-40,2 mM PMSF, 5 mM EDTA, 20 pg/mI aprotinin, 20 
pg/mI leupeptin) 48h post-transfection. The nuclei were discarded following 
centrifugation at 130OOrpm for 2 min and the supernatant lysates incubated at 4*C for 2h 
with specific antibodies and 20-50gl of 50% Glutathione-sepharose beads. The beads 
with the immunoprecipitates were centrifuged at 130OOrpm for 30 sec and washed 5 times 
with RIPA buffer. The immunoprecipitated proteins were eluted with Laemli sample 
buffer and analyzed by 12% SDS-PAGE (see below). Mouse Anti-Myc mAb, 91310 or 
anti-flag IgG (SIGMA) was used for detection of the MYC or FLAG tagged constructs. 
Rabbit anti-PTEN IgG (Cell Signalling) or rabbit anti-phospho-PTEN (Ser380/ 
Thr382/383) IgG (Cell Signaling Technology) was used respectively for detection of 
PTEN or the phosphorylated forms of the PTEN expressed constructs. 
2.3.5 Finase assays 
23.5.1 PAK kinase assay 
Cells were plated to confluency in 9cm dishes, washed 2x with PBS-A containing 
lOmM orthovanadate and lysed with 200ýLl lysis buffer (25mM HEPES [pH 7.3], 300 
mM NaCl, 1.5mM M902, I mM sodium vanadate, 0.5% Triton X-100,5% glycerol, 0.5 
mM EGTA, 0.5 mM PMSF and I gg/ml each of pepstatin, aprotinin, leupeptin). Cells 
were cleared by centrifugation at 130OOrpm for 10min and the supernatant lysates 
incubated at 41C for 2h with 2; ig of anti-PAK (Santa Cruz, CA) IgG and 50ýd of 50% 
Glutathione-sepharose beads. The beads containing the immunoprecipitated PAK protein 
were washed twice with Iml PBS-A containing 0.1% Triton and once with kinase buffer 
(50mM HEPES [pH7.3], l0rnM MgC12,10mM NaF, 2mM MnC12. ImM DTT, 0.05% 
Triton). PAK activity was assayed by incubating the PAK protein containing beads in 
25pl of pre-warmed kinase buffer containing I0pM ATP, 20ptg/ml MBP (SIGMA) and 
3pCi/sample of ý2p_AIT (AMERSHAM) at 370C for 15min and the reactions stopped 
by boiling in 5X Laemli sample buffer. Proteins were analysed by 12% SDS-PAGE and 
transferred to a nitrocellulose membrane by Western blotting. The levels of 
phosphorylated MBP were assessed by exposure to film (KODAK) for the required 
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lengths of time and the immunoprecipitated PAK levels monitored by probing the 
nitrocellulose membrane with anti-Pak IgGs. 
2.3.5.2 PKCý Kinase assay 
Same as for PAK, with the following modifications: RIPA buffer (10 mM Tris/HCI 
[pH 7.5], 140 mM NaCl, I mM orthovanadate and 1% Nonidet P-40,2 mM PMSF, 5 mM 
EDTA, 20 pg/ml aprotinin, 20 gg/ml leupeptin) was used to lyse the cells, anfi-PKC4 
(Santa Cruz, CA) IgG was used to immunoprecipitate PKC4 from the cell lysates and the 
kinase reaction was carried out in 50ptl kinase buffer (ImM DTT, lOmM PNPP, lOmM 
sodium vanadate, I OpM ATP, 20ptg/ml MBP, 3 gCi/sample of y32P-AT? ). 
2.3.6 PTEN Phosphatase assay 
COS-7 cells were transfected with the required Myc-epitope tagged PTEN constructs 
(2 wells of a 6-well dish / construct) with GeneJuice (as described in 2.2.4). Cells were 
lysed 24h post-transfection with cold lysis buffer (1% NP40, lOmM TrisHCI pH7.5, 
140mM NaCl, 2mM MgC12,2mM PMSF, supplemented with 1 complete inhibitor tablet / 
50ml of buffer) and the supernatants, which had been transfected with the same construct, 
pooled. Lysates were cleared by centrifugation at 13000rpm. for 2 min and Myc-PTEN 
immunoprecipitated with Mouse anti-Myc 91310 antibody as described in 2.3.4. 
Following immunoprecipitation, the immunocomplexes were washed twice in coI4 lysis 
buffer and 3 times in phosphatase buffer (50 mM HEPES [pH 7.0], 150 mM NaCl, I Omm 
D'IT) before being incubated in a phosphatase buffer (60pil final volume) at 30'C or 37'C 
for the indicated lengths of time. The reactions were terminated by boiling in 5x sample 
buffer. Proteins were analysed by 12% SDS-PAGE and transferred to a nitrocellulose 
membrane, followed by Western blotting with a phospho-specific PTEN antibody (Cell 
signaling). 
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2.3.7 SDS PolyacryIamide gel electrophoresis (SDS-PAGE) 
Protein samples were boiled in 5x sample buffer (250mM Tris-HCI pH 6.8,0.5M 
DTT, 10% SDS, 50% glycerol, 0.1% bromophenol blue) at 100'C for 5-10 min prior to 
being loaded onto a polyacrylamide gel (stacking gel: 5% acrylamide/ bisacrylamide 
solution, 125mM TrisHCI pH6.8,0.1% SDS; resolving gel: 10 - 15 % acrylamide/ 
bisacrylamide solution as required, 375mM TrisHCl pH8.8,0.1% SDS). lOgI of Rainbow 
markers (RPN80OV, Amersham) were also loaded on each gel and the protein samples 
resolved by electrophoresis at 90-120V using a Biorad minigel apparatus. Proteins were 
detected by staining the resolving gel with coomassie blue stain (0.5g brilliant blue R- 
250,10% acetic acid, 50% methanol) for -1h, followed by destaining with 10% acetic 
acid (v/v) / 25% methanol (v/v), until the protein bands were visible and the gel almost 
clear. Alternatively, proteins were transferred onto nitrocellulose membranes (Schleicher 
& Schuell) for Western blotting. 
2.3.8 ImmunobIotting/ Western blotting 
Proteins were transferred from a polyacrylamide gel to nitrocellulose membranes in lx 
cold transfer buffer (10x stock: 30g/L Trizina base, 144g/L glycine) at 0.35A for 2h or 
0.25A overnight at 4'C, using a Biorad 'wet' transfer apparatus. The nitrocellulose 
membrane was incubated in block [5% Marvel (w/v), IM glycine, 5% FCS (v/v), 1% 
albumin (w/v)] for lh at room temperature on a shaker and washed 3x5 min with 5% 
Marvel (w/v) / 0.2% TWEEN-20 (v/v) in PBS-A, prior to incubation with antibodies. 
Primary antibodies were prepared in 2% Marvel/ 0.2% TWEEN-20/ PBS-A to the 
required dilution and applied to the membrane for lh at room temperature or overnight at 
4*C, on a shaker. The membrane was washed 3x 10 min with 2% Marvel/ 0.2 % 
TWEEN-20/ PBS-A at room temperature prior to incubation for 45 min at room 
temperature with the secondary HRP-conjugated antibody, prepared in 2% Marvel/PBS- 
A. Finally, the membrane was washed 3x 15 min with 0.4 % TWEEN-20/ PBS-A and 
developed using ECL reagent detection kit (AMERSHAM) according to the 
manufacturer's specifications. The membrane was exposed to ECL hyperfilm 
(AMERSHAM), as necessary. 
All HRP - conjugated antibodies for immunoblotting were purchased from PIERCE 
and used at a dilution of 1: 2000 unless otherwise indicated (in 2%Marvel/ 0.2 % 
TweenIO/PBS-A). 
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2.3.9 Labelling of cells with r2p]-orthophosphate and phosphatase assay 
COS-7 cells were plated on 6cm dishes at a density of 2x 10' cells/ dish and 
transfected 16h later with the required PTEN constructs by GeneJuice. The cells were 
washed once with 5ml of Phosphate-free DMEM (Gibco) and labeled with 125ýICY dish 
of 3'P-orthophosphate (Amersham) for 4h in 5%CO2, at 37*C. Cells were washed once 
with 5ml of cold PBS-A and lysed for 5min with 400ýLl/ dish of cold lysis buffer (4OmM 
TrisHCl pH7.6, l5OmM NaCl, lmM EDTA, 1% Triton X-100), supplemented with one 
complete inhibitor tablet/ 50ml of buffer. Lysates were cleared by centrifugation at 
13000rprn for 3 min and incubated with 50ýd of 50% Glutathione-sepharose beads for 
30min at 4'C on a rotating wheel. The beads were pelleted (130OOrpm, I min) and the 
lysates were transferred to clean tubes containing 50gl of fresh 50% Glutathione- 
sepharose beads. The Myc epitope-tagged PTEN constructs were precipitated by 
incubating the samples with 5gl of anti-Myc 9E10 antibody for 2h at 4'C on a rotating 
wheel. The immunocomplexes were washed twice with cold lysis buffer, twice with 
wash buffer (4OmM TrisHC1 pH7.6,15 OmM NaCl, I mM EDTA) and finally twice with 
cold phosphatase buffer (25mM HEPES pH7.2,50mM NaCl, 2.5mM EDTA, IOMM 
DTT). The phosphatase reaction was initiated by addition of 60PLI of phosphatase buffer 
to each sample (final reaction volume of 100gl) followed by incubation at 30*C for the 
required times. The reaction was stopped by addition of 5x sample buffer and boiling at 
100'C for 10 min. The protein samples were analysed by SDS-PAGE on a 10% 
polyacrylamide resolving gel. The gel was stained (with coomasie blue stain) and 
destained in order to fix the proteins and visualize the molecular weight markers 
(Rainbow, RPN80OV). Finally, the gel was dried using a Biorad gel drier and radioactive 
proteins visualized by exposing the gel to film (Biomax-MR Kodak) or to the Biorad 
Imaging screen K, as required (usually overnight). The Biorad Imaging screen K was 
'read' using a phosphorimager (Biorad Molecular Imager FX) and the data were analysed 
using Quantity One software (Biorad). 
2.3.10 Peptide maps and phosphoarnino acid analysis 
The required radioactive protein bands were cut out of the gel, washed 3x 30 min in 
destain, 2x 30 min in 50% methanol (v/v) and 2x 30 min in dd1120 prior to drying for 2h 
in a Speed-vac. The proteins in the gel pieces were digested with 500gl of 0.3mg/ml 
Trypsin in I OOmM NH411CO3 for 24h at 37'C. The supernatant was removed to a clean 
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tube and the gel pieces were incubated with 500ýfl of IOOmM NH4HCO3 for 2h at 37*C to 
remove any remaining peptide fragments from the gel. The two supernatants were 
combined and Iyophilized by drying in a Speed-vac. 
The peptide fragments were analysed by thin layer chromatography (TLC) as follows: 
digested dried samples were resuspended in I Optl of H20, followed by heating at 65*C for 
1 min and centffigation at 130OOrpm for 15 min, prior to spotting (Iýfl at a time, 
followed by drying with a hair-dryer) in the middle of a chromatography paper 
(Macherey); 4cm up, 10cm over. One microgram each of basic fuschin and phenol red 
were also spotted on the sample and the chromatography paper was overlayed with 
electrophoresis buffer pH3.5 (acetic acid: pyridine: H20 in a 19: 1: 89 ratio). 
Electrophoresis was performed at 500V (in buffer pH3.5) until the dye was within 4cm of 
the opposite side (-2h). The chromatograph was allowed to dry thoroughly in the fume 
hood and the peptides were resolved in the second dimension using an ascending 
chromatography tank containing I 50n-A of buffer (pyridine: butanol: acetic acid: H20 in a 
15: 10: 3: 12 ratio) until the buffer reached to within 3cm of the top of the chromatograph 
(-4h). The chromatograph was once again allowed to dry thoroughly under the fume 
hood, the covered with saran wrap and exposed to film (Biomax-MR, Kodak). 
Alternatively, the digested peptide fragments were subjected to total phosphoamino 
acid analysis. The dried samples were resupended in 50ptl of ddH20 and incubated with 
6M HCI, for lh at 105*C, followed by Iyophilisation in a Speed-vac. The dried samples 
were resuspended in 10ýd dd. H20, heated at 651C for I min and centrifuged at 130OOrpm 
for 15min. The samples were spotted (I gI at a time, followed by drying with a hair-dryer) 
onto chromatography paper; 4cm up and 4cm over. One microgram each of 
phosphoserine, phosphothreonine and phenol red were spotted on each sample and the 
chromatography paper was overlayed with electrophoresis buffer pHl. 9 (formic acid: 
acetic acid: H20 in a 1: 10: 89 ratio). Electrophoresis was allowed to proceed at 500V (in 
buffer pHl. 9) until the dye had moved -5cm. The chromatograph was then moved to an 
electrophoresis tank containing buffer pH3.5 and electrophoresis was allowed to proceed 
until the dye had moved -7cm. The chromatograph was allowed to dry and 
phosphoserine and phosphothreonine standards were visualized as purple spots by 
application of a few drops of 1% ninhydrin in acetone (w/v). The chromatograph was 
wrapped in saran wrap and exposed to film (Biomax-MR, Kodak). 
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2.4 Yeast Two-Hybrid 
2.4.1 Yeast Plates 
YEPD plates: 20g peptone (Difco, No. 0 118-01-8), 1 Og yeast extract (Difco, No. 0 127-0 1- 
7,20g Bacto-agar (Difco No. 0140-01) in 900ml of H20 + 100ml 20% glucose. 
SC plates: 6.7g yeast nitrogen base (Difco, No. 0919-15-3), 20g Bacto-agar (Difco 
No. 0140-01), 2g of drop-out amino acid mix in 900ml of H20 + 100ml 20% glucose. 
According to the selection conditions, one or more of the following supplements were 
added: 0.1 g tryptophan (Trp), 0.2g leucine (Leu), 0.1 g histidine (His). 
3-AT Plates: Same as for Sc-Trp-Leu-His plates + 25ml of a IM sterile-filtered 3-amino- 
1,2,4-triazole solution (SIGMA) per litre of SC medium. 
2.4.2 Cloning 
A cDNA encoding PTENACATAPDZBM was fused to the sequence encoding the 
GAL4 DNA-binding domain (GAIADB) in the pYTH9 vector. The construct was 
subsequently transformed into the yeast strain Y190. To facilitate integration of the 
construct into the yeast genome (through homologous recombination), the plasmid was 
linearised with Xba I (New England Biolabs). 
2.4.3 Yeast transformations 
SmIs of YEPD [20g peptone (Difco, No. 0 118-01-8), 1 Og yeast extract (Difco, No. 
0127-01-7), 20% glucose, in a final volume of Ilt] were inoculated with one colony of 
yeast and incubated overnight at 30*C with vigorous shaking. The overnight culture was 
diluted into 50ml YEPD and allowed to grow until the OD600 had reached approximately 
0.6. The cells were centrifuged at 3000rprn for 5min and washed once with 5ml TE 
[pH8.0], followed by a single wash with 5ml 1X LiAc/TE (IOX LiAc/TE: IM lithium 
acetate, IOOmM TrisHCl [pH 7.5], 5mM EDTA). The cells were resuspended in 500gl 
IX LiAc/TE. To 100gl of yeast cells were added 1.5gg of transforming DNA + 50gg of 
carrier DNA (QBiogene Inc. ) and the mixture was incubated at 30'C for 30min. The 
yeast cells were then induced to take-up DNA by heat shocking at 421C for 10min in the 
presence of I lOgI of DMSO. The cells were pelleted at 13000rprn for Imin, washed 
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Yeast colonies were allowed to grow by placing the plates in an incubator at 30'C for 2 
days. 
2.4.4 Yeast lysates 
2mls of SC medium were inoculated with each of the yeast colonies and incubated 
overnight in a 30'C shaker-incubator. The following day, 1.5mls of each culture were 
transferred to a microfuge tube and centrifuged at 13000rprn for 1 min at room 
temperature. The cell-containing pellet was re-suspended in I ml of ddH20 and cells were 
pelleted for I min at 130OOrpm at room temperature. The pellet was re-suspended in 
100gl of Ix sample buffer and boiled for 5 min at 95*C. The samples were once again 
centrifuged at 130OOrpm for 5 min and 25gl of each lysate were loaded on an SDS- 
polyacrylamide gel. 
2.4.5 Yeast two-hybrid screen 
10ml of YEPD were inoculated with Y190[pYTH9: PTENACATAPDZ] and allowed 
to grow overnight at 300C with vigorous shaking. The overnight culture was diluted into 
100ml YEPD and incubated at 300C for a further 24h with vigorous shaking. The 
overnight culture was diluted further in IL YEPD and incubated at 300C with vigorous 
shaking until it reached an OD600 of approximately 0.6. The culture was then centrifuged 
in a sterile tube at 4000rprn at room temperature for 7min. The cells were resuspended in 
500ml of TE [pH 7.5] and centrifuged at 40OOrpm at room temperature for 7min. The 
cells were then resuspended in I 00ml Of IX LiAc/TE (I OX LiAc/TE: IM lithium acetate, 
I OOmM TrisHCI [pH 7.5], 5mM EDTA) and incubated in a shaking incubator at 3 O'C for 
I h. The cells were pelleted at 40OOrpm at room temperature for 7min and resuspended in 
10ml IX LiAc/TE. 5001il carrier DNA (a gift by Steve Moss) and 450ýtl of brain library 
cDNA were added to the yeast cells and the mixture was incubated in a 30*C waterbath 
for 30min. 100ml of 40% PEG [polyethylene glycol 3,350 (w/v)] in OAM LiAc/TE were 
added to the mixture and incubated in a 300C waterbath for a further 30min. Cells were 
induced to take up the DNA by heat shocking at 42*C for I Omin in the presence of II ml 
of DMSO. The cells were pelleted at 40OOrpm at room temperature for 7min, resuspended 
in 500ml YEPD and incubated at 30'C for lh in a shaking incubator. The culture was 
centrifuged at 40OOrpm at room temperature for 7min and the pelleted cells were washed 
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3x with 200ml of TE [pH 7.5], prior to being resuspended in 10ml of TE [pH 7.51. The 
yeast were then plated out on 10 large 3-AT plates (Iml/plate) and lOgI, 50gl and 100gl 
were each plated out on SC-Trp-Leu plates in order to calculate the transformation 
efficiency. The 3-AT plates were incubated at 301C and yeast colonies were picked every 
2 days for 9 days, starting at day 3 and streaked onto Sc-Trp-Leu plates. The freshly 
grown yeast clones were tested for a positive interaction by re-streaking on 3-AT plates. 
The DNA form the positive colonies was then isolated and transformed into DHSa E. CoU 
and the presence of an insert was examined by restriction digest mapping. 
2.4.6 IsoIation of yeast DNA 
2ml of SC-Trp-Leu solution were incubated with individual yeast colonies and 
incubated overnight at 37*C with vigorous shaking. Cells were pelleted at 130001pm for 
3min at room temperature and the pellets were resuspended in 200gl breaking buffer (2% 
Triton X-100,1% SDS, IOOmM NaCl, lOmM TrisHCI [pH 8.0], ImM EDTA [pH8.0]. 
200111 of glass beads (SIGMA) and phenol/chloroform solution were added to each tube, 
before vortexing at full speed for 5 min. To isolate the yeast DNA, which was present in 
the aqueous layer, the samples were spun down at 13000rpm for 5min at room 
temperature. 
2.4.7 Transformation of yeast DNA into DH5cc 
5gl of yeast DNA were added to electro-competent DH5(x cells on ice and transferred 
to an electroporation cuvette (2mm) on ice. The DNA was transformed into the DH5a 
cells by an electric pulse at 200 Ohm, 251E, 1.8kV and Iml of L-Broth was added to the 
cells in the cuvette and the mixture was transferred to a 1.5ml microfuge tube. The 
bacteria were incubated for Ih at 3 70C, pelleted, resupsended in I 001il L-Broth and plated 
on ampicillin-plates. The plates were then incubated at 37"C overnight, to allow for 
bacteria growth. 
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2.4.8 Minipreps and digests 
2x 2ml of L-Broth containing 100ýtl/ml ampicillin were inoculated with a single 
colony of each bacterial clone and allowed to grow at 37*C overnight. The DNA was 
purified as described in section 2.1.7 and digested in the following way to check for the 
presence of an insert: 5ýd DNA + 1.5ýtl RNAse A (Img/ml) + I. Spl Buffer B (ROCHE) 
7gl H20 +I gl of each Xhol and ECOR I/ per 12 constructs, at 3 7'C for lh. 
2.4.9 Fast tranformation of yeast 
Half of a YEPD plate was densely streaked with Y190[pYTH9: PTENACATAPDZ] 
and incubated at 30"C overnight. Cells were scraped off the plate using a sterile 
inoculation loop and resupended in Iml sterile water. Cells were pelleted at 13000rprn for 
1 min and resuspended in Iml of 1X LiAc/TE (IOX LiAc/TE: IM lithium acetate, 
I OOmM TrisHCl [pH 7.5], 5mM EDTA). Cells were pclleted once again and resuspended 
in 500gl of 1X LiAc/TE. To each 50ýd of cell suspension were added Igg of 
transforming DNA, 50jig of carrier DNA (QBiogene) and 300111 of 40% PEG 
[polyethylene glycol 3,350 (w/v)] in OAM LiAc/TE. The yeast were incubated at 30*C 
for 30min and induced to take-up the DNA by heat shocking at 42'C for 10min in the 
presence of 30ttl of DMSO. Cells were then washed 3x with Iml TE [pH7.5], 
resuspended in in 50gl TE [pH 7.5] and allowed to grow on Sc-Trp-Leu plates at 30*C 
for 2 days. 
2.4-10 P-galactosidase filter transfer assay 
Yeast cells grown on SC-Trp/-Leu plates containing bait and prey constructs were 
replica plated on to Whatmann, number I filter discs (9cm), which were then dipped three 
times into liquid nitrogen for 20s and allowed to thaw to induce cell lysis. The discs were 
placed in 10cm plates already containing a filter disc pre-soaked in 2ml of buffer Z 
(60mM Na2HP04.7H20,4OmM Na2HP04.4H20, I OmM KCI, I mM MgS04. H20) with 
5OmM P-mercaptoethanol and 0.5mg/ml 5-bromo-4-chloroindolyl-P-D-galactoside (X- 
gal). Positive bait and prey protein interactions were detected by the presence of a blue 
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coloured product released by the action of P-galactosidase on X-Gal after incubation 
between 5h and 16h at 30T. 
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Results - Glioma migration and the Rho GTPases 
3.1 Summary 
Rho GTPases play a key role in regulating cell migration. Astrocytes, the principal 
macroglial cells of the CNS, riiigrate relatively slowly, while gliomas, which are highly 
invasive astrocyte-derived tumours, are highly motile and able to infiltrate the 
surrounding tissue and spread diffusely in the brain. In this chapter, the aberrant 
migration of three increasingly malignant human glioma cell lines (U373, U138, U87) 
was characterised using a wound-healing assay and compared to the migration of primary 
rat astrocytes. Furthermore, the contribution of Rho GTPases to the motility of these 
gliomas cell lines was investigated. Microinjection experiments showed that Rac and 
Cdc42 are essential for the migration of both astrocytes and the glioma cell lines. 
Interestingly, however, the higher migration rate observed for the gliomas does not 
correlate with the levels of active Cdc42 or Rac. Nevertheless, the activity of the Rac 
downstream effector Idnase, p65PAK, was increased in the higher malignant cell lines 
U138 and U87. In contrast, the activation levels of a Cdc42 target kinase, PKCý, 
remained unchanged across the three glioma cell lines. 
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3.2 Introduction 
Cell migration is a complex process that is driven primarily through the remodeling of 
the actin cytoskeleton. A large variety of signaling molecules have been implicated in the 
control of cell migration, including MAPK cascades, lipid Idnases, phospholipases, 
Ser/'Ibr and Tyr kinases and scaffold proteins, and in particular, one family of proteins 
seems to play a critical role in regulating the biochemical pathways central to cell 
migration, the Rho GTPases (Ridley, 2001a). In order for the cell to migrate in the 
correct direction and to know where to stop and differentiate the activity of these 
signaling molecules must be tightly regulated both in time and space. In most aggressive 
turnours, however, this tight regulation has been lost, resulting in tumour invasion and 
metastasis. 
Genetic mutations identified in human gliomas often target receptor tyrosine kinase 
signaling pathways (e. g. EGFR or PDGFR), resulting in their constitutive activation. Rho 
GTPases have been shown to be activated downstream of several such receptor tyrosine 
kinases and their activities are thus potentially misregulated in these turnours and this 
may contribute to their aberrant migratory behaviour. To gain a better understanding into 
how glioma cell migration is regulated, the migration of three human glioma cell lines 
(U3 73, U 13 8 and U87) and of primary astrocytes was examined using an in vitro wound- 
healing assay. Furthermore, the activity state of Rho GTPases in these gliomas as well as 
their contribution to the glioma migration behaviour was investigated. 
3.3 Results 
3.3.1 General characteristics of glioma behaviour 
To characterise the behaviour of the gliomas in culture, the migration, polarity and 
proliferation rate of three increasingly malignant human glioma cell lines (U373, U138, 
U87) was analysed under conditions when the cells were grown with (10% FCS) or 
without any serum. The results are summarized in table 3.1. Unsurpisingly, astrocytes are 
the only cells that cannot divide in the absence of serum. All three gliomas, are known to 
have acquired several mutations in genes regulating cell cycle arrest and apoptosis, and 
can by-pass the requirement for serum in order to grow and divide (Maher et al., 2001). 
Furthermore, when the rate of proliferation of the gliomas is compared to that of 
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astrocytes in figure 3.1, astrocytes are much slower and their proliferation rate plateaus 
after day 5. The rate of proliferation of gliomas reflects their malignancy grade, with the 
highly aggressive U138 and U87 cells dividing much faster than U373 cells. Even though 
U373 cells seem to initially form a monolayer, they do not seem to be contact inhibited 
for division as they keep dividing long after they have reached confluency at day 7. U 13 8 
and U87 cells, on the other hand, do not form a monolayer and cells keep dividing on top 
of each other, resulting in the forination of foci. 
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FIGURE 3.1 
Quantitation of cell growth relative to time. A confluent 9cm dish of cells was split 1: 5 and 
Iml was split equally into a 24-well dish, resulting in a cell density of 2x 104 cells / well at 
day 0. Everyday, cells in one of the wells were trypsinised and counted using a 
haemocytometer. The experiment was performed in duplicate for each cell line. 
When the migratory behaviour of these cells was analysed, as indicated in table 3.1, 
astrocytes and U373 do not migrate in the absence of serum, but instead grow long 
extensions/protrusions and stop (data not shown). U87 and U138, however, can still 
migrate in the absence of serum, albeit more slowly. A plausible explanation for these 
differences could be that U138 and U87 secrete the necessary growth factors and matrix 
proteins required for cell migration. Gliomas have previously been shown to acquire 
mutations such as gene duplications of the EGFR and PDGFR and also to upregulate the 
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corresponding receptor ligands thus resulting in a positive feedback loop (Fenstermaker 
and Ciesielski, 2000; Lokker et al., 2002). Both EGFR and PDGFR are key regulators of 
cell migration and have been shown to activate the small GTPase Rac (discussed in 
section 1.3.4.2). 
DIVISION MIGRATION CONTACT POLARITY 
INHIBITION 
SERUM + + 
-- ASTROCYTES - ----- --- x ........... x n/a n/a 
U373 n/a n/a 
U138 X n/a x x 
U87 X n/a X X 
TABLE 3.1 
Table summarizing the key observations of glioma behaviour as seen by time-lapse 
microscopy recordings of cells migrating in a wound-healing assay. N/a stands for non- 
applicable. 
3.3.2 Increased malignancy of glioma cells corresponds to an increase in 
their migration rate 
fn order to investigate the migration behaviour of the gliomas more closely, time-lapse 
movies of U373, U138 and U87 cells migrating in a wound-healing assay were recorded 
over a period of 16 hours (Figure 3.2 and Table 3.1). These were then compared to time- 
lapse recordings of migrating astrocytes. 
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FIGURE 3.2 
The migration rate of glioma cells increases and polarity of movement decreases with an 
increase in malignancy. Astrocytes (A-F) and U373 (G-L) cells migrate as a sheet in a 
polarised way, whereas the U87 (M-R) migrate as individual cells and are non-polarised. 
Movie stills are shown for astrocytes migrating at t--Omin (A), t--3h (B), t--10h (C), t=16h (D), 
t--24h (E) and t--30h (F), and for U373 and U87 cells migrating at t--Omin (G, M), t--Ih (H, 
N), t=4h (1,0), t--8h (J, P), t--12h (K, Q), and t--16h (L, R) of time-lapse movies taken in 
phase at I frame/5 minutes, usinga lOx objective. The scale bar represents 150Am. 
Similarly to primary rat astrocytes, U373 cells, the least malignant tumour cells, 
migrate as a sheet and are mainly polarised in their migration, i. e. migrate in a direction 
perpendicular to the wound. However, they migrate faster than primary astrocytes (0.21 
Am/min compared to 0.11 gm/min) and are able to close the wound, taken as the time- 
point when cells from each side of the wound touch each other, in approximately 12h, 
while astrocytes typically take more than 24 hours to close a wound of the same size 
[Figure 3.2 (A-F)]. In contrast, the more malignant cells U87 and U138 do not form a 
monolayer; cells migrate independently of each other and exhibit a non-polarised, random 
migratory behaviour. Although the overall rate of migration for the U87 and U138 is 
higher (0.56 gm/min and 0.35 gm/min, respectively) than that of U373, they also close 
the wound in approximately 12h, presumably because of their non-directed migration 
behaviour (Figure 3.3a). If the average absolute angle of migration is calculated, by 
taking as 90* the angle when the migration is perpendicular to the wound, then it can be 
seen that U87 and U138 cells do not exhibit a polarised migratory behaviour, like the one 
observed for astrocytes and U373 cells (Figure 3.3b). 
In addition, compared to primary astrocytes or U373 cells, the highly malignant 
tumour cells U138 and U87 are not contact inhibited for migration, Le when meeting 
another cell they do not stop and change direction, but frequently crawl on top of each 
other. A summary of the migration behaviour of these cells is presented in Table 3.1. 
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FiGURE 3.3 
(a) The higher malignancy U87 and U138 cells migrate faster than the lower malignancy cells 
U373 or primary astrocytes. The graphs were drawn using the measurements acquired with 
the Metamorph software by tracking 10 individual cells from each time-lapse movie of the 
U373, U138 and U87. The measurements for the primary astrocytes were provided by Dr. 
Sandrine Etienne-Manneville. The y-axis represents the mean velocity (Vm)/ speed of 
migration measured as lim/min. (b) U138 and U87 cells do not exhibit a polarised directed 
migration and do not migrate at a 9011 angle to the wound like astrocytes. The angle 
measurements were acquired with the Metamorph software. 
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3.3.3 Analysis of cell migration after microinjection - Role of Rac and 
Cdc42 
Rac and Cdc42 have been shown to be essential for cell movement and cell 
polarisation respectively, in astrocytes (Etienne-Manneville and Hall, 2001). Since all 
three gliomas have a higher rate of migration than primary astrocytes, and the U138 and 
U87 are no longer polarised in their migration, the requirement of Rac and Cdc42 for 
their migration behaviour was assessed. Due to the different migratory behaviours of the 
three gliomas, slightly different assays were used in each case. 
3.3.3.1 Assay for U373 cells 
For U373 cells, cDNA expression constructs of dominant negative and constitutively 
active forms of Rac and Cdc42, as well as GFP as a negative control, were injected into 
the nucleus of cells in the front row of a wound. To examine the effects of the various 
constructs on migration, the cells were allowed to migrate for 8h and were then fixed and 
stained for expression of the injected constructs and in order to visualise the position of 
the injected cells relative to the leading edge of the wound. Phalloidin was used to 
visualise filamentous actin in all the cells. Since U373 cells, like astrocytes, migrate as a 
sheet and in a polarised manner, cells in the front row of the wound not inhibited in their 
migration, are still present at the leading edge after 8h, and are thus scored positively. 
Cells that have been inhibited in their ability to migrate, on the other hand, are overtaken 
by the back rows of cells and therefore are no longer present at the leading edge of the 
wound and these are scored negatively. Figure 3.4 shows that expression of a dominant 
negative Rac (Nl7Rac) construct inhibits migration of U373 cells by more than 80% 
compared to control GFP - injected cells. Interestingly, expression of a constitutively 
active form of Rac (L6lRac) also inhibits migration of U373 cells to a similar extend as 
NPRac. This could be due to the fact that overexpressed L6lRac is no longer 
specifically localised and activated at the front of the cell and that the cell is thus unable 
to form a polarised protrusion and specify new adhesion sites at the front. Indeed, as seen 
in figure 3.4b E, F, U373 cells overexpressing L61Rac extend lamellipodia all around the 
cell, 'pulling' the cell in all directions at once. Similarly to L61 Rac, microinjection of 
constitutively active Cdc42 also inhibits migration and cells show lamellipodia all 
around, presumably because Cdc42 can activate Rac (see above). Interestingly, 
microinjection of dominant negative Cdc42 also inhibits migration. 
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FIGURE 3.4 
Migration of U373 is dependent on Rac and Cdc42. (a) Representative examples are shown of 
U373 cells microinjected in a wound-healing assay with cDNA constructs encoding, control 
GFP (A, B), Myc-epitope tagged L6lRac (C, D), N17Rac (E, F), L6lCdc42 (G, H) or 
N17Cdc42 (1, J). Microinjected cells were fixed and detected by staining with 9E10 anti-Myc 
antibody. The actin was visualized using Rhodamine-conjugated phalloidin. Scale bar, 50pin. 
A white line is drawn to indicate the leading edge of the wound. (b) Quantification of the 
number of U373 n-dcroinjected cells that are found at the leading edge of the wound after 
migration for 8h. The effect of microinjected cDNA constructs encoding Myc-epitope tagged 
don-dnant negative Rae (Nl7Rac), constitutively active Rac (LORac), dominant negative 
CdC42 (N17Cdc42) or constitutively active Cdc42 (L6lCdc42) is shown. Results are 
represented as a percentage of the number of cells found at the leading edge of the wound 
over the total number of cells injected. Data shown are the mean + SEM of three independent 
experiments where an average of 100 cells (20cells in each of 5 separate wound edges) were 
injected for each construct. 
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3.3.3.2 Assay for U87 ceHs 
Since U138 and U87 cells do not migrate as a sheet but as individual cells, the assay 
used to examine the effects of microinjecting cDNA expression constructs of don-dnant 
negative and constitutively active forms of Rac and Cdc42, as well as GFP as a negative 
control on the migration of these cells was the following. The various constructs were 
microinjected into the nucleus of cells in a straight line parallel to that of the 'scratch'. 
The cells were left to migrate for a total of 8h and were fixed and stained in order to 
visualize the microinjected cells. Phalloidin was used to visualize filamentous actin of all 
cells. Cells expressing the various constructs and that were still found in a straight line 
parallel to the original wound were scored as non-n-ýigratory, whereas cells that exhibited 
a random distribution were scored as positive, i. e. still retaining the ability to migrate. 
Similarly to U373 cells, the migration of U87 and U138 cells was found to be 
dependent on Rac, as overexpression of both dominant negative and constitutively active 
forms of Rac inhibited their migration by more that 90% (Figure 3.5, and data not 
shown). In contrast to astrocytes (data not shown) and U373 cells however, 
microinjection of dominant negative Cdc42, had no effect on the migration of U87 and 
U138 cells. U87 and U138 cells are not polarised and would therefore be expected to 
already have very low endogenous levels of active Cdc42, or to have acquired mutations 
downstream of Cdc42. In contrast, a constitutively active form of Cdc42 inhibited 
migration of U87 cells, but this could simply reflect the subsequent activation of Rac, as 
discussed earlier for the U373 cells. The cells acquire a much more spread, flattened 
morphology, with a lamellipodium extending all around the cell, reminiscent of an 
L6 I Rac phenotype [Figure 3.5b, (C, G)]. 
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FiGURE 3.5 
Migration of U87 cells is dependent on Rac and is not inhibited by N17Cdc42. (a) 
Representative examples are shown of U87 cells microinjected in a wound-healing assay with 
vectors encoding, control GFP (A, B), Myc-epitope tagged L6lRac (C, D), N17Rac (E, F), 
L6 I Cdc42 (G, H) or NI 7Cdc42 (1, J). Microinjected cells were fixed and detected by staining 
with 91310 anti-Myc antibody. The actin was visualized using Rhodamine -conjugated 
phalloidin. Scale bar, 501im. A dotted white line is drawn to indicate the direction of the 
wound parallel to which cells were n-dcroinjected in a straight line. (b) Quantitation of the 
number of U87 microinjected cells that are found still aligned in the direction of the wound 
after migration for 8h. The effects of vectors encoding Myc-epitope tagged cDNAs of 
dominant negative Rac (N17Rac), constitutively active Rac (L61Rac), dominant negative 
Cdc42 (N17Cdc42) or constitutively active Cdc42 (L6lCdc42) are shown. Results are 
represented as a percentage of the number of cells still aligned in the direction of the wound 
over the total number of cells injected. Data shown are the mean + SEM of three independent 
experiments where an average of 100 cells (20 cells in each of 5 separate wound edges) were 
injected for each construct. 
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3.3.4 Relative levels of active Rac and Cdc42 in gliornas 
To examine whether the endogenous levels of active Rac and Cdc42 could account for 
the observed increase in migration rate and loss in polarity, pull-down assays were 
performed to investigate the GTP-loading on each of the GTPases. These assays take 
advantage of the fact that effector proteins bind specifically only to the active, GTP- 
bound form of the small GTPases and can be used to precipitate only the activated 
GTPases directly from cell lysates. In the case of Rac and Cdc42, the Cdc42/Rac 
interacting binding (CRIB) region of the effector protein p65PAK was used to 
specifically precipitate Rac-GTP and Cdc42-GTP. 
Figure 3.6 shows that while the levels of active Rae are higher in U373 than primary 
astrocytes, they are lower in U87 and U138 cells. In fact they are almost undetectable in 
these two cell lines, even though the total levels of Rae protein are similar. This is very 
surprising given that the migration rate of these gliomas is much higher than that of U373 
cells or astrocytes. There are several possible explanations for this finding: First, 
although the total cellular levels of active Rae are decreased, the amount of active Rae at 
the leading edge of the cell where it is required for migration, could still be increased (this 
could, for example, be measured with the use of FRET). Secondly, there could be an 
increase in the stable downstream association of Rae with targets, which prevent it to be 
accessible in the 'pull-down' assay. Thirdly, the pull down assay might not be a true 
representation of the activation of Rae in cells, if Rae is rapidly cycling between its GTP 
and GDP forms (Lin et al., 1997). 
Using the pull-down assay to look at levels of active Cdc42, it was found that U87 and 
U138 cells have lower levels of active Cdc42 compared to the U373 and primary 
astrocytes. This correlates with the loss in polarity observed previously in the migration 
assay. However, given the similar results found for Rac (see above), interpretation of 
this result is not straightforward. 
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FIGURE 3.6 
Comparison of the levels of active Rae and Cdc42 in astrocytes, U373, U 138 and U87. U87, 
U138, U373 cells and primary astrocytes were lysed and incubated with GST-PAK-CRIB to 
isolate GTP-bound Rae and Cdc42. Levels of Rae and Cdc42 were monitored by Western blot 
analysis using anti-Rac and anti-Cdc42 antibodies. Total protein levels were monitored using 
an anti-tubulin antibody. U87 and U 138 cells have lower levels ofactive Rae and Cdc42. 
In order to investigate further the cellular activity of Cdc42 and Rac, two approaches 
were taken. The first was to look at the cellular GEF activity (discussed in section 3.3.5) 
and the second was to look at the activation level of downstream effectors of the Rac and 
Cdc42 (see section 3.3.6). 
3.3.5 Determination of cellular GEF activity 
To investigate the activation rate of Rac and Cdc42, in vitro GEF assays were 
performed with lysates from each of the three glioma and astrocytes, using bacterially 
purified GST-tagged Rac protein. Rac is loaded in vitro with GDP and subsequently 
incubated with control buffer or with cell lysate and the exchange reaction is allowed to 
proceed in the presence of [3 H]-GTP (ON-rates). Aliquots are taken at fixed time-points 
and the reaction is terminated by diluting in cold buffer. The time-course of exchange of 
GDP for [3 H]-GTP is assessed by scintillation counting (see Materials and Methods). 
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As shown in figure 3.7, GTP-loading of Rac with extracts trom U87 cells is 
sigrilficantly higher compared to U138, U373 and astrocyte lysates. This supports the 
possibility of an active GEF promoting fast cycling of Rae compared to the astrocytes and 
U373 and could, perhaps contribute to the observed increase in migration rate. However, 
U138 cells also migrate faster, yet did not show an increased rate of GTP-binding to Rac. 
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FIGURE 3.7 
The overall GEF activity towards Rae in U87 cells is increased compared to the other gliomas 
and astrocytes. The exchange rate of GDP-loaded Rae for [3H]-GTP was measured for every 
cell lysate or control buffer by taking aliquots at t-0,5,10,15,20 and 30 minutes, followed 
by scintillation counting. The graph represents the change in the number of counts per minute 
for each sample over time. 
3.3.6 PAK and PKCý activity as downstream effectors of Rac and Cdc42 
To gain further insight into the signaling mechanisms involved in the faster migration 
rates and loss of polarity observed in the gliomas, the activation state of downstream 
effectors of Rae and Cdc42 was examined. PAK, a Ser/Thr kinase, is believed to be one 
of the main targets of active Rac and/or active Cdc42 and an important player in the 
regulation of actin dynamics during cell adhesion and migration. 
In order to look at the activation levels of endogenous PAK in the gliomas, PAK was 
immunoprecipitated from cell lysates and its activity towards myelin basic protein (MBP) 
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was assessed in an in vitro kinase assay. As shown in figure 3.8, MBP phosphorylation is 
significantly higher in U138 and U87 cells (-3.8 and 3.3 fold respectively) compared to 
U373 cells. This suggests an increase in PAK activation in U138 and U87 probably 
reflecting an increase in the activation levels of Rac and/or Cdc42, despite the very low 
levels of Rac and Cdc42 found in the 'pull-down' assays. 
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FIGURE 3.8 
PAK activity is higher in U138 and U87 compared to U373. Endogenous PAK was 
immunoprecipitated from cell lysates and incubated for 15min at 37'C with myelin basic 
protein (MBP) in the presence of [32p] -ATP. The phosphorylation of MBP was assessed by 
SDS-PAGE and subsequent Western blot analysis and exposure to film. The levels of PAK in 
the IP and in the total lysates was analysed by blotting with an anti-PAK antibody. 
In its active state, Cdc42 can also activate the atypical protein kinase Cý (PKCý) 
when complexed with Pai-6. The specific activation of this complex at the leading edge of 
migrating cells is required to determine the polarity and direction of movement of 
primary astrocytes (Etienne-Manneville and Hall, 2001). Therefore, the activation of 
endogenous PKCý, as a direct downstream target of Cdc42-GTP, was assessed in an in 
vitro kinase assay. MBP was used as a substrate. As shown in figure 3.9, there is no 
significant difference in the phosphorylation of MBP by PKCý when immunoprecipitated 
form the various glioma lysates. This suggests that deregulation in the overall activation 
of PKCý is not the main cause for the observed loss in polarity of the U138 and U87 
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cells, although it is still possible that the mislocalisation or mislocalised activation of 
PKCý in the gliomas, could contribute to loss of polarity. 
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FIGURE 3.9 
PKC,, activity does not reflect the decrease observed in the levels of Cdc42-GTP or the 
' was immunoprecipitated from cell lysates and subsequent loss in polarity. Endogenous PKC, 
incubated for 15min at 37'C with MBP in the presence of [32p] -ATP. The phosphorylation of 
MBP was assessed by SDS-PAGE and subsequent Western blot analysis and exposure to 
film. The levels of PKC in the IP and in the total lysates was analysed by blotting with an 
anti-nPKCI, antibody. 
3.4 Discussion 
Migration is a complex process that requires the precise co-ordination of a large 
number of signaling pathways. In human gliomas, most of the genetic mutations 
identified to date result either in the disruption of cell cycle regulation pathways, or in the 
disruption of signaling cascades downstream of receptor tyrosine kinases. These 
mutations account for the increase in proliferation, cell survival and invasion 
characteristics acquired by these turnours. For example, amplification of the EGFR or 
PDGFR and/or over-expression of their corresponding ligands, results in constitutive 
activation of the corresponding downstream signaling pathways, which lead among other 
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things, to cell de-differentiation and tumour invasion by reactivation of the mechanisms 
underlying early glial migration during developmenL 
In this chapter, the aberrant migration of three human glioma. cell lines (U373, U138 
and U87) was characterised by use of a wound-healing assay and, consistent with 
previous studies in other cell types, the small GTPases Rae and Cdc42 were shown to 
also play a role in the regulation of turnour cell migration. 
3.4.1 Glioma migration is different from that of astrocytes 
Astrocytes, when migrating in a wound-healing assay, migrate as a sheet and begin by 
extending a long protrusion into the wound perpendicular to the direction of the 'scratch'. 
The cells then migrate into the empty space at right angles to the wound and stop when 
the two wound edges meet each other (Etienne-Manneville and Hall, 2001). The 
results in section 3.3.2 show that gliomas exhibit a very different migratory behaviour. 
The lowest grade glioma cell line U373 exhibits a mesenchymal form of migration. The 
cells still migrate as a sheet, they polarise a lamellipodium into the wound and when the 
two wound edges meet and the wound closes they stop. Compared to astrocytes, however, 
their migration rate is higher (almost 2-fold) and the protrusion at the front of the cell is 
much smaller. The more malignant U138 and U87 cells both show a similar mode of 
migration that differs greatly from that of astrocytes and U373 cells. U138 and U87 cells 
do not form a confluent monolayer and do not migrate as a sheet but as individual cells 
and display a much more characteristic arnoeboid movement (Friedl and Wolf, 2003). 
The cells are not poIarised for migration at right angles to the wound but instead their 
movement is much more random. They eventually close the wound, but they are not 
contact inhibited in their migration, i. e. they do not stop when they meet each other. They 
also have a much faster rate of migration compared to that of U373 and astrocytes. 
3.4.2 A role for Cdc42? 
Cdc42 has been shown to play a crucial role in specifying cell polarity in various cell 
types, including primary astrocytes and fibroblasts, where it most likely specifies the 
location of the cell protrusion or lamellipodium. (Etienne-Manneville and Hall, 2001; 
Nobes and Hall, 1999). Futhermore, inhibition of Cdc42 has been shown to block 
macrophage chernotaxis towards a gradient of CSF-I, probably by disrupting the cells' 
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ability to sense the gradient, since the macrophages are still able to move 
(Vanhaesebroeck et al., 1999). 'Me mechanism of how Cdc42 regulates chemotaxis is not 
known. Cdc42 promotes localised actin polymerization to form filopodia, which are 
thought to be important in probing the extracellular milieu and this might contribute to its 
role in chemotaxis and the specification of the cell protrusion/lamellipodium. 
A role for Cdc42 in the aberrant migration of glioma cells was demonstrated here by 
expressing a dominant negative form of Cdc42 (Nl7Cdc42). As had previously been 
shown for primary rat embryonic fibroblasts, microinjection of N17Cdc42 in a wound- 
healing assay significantly impaired the migration of the normally polarised U373, as the 
cells were no longer found at the leading edge of the wound in contrast to control-injected 
cells. N17Cdc42, however, did not seem to affect the migration of the already non- 
polarised U87 cells. An investigation in the levels of active Cdc42 in this chapter showed 
that a decrease in the levels of Cdc42-GTP is consistent with a loss in polarity and 
confirmed the role of Cdc42 as a key regulator in this process. The highly malignant 
U138 and U87 cells, which were shown not to be polarised in their migration in a wound- 
healing assay, unlike the lower malignancy grade U373 and primary astrocytes, exhibited 
very low levels of active Cdc42 as seen by pull-down assay. Care should be taken 
however in interpreting pull-down assays, since, the levels of Rac-GTP were clearly not 
consistent with the observed rates in migration. Pull-down assays are typically a 
reflection of steady-state levels of GTP loading on the GTPases and may not account for 
differences in the GTPase rates of cycling. Therefore, even though U138 and U87 cells 
displayed lower levels of Cdc42-GT? compared with the polarised U373 and primary 
astrocytes, the possibility of a faster cycling of the GTpase (see also section 3.4.3 on 
RAO, cannot be excluded, especially when an increased GEF activity for Cdc42 was 
demonstrated for the U87 and U138 cells, by in vitro GEF assays (data not shown). 
The precise mechanism of how Cdc42 regulates polarity is not known, but work in 
neutrophils and astrocytes has identified some of the players involved. In astrocytes, 
CdC42 regulates the re-orientation of the MTOC and hence the direction of movement by 
specifying the formation of the protrusion at the front of the cell, in this case at right 
angles to the wound. It is thought to do so by binding and activating, in its GTP-bound 
state, a complex of Par-6 and PKCý. The specific activation of this complex at the front 
of these cells is crucial for determining the direction of movement (Etienne-Manneville 
and Hall, 2001). It is therefore not surprising that overexpression of a constitutively active 
form of Cdc42 (L6lCdc42) inhibited the migration of U373 cells, as shown in section 
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3.3.3. U87 cells, even though already not polarised, were also inhibited in their migration. 
When the activation levels of PKCý were assessed by an in vitro Idnase assay, however, 
no difference was observed between the levels of active PKCý in the U373 and the U138 
and U87 cells. Recently, it was shown that the Cdc42/Par-6/PKC complex regulates cell 
Polarity by promoting the phosphorylation of the Idnase GSK3P specifically at the 
leading edge of migrating cells and thus allowing the scaffold protein APC to associate 
with the plus ends of microtubules (Efienne-Manneville and Hall, 2003). Therefore, the 
observed loss in polarity of the U87 and U138 glioma cells could be at the level of GSK3 
or APC. 
3.4.3 A role for Rac? 
Rac has previously been shown to be a key regulator of cell migration (Nobes and 
Hall, 1999; Ridley et al., 1992). In Drosophila, it regulates border cell migration during 
oocyte maturation (Duchek et al., 2001). In this chapter, the role of Rac in glioma 
migration was investigated and, in agreement with what is known for the migration of 
other cell types, Rac was found to be essential for the migration of all three gliomas. 
Overexpression of dominant negative and constitutively active forms of Rac inhibited the 
migration of U373, U138 and U87 cells. Interestingly, - looldng by pull down assay - less 
activated Rac was found in the highly malignant U138 and U87 glioma cells compared to 
Primary astrocytes. This is very different from what has been found in other turnours; in 
breast cancer tumours, an increase in cell migration corresponds to an increase in Rac 
activation through overexpression of the Rac-specific GEF TIAM-I (Bourguignon et al., 
2000). One explanation for this could be that other additional genetic mutations acquired 
by these aggressive gliomas lead to the downregulation of active Rac. Alternatively, the 
lower levels of Rac-GT? could be a reflection of a faster cycling of the GT? ase or that 
the GTPases are more efficiently localised at the front of the migrating cells in the 
gliomas (as discussed in section 3.3.4). A closer look at the total GEF activity in the 
various cell lysates revealed a very high GEF activity towards Rac in the U87 cell lysate, 
whereas the U138, and U373 cell lysate GEF activity was not significantly affected. 
There have been approximately 60 GEFs identified in humans and the GEF activity seen 
in U87 cells could be attributed to either a single GEF or a mixture of GEFs (Schmidt and 
Hall, 2002). Isolation of the active GEF(s) from U87 lysate would be a huge challenge, 
and instead, an alternative approach was chosen, in order to examine possible regulatory 
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pathways upstream of GEFs, focusing on the P13-kinase/PTEN pathway (see section 
3.4.4 and chapters 4,5). 
Investigation into the activation state of PAK, a common downstream effector of Rae 
and Cdc42, revealed that PAK was significantly more active in both U87 and U138 cells 
compared to U373 cells. PAK had previously been shown to lie downstream of the 
receptor tyrosine kinases PDGFR and EGFR, which are frequently upregulated in 
gliomas. Activation of PAK in U138 and U87 is therefore consistent with a pathway 
leading from PDGFR/EGFR to the activation of Rae and the subsequent activation of 
PAK (He et al., 2001; Nobes et al., 1995; Ridley et al., 1992). 
3.4.4 Regulation of Rac and Cdc42 
This chapter presented a more thorough investigation of the key features that define 
the aberrant migration of three human gliomas and confirmed the role of Rac and CdC42 
as key regulators of cell polarity and migration. Still, however, very little is known about 
the mechanisms by which Rac and Cdc42 control cell movement and especially how they 
control directed cell migration. Recent work in neutrophils suggests the establishment of 
a cellular asymmetry that involves the interplay of Rho GTPases and the lipid PI(3,4,5)P3, 
a product of PI 3-kinase, in the establishment of cell chemotaxis. Whether P13K and 
PI(3,4,5)P3 lie upstream or downstream of the Rho GTPases in the regulation of cell 
movement is not yet clear. It has previously been shown, however, that several GEFs, like 
Vav, TIAM-1, SWAP-70 and p-Rex-1, are subject to PI(3,4,5)P3 activation (Schmidt and 
Hall, 2002). PTEN, a lipid and protein phosphatase, is believed to be the main antagonist 
of the PI 3-kinase signaling pathway by down-regulating the levels of PI(3,4,5)P3 in the 
cell and is absent in all three glioma cell lines studied here. Increased levels of PI(3,4,5)P3 
in the gliomas could therefore account for the increase in GEF activity observed in U138 
and U87 cells. Indeed, treatment of U138 and U87 cells with wortmannin (100nM), 
inhibited their ability to close the wound in a wound-healing assay, compared to non- 
treated control cells (section 4.3.3), confirming therefore a role of PI(3,4,5)P3 in the 
migration of these cells. The role of PTEN in glioma cell migration was therefore more 
closely investigated in the results chapters that follow. 
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Results - The Role of PTEN in - Glioma Cell 
Migration 
4.1 Summary 
Many GEFs for Rac are regulated by PI(3,4,5)P3 levels, and the results in chapter 3 
suggest that there might be an increased GEF activity towards Rac in at least the U87 
cells. The levels of PI(3,4,5)P3 in the cell are controlled primarily by P13-kinase and 
PTEN. Interestingly, PTEN is a turnour suppressor protein that is frequently deleted in 
many human cancers, including gliomas. In this chapter the role of PTEN in the 
migration of the glioma cells was investigated. It was confirmed that all three glioma 
cell lines studied (U373, U138, U87) lack PTEN and have thus higher levels of 
PI(3,4,5)P3. This suggests that the resultant increase in PI(3,4,5)P3 levels could account 
for the higher rate of migration described in the previous chapter, possibly through the 
activation of Rac. Microinjection of wtPTEN inhibits the migration of these gliomas, but 
does not affect astrocyte migration. Interestingly, however, it was revealed that the 
protein, but not lipid phosphatase activity is needed to inhibit migration. Furthermore, 
deletion analysis revealed that PTEN inhibits glioma cell migration through a previously 
uncharacterized mechanism. 
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4.2 Introduction 
The dual lipid/protein phosphatase PTEN is a turnour suppressor frequently 
deleted in multiple human advanced cancers, including astrocytomas and glioblastomas 
(Li et al., 1997a). The major physiological substrate of PTEN is PI(3,4,5)P3 and to a 
lesser extent PI(3,4)P2 and PI(3.5)P2, and it acts, therefore, as an antagonist of the PI 3- 
kinase signaling pathway (Lee et al., 1999; Maehama and Dixon, 1998). Studies in C 
elegans, Drosophila and mammalian cells have revealed that PTEN and PI 3-kinase play 
major roles both during development and in the adult to control cell size, growth and 
survival (Huang et al., 1999; Mihaylova et al., 1999). The loss of PTEN found in human 
tumors leads to an increase in PI(3,4,5)P3 and the uncontrolled stimulation of growth and 
survival signals (Downes et al., 2001). 
The PTEN protein consists of a PI(4,5)P2 binding motif at the start of its N- 
terminus, followed by the catalytic phosphatase domain, which can act on both protein 
and lipid substrates, a C2 domain and a PDZ binding motif at its extreme C-terminus. In 
this chapter the role of PTEN in the migration of the gliomas was examined and the 
contribution of the various PTEN domains on cell migration was investigated. 
4.3 Results 
4.3.1 PTEN is not expressed in U373, U138 and U87 cells 
The U373, U138 and U87 glionias have been reported to have mutations in the PTEN 
gene that are predicted to abolish PTEN protein expression (Chiariello et al., 1998; Wang 
et al., 1997). This was confirmed by Western analysis of glioma cell extracts using a 
commercially available antibody specific for PTEN. As expected, no signal was detected 
in the U373, U138 and U87 cell lysates, while PTEN was expressed both in primary 
astrocytes and COS-7 cells (Figure 4.1). 
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FIGURE 4.1 
PTEN is expressed in primary astrocytes and COS-7 cells, but not in U373, U138 or U87 
cells. 20gg of each cell lysate were analysed by SDS-PAGE and Western blot analysis using 
an antibody raised against the C-terminus of PTEN. An antibody against tubulin was used as a 
loading control. 
As mentioned above, PTEN has been shown to be a direct antagonist of the PI 3- 
kinase pathway by directly dephosphorylating PI(3,4,5)P3 leading to decreased levels of 
PI(3,4,5)3 in the cell. To investigate if the absence of PTEN in the glioma cells indeed 
leads to increased levels of PI(3,4,5)P3, the phosphorylation state of protein kinase 
B(PKB)/Akt was assessed. PKB is a key regulator of cell survival and is activated in a PI 
3-kinase-dependent mechanism by binding PI(3,4,5)P3 and translocating to the plasma 
membrane where it becomes phosphorylated (Vanhaesebroeck and Alessi, 2000). Its 
phosphorylation state, therefore, can serve as an indirect readout of cellular PI(3,4,5)P3 
levels, and previous studies have shown that in cells that lack PTEN, PKB 
phosphorylation is higher than in cells where PTEN is present (Higuchi et al., 2001; 
Myers et al., 1998). Protein extracts of astrocytes, U373, U138 and U87 cells were 
prepared, subjected to SDS-PAGE and Western analysis using an anti -phospho-PKB 
antibody. As shown in figure 4.2, the lack of PTEN expression correlates well with an 
increase in phospho-PKB levels. U373, U138 and U87 cells all have higher levels of 
phospho-PKB compared to primary astrocytes, which express PTEN normally. 
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FIGURE 4.2 
Lack of PTEN expression in U373, U 138 and U87 cells leads to increased levels of phospho- 
PKB compared to the levels observed in PTEN-expressing astrocytes. 20 Pg of each cell 
lysate were analysed by SDS-PAGE and blotted for levels of phospho-PKB, PKB or ot- 
tubulin (as loading control). 
4.3.2 PTEN overexpression inhibits the migration of gliomas but not 
astrocytes 
It has previously been shown that PTEN overexpression in PTEN null fibroblasts, as 
well as in the glioma cell line U87, inhibits their migration (Tamura et aL, 1998). To 
confirm these results, and to extend the analysis to the other gliomas cell lines, wtPTEN 
was microinjeted into the gliomas cells in a wound-healing assay. As shown in figures 4.3 
and 4.4, both U373 and U138 glioma cells are inhibited for migration when PTEN is re- 
introduced by about 75 %. Overexpression of PTEN in primary astrocytes, however, does 
not inhibit their migration (figure 4.4). 
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FIGURE 4.3 
PTEN inhibits migration of gliomas. U373 cells (A-D) or U87 cells (E-H) microinjected with 
control GFP vector (A, B, E, F) or with a vector encoding HA-epitope-tagged PTEN (C, D, G, 
H) are shown. Cells were left to migrate for 16h (A-H). Expressing cells were detected after 
fixation by staining with rat anti-HA antibody (A, C, E, G) and all cells were visualized using 
rhodamine-conjugated phalloidin (13, D, F, H). A white line is drawn to indicate the leading 
edge of the wound (A-D) in U373 cells, or the direction of the wound (E-H) parallel to which 
U87 cells were microinjected in a straight line. Scale bar 50l. Lm. 
4.3.3 The protein phosphatase activity of PTEN is necessary to inhibit 
migration 
PTEN is an unusual phosphatase in that it has been shown to exhibit phosphatase 
activity towards both lipids and protein substrates. In vitro studies using highly acidic 
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phosphopeptides demonstrated an activity of PTEN towards phospho-tyrosine and 
phospho-serine/threonine substrates (Myers et al., 1997). However, due to its unusually 
large active site, PTEN's major physiological substrate is thought to be 111(3,4,5)1', and to 
a lesser extent 1)1(3,5)P, (Maehama and Dixon, 1998). 
To test whether the ability of' PTEN to inhibit migration of' gliomas was dependent 
upon its lipid or its protein phosphatase activities, two naturally occurring catalytic 
mutants were used: PTEN(C124S) lacks both lipid and protein phosphatasc activity, 
while PTEN(G]29E), a mutant first isolated from a Cowden disease patient, lacks 
detectable activity towards lipids but retains its ability to dephosphorylate peptidc 
substrates (Han et al., 2000; Myers et al., 1998). Both mutants, as well as 6111 as a 
negative control, were microinjected in U373 cells, U87 cells and primary astrocytcs 
(Figure 4.4). 
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Fhe protein, but not lipid, phosphatase activity of PTEN is required to inhibit glionla ccll 
migration. Quantitation of the microinjecoon results. The number of' cells c\pressing the 
various constructs that are still found at the leading edge of each wound 16h (Cor I J373 or U87 
cel Is) or 24h (for astrocytes) after injection was counted. Results are sho%N n as a percentaiN Of 
the total number of' expressing cells. Data shown arc the mcan i SEM of' three to tl%c 
independent experiments where an average of 100 cells (20 cells in each of5 separate %NOUnd 
edges) were injected for each construct. 
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As expected, the catalytically dead mutant, PTEN(C I 24S), is no longer able to inhibit 
migration of U373 and U87 cells. Surprisingly, however, PTEN(G129E), which still 
retains catalytic activity towards phospho-peptides, inhibits the migration of both U373 
and U87 cells similarly to the wild type protein. This is in agreement with previous 
studies by Tamura et al., demonstrating that PTEN's ability to inhibit migration of U87 
cells or PTEN-/- fibroblasts is dependent on its protein and not its lipid phosphatase 
activity (Tamura et al., 1998; Tamura et al., 1999). 
This finding is further supported by studies using the PI 3-kinase specific inhibitor, 
wortmannin. The results are summarized in table 4.1. Wortmannin does not inhibit 
migration of astrocytes or U373 cells. PI 3-kinase does not, therefore, seem to play a role 
in the migration of these cells. It is thus not surprising that a lipid phosphatase-inactive 
mutant of PTEN (G129E) can still inhibit migration of U373 cells independently of 
PTEN's effect on the PI 3-kinase pathway. PI 3-kinase does, however, seem to regulate 
migration of the highly malignant U87 cells. This may be explained by the fact that 
additional mutations have made these cells more sensitive to varying PI(3,4,5)P3 levels. 
Wortmannin concentration 
Cell Type OnM 100nM 500nM 
Astrocytes 
U373 44x 
U87 4xx 
TABLE 4.1 
Effect of wortmannin on cell migration as measured in a wound healing assay. Cells were 
scratched 30 min after addition of wortmannin and left to migrate for as long as it took control 
cells (OnM wortmannin) to close the wound. The ability of cells to close the wound is 
indicated by a tick mark (ý), whereas inhibition of wound closure by addition of wortmannin 
is indicated by a cross (X). 
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4.3.4 Additional domains in PTEN are required for inhibition of glioma 
migration 
Deletion analysis was performed to test whether, in addition to the catalytic domain, 
any other domains present in PTEN contributed to the effect on cell migration. PTEN 
fragments (Figure 4.5) were cloned into mammalian expression vectors encoding a Myc 
or Flag- epitope and microinjected into U373 and U87 cells in a wound-healing assay. 
Microinjection of GFP and wtPTEN was used as positive and negative control, 
respectively, for inhibition of migration. 
CAT 1 -7 t-C C2 domain 1 90 142 180 353 403 
1 
PTENAPDZBM 
CA C2 main PTENATAIL 
353 
[I CAT C2 domain PTENAN 
86 403 
179 
PTENAC 
=2 domain--= PTENACAT 
179 403 
Fi(; t'RE 4.5 
Schematic representation of the PTEN deletion constructs. The PI(4,5)P, and PDZ binding 
motifs are represented by a green box or a red box respectively. 
As shown in figure 4.6, deletion of the PI(4,5)P2 (PTENAN) or PDZ binding motifs 
(PTENAPDZBM) or of the last 50 residues (PTENATail) has no significant effect on the 
ability of PTEN to inhibit migration in U373 cells. It is possible that the PI(4,5)P, binding 
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motif serves to localise the endogenous PTEN protein to PI(4,5)P2-enriched regions on 
the plasma membrane, as suggested previously by Iijima et al. Similarly, the PDZ binding 
motif might serve to localise the protein through the binding to PDZ containing proteins 
to sites where PTEN's action is needed. The finding that these domains are not required 
here could be due to the fact that both PTENAN and PTENAPDZBM constructs are 
overexpressed and this bypasses the need for proper localisation. Alternatively, proper 
PTEN localisation has been shown to be essential for gradient sensing during chemotaxis, 
but not for migration per se, and therefore deleting the putative PI(4,5)P2 binding motif 
would not be predicted to disrupt its mode of action regarding migration (Iijima and 
Devreotes, 2002). The catalytic domain of PTEN alone is unable to inhibit migration of 
U373 cells (Figure 4.6). This could be due to improper folding or to the fact that the 
construct is expressed at much lower levels compared to the wtPTEN (as seen by 
immunofluorescence). Alternatively, other domains in addition to the catalytic domain 
might be required. Previous studies using PTEN C-terminal truncation mutants have 
shown that deleting all the amino acids C-terminally of the C2 domain, does not abrogate 
PTEN's catalytic activity towards PI(3,4,5)P3. A PTEN mutant, however, which lacks a 
portion of the C2 domain is no longer active towards phospholipids (Georgescu et al., 
1999; Leslie et al., 2000). 
Surprisingly and as shown in figure 4.6, the C-terminus of PTEN lacking the catalytic 
domain (PTENACAT) was able to block migration of U373 cells to levels similar to the 
full-length wild type protein. This suggests that PTEN is exerting its effect on cell 
migration through its C-terminal domain. Since the catalytic domain is only required in 
the full-length protein, it is likely that its role is to regulate the activity or accessibility of 
the C-terminal domain. 
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Effect of PTEN deletion constructs on U373 migration. (a) Representative examples of the effect of 
microinjecting Myc-epitope tagged PTENAC (A, B) and PTENACAT (C, D) into U373 is shown. 
Microinjected cells were fixed and detected by staining with 9EI0 anti-Myc antibody. The actin was 
visualized using Rhodamine-conjugated phalloidin. Scale bar, 50pm. A white line is drawn to indicate the 
leading edge of the wound. (b) Quantitation of the microinjection results. The number of U373 cells 
expressing control vector or the various Myc-epitope tagged constructs that are still found at the edge of each 
wound 16h after injection of U373 cells was counted. Results are shown as a percentage of the total number 
of expressing cells. Data shown are the mean + SEM of three to five independent experiments where an 
average of 100 cells (20 cells in each of 5 separate wound edges) were injected for each construct. 
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To further investigate which part of the C-terminus of PTEN is required to inhibit 
glioma. migration, the following deletion mutants of PTENACAT were made; 
PTENACATAPDZBM, a C-terminal domain lacking the PDZ binding motif, and PTEN- 
C2, which consists only of the C2 domain of PTEN (Figure 4.7). 
C2, domain PTENACAT 
179 403 
PTENACATAPDZBM 
179 394 
IL C2 domain PTEN-C2 
179 353 
FIGt RE 4.7 
Schematic representation of C-terminal PTEN deletion constructs. The red box represents the 
PDZ binding motif 
As shown in figure 4.8, PTENACATAPDZBM can still inhibit migration of U373. In 
fact, the C2 domain of PTEN alone (PTEN-C2) is sufficient to inhibit migration of these 
cells. Very little is known about the function of PTEN's C2 domain. It is thought to be 
involved in targeting PTEN to membranes by binding to phospholipids in a Ca 2 
independent way (Lee et al., 1999). The effect of PTEN's C2 domain on migration could, 
therefore, be due to a non-specific displacement of other C2-domain containing proteins 
because of it being overexpressed. To test this, two other C2 domains (Figure 4.8), the 
Ca 2, -dependent C2A domain and the Ca 2-_ independent C213 domain of synaptotagmin (a 
protein involved in vesicle trafficking) were also tested for their ability to inhibit 
migration. Unlike the C2 domain of PTEN, these had no effect on U373 cell migration 
(Murray and Honig, 2002). 
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FIGURE 4.8 
PTEN's C2 domain is sufficient to inhibit migration of U373. (a) Representative examples of 
the effect of microinjecting Myc-epitope tagged Syt-C2 (A, B) and PTEN-C2 (C, D) into 
U373 is shown. Microinjected cells were fixed and detected by staining with 9EIO anti-Myc 
antibody. The actin was visualized using Rhodamine -conjugated phalloidin. Scale bar, 
50pm. (b) Quantitation of the microinjection results. The number of U373 cells expressing 
control vector or the various Myc-epitope tagged constructs that are still found at the edge of 
each wound 8h after injection of U373 cells was counted. Results are shown as a percentage 
of the total number of expressing cells. Data shown are the mean + SEM of three to five 
independent experiments where an average of 100 cells (20 cells in each of 5 separate wound 
edges) were injected for each construct. 
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4.3.5 The inhibition of migration by the C-terminus of PTEN is not unique 
to U373 cells 
To see whether these results were specific to U373 cells, the PTEN deletion constructs 
were also microinjected into U87 cells. As shown in figure 4.8, similar to what was seen 
for U373 cells, the C-terminus of PTEN lacking the catalytic domain (PTENACAT) also 
inhibits migration of U87 cells, while the catalytic domain on its own is not sufficient to 
inhibit migration (PTENAC). However, as shown in figure 4.9, a C-terminal construct 
that lacks the PDZ binding motif (PTENACATAPDZBM) is no longer able to inhibit 
migration of U87 cells, whereas it did inhibit U373 cells. Since the PDZ motif is likely to 
affect sub-cellular localization of PTEN, this could be due to a more stringent 
requirement for specific localization in U87 cells. 
a. 
PTEN-C2 
PTEKICATA PDZBM 
PTERSCAT 
PTENAC 
PTENAN 
PTENwt 
Control 
0 10 20 30 40 50 60 70 80 90 100 
% of migrating cells 
135 
THE ROLE OF PTEN IN Gl. /OAIA CEU MIGRA 77ON 
b. 
FIGURE 4.9 
Effect of the PTEN deletion constructs on U87 migration. (a) Quantitation of the microinjcction results. 
The number of U87 microinjected cells expressing control vector or the various Myc-epitopc tagged 
constructs that are found still aligned in the direction of the wound after migration for 8h was counted. 
Results are represented as a percentage of the number of cells still aligned in the direction of the wound 
over the total number of cells injected. Data shown are the mean + SEM of three to five independent 
experiments where an average of 100 cells (20 cells in each of 5 separate wound edges) were injected 
for each construct. (b) Representative examples of the effect of microinjecting Myc-epitope tagged 
PTENAC (A, B), PTENACAT (C, D), PTENACATAPDZBM (E, F) and PTEN-C2 into U87 cells is 
shown. Microinjected cells were fixed and detected by staining with 9EIO anti-Myc antibody. The actin 
was visualized using Rhodamine-conjugated phalloidin. Scale bar, 50pm. A white line is drawn to 
indicate the direction of the wound parallel to which cells were microinjected. 
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4.4 Discussion 
PTEN is a turnour suppressor protein that is thought to exert its effects primarily 
through its lipid phosphatase activity, which directly antagonizes the PI 3-kinase pathway 
by decreasing the cellular pool of PI(3,4,5)P3. PTEN has also been shown to exhibit 
phosphatase activity towards phospho-peptides and with the use of both the C124S and 
G129E mutants, Weng et al., were able to show that PTEN can downregulate cyclinDI 
expression downstream of its protein-phosphatase activity (Weng et al., 2001). However, 
there has been much controversy as to the importance of the protein phosphatase activity 
and what its natural substrate might be. 
4.4.1 PTEN's role in cell migration 
Not much is known about how PTEN controls cell migration and spreading (discussed 
in chapter 6) and there is conflicting evidence as to whether the lipid or the protein 
phosphatase of PTEN is required. Early studies in PTEN-/- fibroblasts and transfection of 
PTEN into U87 glioma cells suggested that PTEN regulates cell spreading and migration 
through the direct dephosphorylation of the signaling proteins FAK and Shc, proteins 
involved in integrin-mediated cell spreading and motility (Tamura et al., 1998; Tamura et 
al., 1999). Other studies, however, showed that the lipid phosphatase activity of PTEN is 
required to block anchorage-independent cell growth of U87 cells in soft agar and PDGF- 
induced ruffling of fibroblasts, by acting as a direct antagonist to the P13-ldnase pathway 
(Georgescu et al., 1999; Leslie et al., 2001; Leslie et al., 2000). Furthermore, re- 
introduction of PTEN into PTEN-/- fibroblasts reduced their speed of migration, most 
likely by downregulating the activation of the small GT? ases Rac and Cdc42 through 
lowering the levels of PI(3,4,5)P3 in the cell (Liliental et al., 2000). The results in this 
chapter reveal a completely different mechanism of action, at least in glioma cells. 
4.4.2 Distinct functions for the different PTEN domains 
PTEN is comprised primarily of two domains: an N-terminal catalytic domain and a 
C-terminal C2 domain. Its PDZ binding motif, at its extreme C-terminus, has been shown 
to bind several PDZ domain-containing proteins, including those that belong to the 
MAGLJK superfamily, like hDLG and MAGI-2, and to MAST205 (Adey et al., 2000; Wu 
et al., 2000b). It is thought that these proteins may serve to localize PTEN to the 
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necessary sites where PTEN is active. Work in this chapter has revealed that the PDZ 
binding motif is dispensable for inhibition of U373 glioma migration by PTEN. This is 
supported by previous studies by Leslie et al., which have shown that the PDZ binding 
motif is not needed for PTEN to lower the levels of PI(3,4,5)P3 in a cell. On the other 
hand the same group also showed that the PDZ binding motif is necessary for inhibition 
of cell spreading and PDGF-induced membrane ruffling (Leslie et al., 2001; Leslie et al., 
2000). Recently, studies in Dictyostelium, revealed a putative PI(4,5)P2 binding motif on 
the N-terminus of PTEN, which was required for membrane localisation and proper cell 
chemotaxis (Iijima and Devreotes, 2002). In this chapter, however, it was found that this 
PI(4,5)P2 binding motif was dispensable for PTEN's ability to inhibit migration of 
gliomas. 
A third domain implicated in regulating the localisation of PTEN is the C2 domain. 
When the crystal structure of PTEN was solved, it was shown that the catalytic and the 
C2 domains associate with each other over an extensive surface and that the C2 domain 
may be required for the correct positioning of the catalytic domain onto the membrane 
(Lee et al., 1999). Interestingly, the studies reported in this chapter have demonstrated 
that the C-terminus of PTEN, including the C2 domain, is both necessary and sufficient to 
inhibit glioma migration. 
Further investigation into the minimal domain required for inhibition of migration, 
revealed that the mechanism of PTEN function is different between the two glioma cell 
lines studied. The PDZ binding motif is dispensable and the C2 domain is both necessary 
and sufficient to inhibit migration of U373 cells. This appears to be specific to the PTEN 
C2 domain, since overexpression of other C2 domains does not inhibit their migration. In 
U87 cells, however, deletion of the PDZ binding motif from the C-terminal fragment of 
PTEN, abrogates this mutant's ability to inhibit cell migration. 
4.4.3 A function for the C2 domain 
Little is known about C2 domains and their precise cellular function. C2 was first 
identified as a structural Ca 2'-binding domain in conventional PKCs- Since then it has 
been identified in several signaling proteins, including PLCs and PI 3-kinases. C2 
domains have a characteristic fold composed of a sandwich of eight antiparallel P strands 
connected by variable loops and they are primarily believed to bind membranes in a Ca 2+_ 
dependent way, like the C2A domain of synaptotagmin (Murray and Honig, 2002; Rizo 
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and Sudhof, 1998). Originally, C2 domains were believe to be Ca 2'-dependent 
membrane-targeting domains. Meanwhile it has emerged, that many C2 domains bind 
membranes in a Ca"- independent way and some of them have no membrane-binding 
potential at all, but rather are involved in protein-protein interactions. 
The C2 domain of PTEN has been shown to bind membranes in vitro, in a Ca 2% 
independent way, though there is also some evidence for a Ca2+-dependent mechanism. 
Work by Das et al., showed that, even though the isolated PTEN C2 domain can bind 
vesicle membranes in vitro, it does so with a much lower affinity compared to the full- 
length protein and that the C2 domain's membrane affinity is probably not high enough to 
target PTEN to the membrane. The same group showed that it is the phosphatase domain 
that is most directly involved in the electrostatic interaction of PTEN with the membrane 
and that the C2 domain is required for high-affinity binding (Das et al., 2003). This data 
agrees with previous studies by Georgescu. et al., which demonstrated that forcing the 
membrane recruitment of a C2 membrane-binding deficient mutant of PTEN (M-CBR3), 
by adding a myristoylation signal, does not fully restore the tumour suppressor function 
of PTEN (Georgescu. et al., 2000). This suggests that the C2 domain of PTEN cannot 
simply be playing a membrane-targeting role. The same group went further to suggest 
that C2 might serve to stabilise the PTEN protein and to productively position the 
catalytic domain on the membrane for it to gain better access to its substrate. 
In this chapter, evidence is presented for a novel role for the C2 domain of PTEN. 
Microinjection analysis revealed that the C2 domain alone can inhibit migration of U373 
cells, and, in contribution with an intact PDZ binding motif, U87 cells. This supports the 
findings of Freeman et al. for an additional role of the C2 domain. Freeman et al. recently 
showed that the C2 domain of PTEN can bind the tumour suppressor protein p53 and 
enhance its transcriptional activity, albeit to a lesser extent than the full-length protein 
(Freeman et al., 2003). Currently it is not clear how the C2 domain affects cell migration. 
Any mechanism, however, is most likely to require the binding of the C2 domain to 
another protein -rather than to the membrane (especially since no particular membrane 
localization was observed when the C2 domain was overexpressed on its own in U373 
cells). A model to explain why the C2 domain alone can inhibit migration, while in the 
full-length protein, the protein phosphatase activity is also essential, is presented in figure 
4.10. In U373 cells, an extracellular stimulus might lead to the activation of the protein 
phosphatase activity of PTEN, which leads to the subsequent activation of the C2 domain 
(probably through a conformational change, or 'opening up' of the protein) that inhibits 
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migration possibly via the recruitment of other cellular proteins (model 1). In U87 cells, 
an extracellular stimulus leads to the activation of the protein phosphatase activity of' 
PTEN. This is followed by the recruitment of a protein to the PDZ binding motif which 
would then localize the C2 domain to inhibit migration (model 2). PI(3,4,5)P3 could play 
a role in this or a parallel pathway to regulate migration, since wortmannin inhibits U87 
cell migration. 
1 2 
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FIGURE 4.10 
Proposed model for the inhibition of U373 and U87 cell migration by PTEN. See discussion 
for explanation. Model I proposes a mechanism for the regulation of U373 cell migration, 
whereas Model 2 proposes a mechanism for U87 cells. 
This model, however, does not address how the protein phosphatase activity of PTEN 
regulates the activity of the C2 domain, and this is examined in the next chapters. 
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Results - Regulation of PTEN's C2 domain 
5.1 Summary 
PTEN is a dual specificity protein and lipid phosphatase, which can remove the 3' 
phosphate residue from lipid substrates and dephosphorylate phospho-Serfrhr and 
phospho-Tyr substrates. It is the protein phosphatase activity of PTEN that is required for 
the inhibition of glioma cell migration by the full-length protein. Data presented in this 
chapter demonstrates, however, that inhibition of glioma migration by PTEN is mediated 
through its C-terminus. Furthermore, it is shown that, in the full-length PTEN protein, the 
function of the C2 domain in U373 cells is regulated through dephosphorylation of a 
single residue at Thr383 on the PTEN tail. Immunoprecipitation studies also revealed that 
the N-terminus of PTEN binds to the C-terminus. A mechanism is proposed whereby 
PTEN negatively regulates cell motility through its C2 domain, and this depends on the 
protein phosphatase activity of PTEN to mediate dephosphorylation at Thr383. 
5.2 Introduction 
Domain analysis has revealed that PTEN has a number of clearly defined regions in 
addition to an N-terminal catalytic domain and a C-terminal C2 domain (discussed in 
detail in chapter 4). Adjacent to the C2 domain, at the C-terminus, lies a stretch of about 
50 amino acid residues, the tail, which has been shown to be extensively phosphorylated 
on 5 major sites (Birle et al., 2002; Torres and Pulido, 2001; Vazquez et al., 2000). The 
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tail also contains two putative PEST sequences, implicated in PTEN protein stability, 
probably by targeting PITEN for proteosome-dependent degradation (Torres et al., 2003). 
In cells, PTEN is believed to be constitutively phosphorylated on its tail (Torres and 
Pulido, 2001; Vazquez et al., 2000). When cells are labeled with 32P-orthophosphate, 
endogenous and overexpressed PTEN molecules become radioactively labeled. PTEN 
was shown to become phosphorylated on Ser370, Ser385, and to a lesser extent Ser380, 
and on Thr382 and Thr383. Based on in vitro data, a kinase that is responsible for 
phosphorylating PTEN on its tail is believed to be casein kinase 2 (CK2), although 
exactly which sites CK2 targets is unclear (Birle et al., 2002; Miller et al., 2002; Torres 
and Pulido, 2001). In any case, phosphorylation seems to downregulate PTEN's activity 
as assessed by examining the induction of cell growth arrest by overexpressing PTEN 
phosphorylation site mutants (Vazquez et al., 2000). 
Having established a role for the C2 domain of PTEN in U373 cell migration, this 
chapter investigates how this domain is regulated in the full-length protein. Many 
questions arise. For example, what is the role of the phosphatase activity in the full-length 
protein? Does PTEN phosphorylation or protein stability play a role in the regulation of 
PTEN function during cell migration? 
5.3 Results 
5.3.1 Post-translationaI modification of PTEN regulates its function 
From previous studies, it appears that FITEN is constitutively phosphorylated and this 
might regulate its biological activity. To address whether phosphorylation of PTEN 
specifically plays a role in PTEN's ability to control cell migration, four alanine 
substitutions were introduced at four of the major phosphorylation sites at Ser380, 
Thr382, Thr383 and Ser385 in full length, phosphatase-dead PTEN [PTEN(C124S)-A4, 
Figure 5.1,5.2]. This construct was then microinjected in U373 cells in a wound-healing 
assay and its ability to inhibit migration was examined. As shown in figure 5.1, removal 
of these four phosphorylation sites completely rescues the ability of catalytically-dead 
PTEN to inhibit migration of U373 cells. 
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FiGURE 5.1 
The ability of PTEN to regulate U373 migration is dependent on its phosphorylation state. (a) 
U373 cells microinjected with vectors encoding GFP (A, B) or Myc-epitope tagged 
PTEN(CS)-A4 (C, D). Microinjected cells were fixed and detected by staining with 91EIO 
anti-Myc antibody (A, C). Actin was visualized using rhodamine-conjugated phalloidin (13, 
D). Scale bar, 50lim. A white line is drawn to indicate the leading edge of the wound. (b) 
Quantitation of the number of microinjected U373 cells that are found at the edge of the 
wound after migration for 8h. Data shown are the mean + SEM of three to five independent 
experiments where an average of 100 cells (20 cells in each of 5 separate wound edges) were 
injected for each construct. 
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Interestingly, a significant fraction of the PTEN(CS)-A4 protein seemed to localize 
predominantly to the nucleus in around 60% of the injected cells. Although nuclear 
import/ export sequences could not be found in PTEN, it has recently been shown to be 
able to localize to the nucleus of cells in a complex with p53 and this interaction has been 
mapped to the C2 domain of PTEN (Freeman et al., 2003). Mutation of these four 
potential phosphorylation sites of PTEN to alanine residues might therefore uncover the 
interaction site of PTEN's C2 domain and cause it to be retained in the nucleus through 
its binding to p53, but this has not been further investigated. 
5.3.2 Phosphorylation of a single PTEN residue renders the protein 
inactive 
In order to pinpoint which of the four phosphorylation sites are involved in the 
regulation of the C2 function, a series of constructs were made in which only one residue 
at a time was altered to alanine (Figure 5.2). 
CAT C2 PDZ BD 
403 wtPTEN 
1-1 1- - 
403 PTEN(C124S) 
C124S S380A, T382A, 
. T383A, 
S385A, 
-YADAADAD- 403 C124S-A4 
YADTTDSD- 403 C124S-S380A 
YSDATDSD- 403 C124S-T382A 
YSDTADSD- 403 C124S-T383A 
YSDTTDAD- 403 C124S-S385A 
1 YSDTDDSD- 403 wtPTEN-T383D 
FjGuRE 5.2 
Schematic representation of the PTEN phosphorylation site mutants used. 
Interestingly, injection of these constructs in a wound-healing assay revealed that 
mutation of one residue, Thr383, was sufficient to reverse the phenotype of catalytically 
dead PTEN [PTEN(C124S)] and inhibit migration to levels comparable to those of the 
PTEN(C124S)-A4 mutant (Figure 5.3). The other three constructs [PTEN(C124S)- 
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S380A, PTEN(C124S)-T382A and PTEN(C124S)-S385A] had no statistically significant 
effect on migration. This strongly suggests that, in the full-length PTEN protein, '111083 
needs to be dephosphorylated in order for the C2 domain to regulate migration of' U373 
cells. 
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FicURE 5.3 
Dephosporylation Of ThT383 is critical for PTEN's ability to inhibit migration of U373. (a) 
U373 cells microinjected with vectors encoding GFP (A, B) or Myc-epitope tagged 
PTEN(CS)-S380A (C, D), PTEN(CS)-T382A (E, F), PTEN(CS)-T383A (G, H) or 
PTEN(CS)-S385A (I, J). Microinjected cells were fixed and detected by staining with 91310 
anti-Myc antibody (A, C, E, G, 1). Actin was visualized using rhodamine-conjugated 
phalloidin (13, D, F, H, J). Scale bar, 50pm. A white line is drawn to indicate the leading edge 
of the wound. (b) Quantitation of the number of microinjected U373 cells that are found at the 
leading edge of the wound after migration for 16h. Data shown arc the mean + SEM of three 
to five independent experiments where an average of 100 cells (20 cells in each of 5 separate 
wound edges) were injected for each construct. 
In order to confirm that regulation of phosphorylation at Thr383 is critical for PTEN's 
biological activity, the converse experiment was performed where the same residue was 
mutated to an aspartic acid in the full-length, wild type protein (PTENwt-T383D). When 
microinjected in U373 cells, this phospho-mimic mutant could no longer inhibit 
migration of U373 cells (Figure 5.4). 
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FIGURE 5.4 
A PTEN phospho-mimetic mutation at Tbr383 abrogates PTEN's ability to inhibit migration. 
(a) Quantitation of the number of microinjected U373 cells that are found at the edge of the 
wound after migration for 8h. Data shown are the mean + SEM of three to five independent 
experiments where an average of 100 cells (20 cells in each of 5 separate wound edges) were 
injected for each construct. 
In conclusion, the data indicates that Thr383 must be dephosphorylated to allow the 
C2 domain to inhibit migration and that this depends on the protein, but not lipid, 
phosphatase activity of PTEN. 
5.3.3 The N-terminus of PTEN binds its C-terminus 
As inferred from the crystal structure, there is a significant overlap between the 
catalytic domain and the C2 domain of PTEN, showing that PTEN exists in a folded state. 
To gain further insight into the possible mode of regulation of C2 activity, PTEN's 
intramolecular interactions were explored. We first examined whether the C-terminus of 
PTEN could be co-precipitated with the N-terminus. The following constructs were 
cloned into pRK5-Myc or pRK5-Flag mammalian expression vectors. 
147 
Rr(; t TA TION OF PITN's c2 DOA I. I IN 
Nýj -I CAT I= C2 domain = 
--- 
JI-C 
1 90 142 180 353 403 
C124S 
= 
PTEN(C124S)AC 
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1 24Sj PTEN(Cl24S)(86-147) 
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PTENACAT 
179 403 
II PTENACATAPDZBM 
179 394 
179 353 
PTEN-C2 
FIGt RE 5.5 
Schematic representation ofthe PTEN truncation mutants used in the immunoprecipitation 
assays. 
COS-7 cells were co-transfected with the catalytically inactive N-terminus of PTEN 
[PTEN(C124S)AC] and either the C-terminus (PTENACAT), the C-terminus minus the 
PDZ binding motif (PTENACATAPDZBM), or the C2 domain of PTEN (PTEN-C2) (see 
Figure 5.5). In each case an anti-Flag antibody was used to immunoprecipitate the N- 
ten-ninus and an anti-Myc antibody to detect for binding of the different C-terminal 
constructs (Figure 5.6). Immunoprecipitation of the N-terminus [residues 1-175; 
PTEN(C 124S)AC] efficiently precipitated the C-ten-ninus (residues 175-403; 
PTENACAT). However, despite the large surface of interaction revealed in the crystal 
structure, the C2 domain alone (residues 175-353; PTEN-C2) was not present in 
immunoprecipitates of the N-terminus (Figure 5.6a), indicating that the C-terrn, nal 50 
amino acid tail is essential for strong interaction. The interaction was also confirmed by 
immunoprecipitating with an anti-Myc antibody and blotting with an anti-Flag antibody 
to detect the N-tenninus (Figure 5.6). 
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The N-terminus of PTEN binds the C-terminus of PTEN. (a) COS-7 cells were co-transfected 
using Myc-epitope tagged PTENACAT, PTENACATAPDZBM or PTEN-C2 with, (lanes I- 
3), or without, (lanes 4-6), Flag-epitope tagged, catalytically inactive N-terminus of PTEN 
[PTEN(C124S)AC]. PTEN(C124S)AC was immunoprecipitated (IP) with anti-Flag antibody 
and the precipitates analysed on Western blots with 9EI0 anti-Myc antibody or anti-flag 
antibody. One tenth of the total lysate was also immunoblotted with 9E 10 anti-Myc antibody. 
(b) COS-7 cells were co-transfected using Myc-epitope tagged PTENACAT, 
PTENACATAPDZBM with Flag-epitope tagged, catalytically inactive N-terminus of PTEN 
[PTEN(C124S)AC-flag]. PTENACAT and PTENACATAPDZ were immunoprecipitatcd (IP) 
with anti-myc antibody and the precipitates analysed on western blots with anti-Flag antibody 
or 9EI0 anti-Myc antibody. One tenth of the total lysate was also immunoblotted with anti- 
Flag antibody. 
To test whether the minimal catalytic active site pocket of PTEN is required for the 
binding of the N-terminus to the C-terminus, a PTEN(C124S)(86-147) construct was co- 
transfected in COS-7 cells with each of the C-terminal constructs (figure 5.7). An anti- 
Flag antibody was used to immunoprecipitate the catalytic domain and an anti-Myc 
antibody to detect binding of the C-terminal constructs. None of the C-terminal constructs 
co-Immunoprecipitated with PTEN(C 124S)(86-147), suggesting that the site where the C- 
terminus tail interacts with the N-terminus lies outside the 86 to 147 region of the 
catalytic domain. 
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FIGt'RE 5.7 
The C-terminus of PTEN interacts with the N-terminus in a region outside residues 86 to 147. 
COS-7 cells were co-transfected using Myc-epitope tagged PTENACAT, PTENACATAPDZ 
or PTEN-C2 with flag-epitope tagged, catalytically inactive N-terminus of PTEN residues 90- 
142 [PTEN(CS)-(90-142), (lanes 1-3), or using Myc-epitope tagged PTENACAT with flag- 
epitope tagged PTEN(C124S)AC, (lane 4), to control for the immunoprccipitation. 
PTEN(C]24S)(86-147) was immunoprecipitated (IP) with anti-flag antibody and the 
precipitates analyzed on western blots with 9EI0 anti-myc antibody or anti-flag antibody. 
One tenth of the total lysatewasalso immunoblotted with 9EI0 anti-myc antibody. 
To determine whether this interaction is dependent on the PTEN tail being 
phosphorylated on one or more residues, the phosphorylation state of PTENACAT was 
examined by transfection in COS-7 cells and blotting with a commercial phospho-specific 
antibody raised against a synthetic PTEN-derived peptide triply phosphorylated at 
Ser380, Thr382, Thr383 (also used by (Das et aL, 2003)). To control for the specificity of' 
the antibody, full-length PTEN, PTEN-C2 and PTENACAT-A4, a C-terminal domain 
construct containing alanine substitutions that remove the four previously described 
phosphorylation sites at Ser370, Thr380, Thr382 and Ser385, were also transtlected. 
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Figure 5.8 shows that the antibody specifically recognizes the full length 11TEIN construct 
as expected, whereas there is no signal detected in the lanes transtlected with the I'TII'IN- 
C2 and PTENACAT-A4 constructs, showing the specificity of the antibody. Furthermorc, 
the fact that the antibody recognizes PTENACAT, suggests that the truncated protein can 
be phosphorylated independently of the C-terminus, raising the possibility that binding 
of the PTEN N-terminus to the tail region depends upon phosphorylation. 
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The C-terminus of PTEN when expressed alone in cells is still a substrate for 
phosphorylation. COS-7 cells were transfected with Myc-epitopc tagged PTEN%%t, 
PTENACAT, PTEN-C2 and PTENACAT-A4. Anti-Myc 9EI0 antibody was used to 
immunoprecipitate the constructs and this was followed by SDS-PAGE and Western blot 
analysis. Phosphorylation of these constructs was examined by blotting with an anti- 
phospho-PTEN specific antibody. 
To examine whether phosphorylation affects the intermolecular interaction between 
the N- and C-termini, the N-terminal catalytic domain [PTEN(C124S)ACI was co- 
expressed with PTENACAT-A4 or the phospho-mimetic constructs substituted at'l'hr383 
(PTENACAT-T383D) or Sei-380, Thi-382 and Sei-385 (PTENACAT-DD'I'D) to aspartic 
acid residues. As shown in figure 5.9, all mutant C-terminal constructs, PTENACAT-A4. 
PTENACAT-T383D and PTENACAT-DDTD, and the wild type C-terminus intcract 
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equally well with the N-terminal phosphatase domain in this assay. It appears, thercilore, 
that the interaction of the N- and C-termini is neither promoted nor inhibitcd by 
phosphorylation, at least at these four sites. 
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HGURE 5.9 
The intramolecular interaction of the N- and C-termini of PTEN is independent of the 
phosphorylation state of the C-terminus. COS-7 cells were co-transfected with the Flag- 
tagged, catalytically inactive N-terminus of PTEN [ PTEN(C I 24S)AC- Flag] and either Myc- 
tagged PTENACAT (lane 1) or PTENACAT with residues Scr380, Thr382, Thr383 and 
Ser385 all mutated to alanine (PTENACAT-A4) (lane 2), or PTENACAT with residues S380, 
Thr382, and Ser385 all mutated to aspartic acid (PTENACAT-DDTD) (lane 3), or 
PTENACAT with residue Thr383 mutated to aspartic acid (PTENACAT-T383D). The N- 
terminus of PTEN was immunoprecipitated (IP) using an anti-Flag antibody and the 
precipitates analysed on Western blots with 9E 10 anti-Myc antibody or anti-Flag antibody. 
One tenth of the total lysate was also immunoblotted with 9EI0 anti-Myc antibody. 
In conclusion, the immunoprecipitation data presented here, along with the 
information from the crystal structure, suggests that PTEN most probably exists in a 
folded conformation. Furthennore, there appears to be a physical interaction between the 
PTEN carboxyl-tail and the N-ten-nmus, which is independent ofthe PDZ binding niotit' 
and does not appear to be regulated by phosphorylation. 
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5.3.4 PTEN regulates its own phosphorylation on Thr383 
PTEN is reported to be a very poor protein phosphatase. Interestingly, howcver, the 
12-residue peptide sequence surrounding Thi-383 (YSDTTDSDPENE) is extremely 
acidic (5 Asp/Glu and 4 phosph-Ser/Thr residues) and the optimal peptide substrates 
previously reported for PTEN are also highly acidic (Myers et al., 1997). To test whether 
PTEN can act intramolecularly in an autocatalytic mechanism to dephosphorylate 
residues in this region, wild type PTEN was immunoprecipitated from transfected COS-7 
cells, washed extensively and incubated in vitro in phosphatase buffer (Myers et al., 
1997). The level of phosphorylation was observed on Western blots using the PTEN 
phospho-specific antibody (see earlier), but no significant decrease in phosphorylation 
could be detected (Figure 5.10). However, using the single alanine substitution mutants 
described in figure 5.2, it was subsequently found that this commercial antibody also 
detects PTEN when phosphorylated at any two residues in this sequence. If PTEN, 
therefore, were able to dephosphorylate only one of the residues, this would not have 
been detectable with the current antibody used. 
PTENwt PTEN(C124S) 
0, lh 2h 0, Ih 2h 
WB: phospho-PTEN - m»- -- 
WB: Myc --ý --ý a Mý - 
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RGURE 5.10 
Comparison of PTEN phosphorylation in a wild type and phosphatase-dead background. 
COS-7 cells were seeded in 6-well dishes and transfected with the Myc-epitopc tagged 
PTENwt or PTEN(C]24S) constructs. Anti-Myc 9EIO antibody was used to 
immunoprecipitate the proteins and following extensive washing, the proteins were incubated 
in phosphatase buffer at 30'C (a) or 370C (b) for the indicated times. Following analysis by 
SDS-PAGE and Western blot, an anti-phospho-specific PTEN antibody was used to detect for 
phosphorylated PTEN. 
The second approach taken was to radioactively label PTEN in cells followed by 
peptide mapping and phospho-amino acid analysis to detect phosphorylation specifically 
at threonine or serine residues by thin layer chromatography (see Materials and Methods, 
(Birle et al., 2002; Vazquez et al., 2000)). Unfortunately, due to technical difficulties, and 
the complexity of having 5 phosphorylated residues at unknown stoichiometry in close 
proximity to one another (Ser370, Ser380, Thr382, Thr383, Ser385), it was impossible to 
compare phosphorylation specifically at Thr383 between a wild type and catalytically 
dead PTEN background (data not shown). To get around this problem, aspartic acid 
substitutions were introduced at four of the five major phosphorylated residues at Ser370, 
Ser380, Thr382 and Ser385, in the full length catalytically-active (PTEN-D4) and full- 
length catalytically-dead protein [PTEN(C124S)-D4]. As a control for phosphorylation at 
other sites, all five residues (Ser370, Ser380, Thr382, Thr383 and Ser385) were also 
mutated in both the catalytically-active (PTEN-S370D-A4) and catalytically-dead 
[PTEN(Cl24S)-S37OD-A4] protein. The PTEN constructs were transfected in COS-7 
cells and immunoprecipitated following [ Jý P] orthophosphate - labeling. The proteins 
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were then analysed by SDS-PAGE and exposed to a phosphorimager scrccn (FiMIrC 
5.11). 
tK 
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PTEN 
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Fi(xRE 5.11 
PTEN is phosphorylated on Thr383 in a catalytically dead background but not in the wild 
type protein. COS-7 cells grown in [32p] orthophosphate were transfected with Myc-epitope- 
tagged versions of (i) catalytically-dead PTEN with residues Ser370, Scr380, Thr382, and 
Ser385 mutated to aspartic acid [PTEN(C]24S)-D4], (ii) wild type PTFN with residues 
Ser370, S380, Thr382, and Ser385 mutated to aspartic acid (PTEN-D4), (iii) wild type PTEN 
with residues Ser370, Ser38O, Thr382, Thr383 and Ser385 all mutated (PTFN-S370D-A4), 
(iv) catalytically-dead PTEN with residues Scr370, Ser3SO, Thr383, Thr383 and Scr385 all 
mutated [PTEN(Cl24S)-S37OD-A4] . Anti-Myc 
9EIO antibody was used to 
immunoprecipitate the PTEN constructs. Phosphorylation of the constructs was detected and 
quantitated by autoradiography using a phosphorimagcr, Anti-Myc 9EIO antibody %ýas also 
used to control for the expression levels of the constructs immunoprecipitated. 
Catalytically-inactive PTEN [PTEN(C124S)-D4] incorporated approximately 10 time, 
more label than the catalytically-active PTEN (PTEN-D4). Furthermore, the residual 
phosphate incorporated into PTEN-134 Is not on Thr383, since the levels of phosphate 
incorporated into catalytically-active PTEN in which all five maj . or phosphorylation sites 
(i. e. including Thr383) had been mutated, are the same as PTEN-D4. This background 
phosphorylation is also present in the catalytically-dead PTEN protein with all five major 
phosphorylation sites mutated [PTEN(Cl24S)-S37OD-A4] (Figure 5.11). These data 
therefore indicate that while the catalytically inactive PTEN is phosphorylated at Thi-383, 
wild type PTEN is not phosphorylated at this site, following immunoprecipitation froill 
COS-7 cells. 
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5.4 Discussion 
Work in chapter 4 identified a novel mechanism by which PTEN inhibits the 
migration of human glioma cells through its C2 domain, independently of its effects on 
the PI 3-kinase pathway. This chapter revealed that in wild type PTEN, 
dephosphorylation of Thr383 is required for C2 activity and that the N-terminus of PTEN 
interacts with its C-terminus in immunoprecipitation studies. It is still unclear, however, 
how the phosphorylation state of Thr383 affects the activity of the C2 domain. A simple 
model would be that dephosphorylation of Thr383 in the tail induces a specific 
conformational change that allows the C2 domain to interact with a cellular target to 
inhibit migration. 
5.4.1 PTEN phosphorylation as key regulator of its function 
Several studies have now shown that PTEN undergoes extensive phosphorylation at 
its C-terminus and this affects its activity as a phosphatase and also its protein stability. 
Work by Tolkacheva et al. has shown that PTEN phosphorylation also affects its binding 
to PDZ-domain containing proteins, and could thus also regulate PTEN localisation 
(Tolkacheva et al., 2001). Most of these studies, however, have been carried out in vitro 
and there is so far no evidence to suggest what the biological significance of PTEN 
phosphorylation would be in vivo. 
In this chapter, it was demonstrated that phosphorylation of only a single site, Thr383, 
is responsible for regulating the activity of the C2 domain in the full-length protein. The 
kinase responsible for phosphorylation of Thr383 is unclear; along with Ser370, Thr380, 
Thr382 and Ser385 it has been reported to be a site for phosphorylation by CK2, however 
others have suggested that CK2 only phopshorylates Ser370 and Ser385, but not Thr383 
(Miller et al., 2002; Torres and Pulido, 2001). It is possible that phosphorylation of 
Thr383 requires priming through phosphorylation at these surrounding sites. Most 
intriguing, however, is the mechanism of dephosphorylation, which was shown here to be 
essential for activation of the C2 domain. The environment surrounding Thr383 is very 
acidic, making this an ideal substrate for the protein phosphatase activity of PTEN itself. 
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5.4.2 Is PTEN a protein phosphatase acting autocatalytically? 
Even though PTEN is reported to be a poor protein phosphatasc, the 12-residue 
peptide sequence surrounding Thr383 (YSDTTDSDPENE) provides for an extremely 
acidic (5 Asp/Glu and 4 phospho-Ser/'Ibr residues) environment, which very closely 
resembles the optimal peptide substrates previously reported for PTEN (Myers et al., 
1997). Moreover, the crystal structure predicts that the C-terminal tail of PTEN would be 
in close proximity to the active site (Lee et al., 1999). Work in this chapter showed that 
regulation of phosphorylation at Thr383 is dependent upon the protein catalytic activity 
of PTEN and that the catalytic domain of PTEN interacts with the carboxyl tail region of 
the protein where Thr383 is found, even though this interaction seems to be independent 
of any phosphorylation event. There is therefore a strong possibility that PTEN acts as an 
intramolecular phosphatase removing the phosphate residue from Thr383, and thereby 
activates the C2 domain (Figure 5.12). This is fin-ffier supported by the finding that 
catalytically-active PTEN, when isolated from cells, is not phosphorylated on Thr383, 
whereas the catalytically-dead protein is. This, however, does not provide complete proof 
for a direct, intramolecular dephosphorylation of PTEN. Formal proof will require 
isolated wild-type PTEN phosphorylated on Thr383, followed by an in vitro phosphatase 
assay. 
Data in this chapter suggest a model in which PTEN acts intramolecularly to 
dephosphorylate Thr383 (model 1, Figure 5.12). This induces a conformational change 
that activates the C2 domain to inhibit cell migration. An alternative would be that the 
protein phosphatase activity of PTEN activates another protein phosphatase to 
dephosphorylate Tbr383 (model 2, Figure 5.12), or inactivates a kinase. In any event, it is 
likely that the competition between the kinase and the phosphatase acting at Thr383 will 
play a major part in controlling cell migration and work in this study suggests that in 
addition to controlling the intracellular levels of PI(3,4,5)P3. the ability of PTEN to 
regulate cell migration through its C2 domain, may be a key feature of its tumour 
suppressor activity and help explain why the PTEN gene is so frequently mutated in 
human cancer. 
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FIGURE 5.12 
PTEN's phosphatase activity is required for dephosphorylation of Thr383 and inhibition of 
migration. Model 1, PTEN acts intramolecularly to dephosphorylate Th3r83, induce a 
conformational change and activated the C2 domain to inhibit migration. Model 2, PTEN's 
protein phosphatase activity is required to activate protein X that dephosphorylates Thr383 
and activates PTEN's C2 domain to inhibit migration. 
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Results - Additional roles for the carboxy-terminus 
of PTEN 
6.1 Summary 
Having established a role for PTEN in cell migration, the research presented in this 
chapter addresses the role of PTEN in cell spreading. In the previous chapters, it was 
shown that PTEN controls migration of the U87 glioma cells in a protein-phosphatase- 
dependent mechanism. This chapter reveals that the C-terminus of PTEN induces a 
morphological change in U87 cells, from an elongated, spindle-like shape to a more flat, 
spread phenotype. This induction of cell spreading is independent of the catalytic domain, 
and in contrast to the effect seen on cell migration discussed in chapter 3, is also 
independent of the PDZ binding motif. "Me same C-terminal region of PTEN also causes 
spreading of the breast cancer cells MDA-MB-435. In an effort to elucidate the possible 
mechanisms involved in the contribution of cell migration and the induction of cell 
spreading by the C-terminus, a yeast-two hybrid screen was performed. This identified 
three potential novel binding partners of PTEN, namely; hVPS41p, a protein involved in 
vesicle docking and fusion, Ash2, a regulator of transcription, and a novel Zinc-finger 
containing protein of unknown function. 
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6.2 Introduction 
In addition to controlling cell growth, arrest and migration, PTEN is also known to be 
a negative regulator of integrin-dependent cell spreading. Similar to the control of cell 
migration, there is conflicting evidence whether the protein or the lipid phosphatase is 
required for the inhibition of spreading. Initial studies suggested that the protein- 
phosphatase activity is needed for PTEN to inhibit spreading of U87 cells and PTEN4- 
fibroblasts, probably by directly dephosphorylating the proteins Shc and FAK, two 
important regulators of integrin-dependent signaling (Gu et al., 1998; Tamura et al., 
1998). Work by Leslie et al., revealed that mutations that abrogate the lipid- but not the 
protein-phosphatase activity of PTEN, or mutations that target the C2 domain (such as the 
M-CBR3 mutant) abolish PTEN's ability to inhibit spreading on fibronectin or collagen 
of U87 cells (Leslie et al., 2001). Furthermore, a C-terminal truncation mutant that lacks 
the PDZ binding motif only partially inhibits spreading of U87 cells, suggesting that the 
interaction with a PDZ domain containing protein might be required to inhibit spreading. 
The precise mechanism of how PTEN inhibits cell spreading is currently unclear. The 
experiments described in this chapter demonstrate a role for PTEN in the activation of 
cell spreading. The C-terminus of PTEN induces spreading of U87 cells and this effect is 
dependent on the C2 domain, the tail region containing the phosphorylation sites, but not 
the PDZ binding motif. To further elucidate the role of the C-terminus in the induction of 
cell spreading as well as cell migration and to identify proteins involved in mediating 
these effects, a yeast-two hybrid screen was performed using PTENACATAPDZBM as 
bait. This revealed three novel potential PTEN interacting proteins. 
6.3 Results 
6.3.1 The role of the C-terminus of PTEN in cell spreading 
While investigating the role of PTEN in cell migration, it was observed that the C- 
terminus of PTEN not only inhibited the migration of U87 cells, but also changed their 
morphology from a spindle-like elongated shape to a much more flat and spread 
phenotype (Figure 6.1). This suggests that PTEN can also have a positive effect in the 
induction of cell spreading, and is in contrast to previous experiments showing that wt 
PTEN inhibits cell spreading. 
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In order to determine the minimal region responsible for this effect, two C-terminal 
deletion mutants, lacking the PDZ binding motif (PTENACATAPDZBM) and one 
consisting of just the C2 domain of PTEN (PTEN-C2) (see Figure 4.8), were introduced 
into sub-confluent U87 cells (Figure 6.1). 
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FIGURE 6.1 
The C-terminus of PTEN induces spreading of U87 cells. (a) Representative examples of sub- 
confluent U87 cells injected with control GFP (A-C) or Myc-epitope tagged cDNAs of 
PTENACAT (D-F), PTEN-C2 (G-1) and PTENACATAPDZBM (J-L) is shown. Cells were 
fixed and stained with anti-Myc antibody to visualize the injected cells (A, D, G, J) and with 
Rhodamine-conjugated phalloidin to visualise the actin cytoskeleton (B, E, H, K). Scale bar 
50pm. (b) Quantitation of the number of injected cells that exhibit a spread morphology. 
As shown in figure 6.1, around 75% of U87 cells injected with the C-terminus of 
PTEN are spread compared to only 28% of control injected cells. This effect is 
independent of the PDZ binding domain, as PTENCACATAPDZBM induced spreading 
to a similar level. The C2 domain of PTEN (PTEN-C2) also induces spreading, albeit to a 
slightly lesser extent (around 50% of cells are spread), suggesting that the C2 domain and 
the region between the C2 domain and the PDZ binding motif, containing the 
phosphorylation sites, is required for the spreading effect. 
To examine whether this effect is unique to U87 cells or represented a more general 
phenomenon, the above PTEN constructs were also tested for their ability to induce 
spreading in the breast cancer cells MDA-MB435, which also exhibit an elongated - 
spindle-like morphology (the previously described U373 glioma cells could not be used 
because they already exhibit a spread phenotype). As can be seen in figure 6.2, the C- 
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terminal domain of PTEN also induces spreading of these cells, and as shown tor the U87 
cells, the PDZ binding motif, but not the tail region (residues 350-398) is dispensable for 
this effect. 
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PTENACATAPDZBM 
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PTENACAT 
GFP 
0 10 20 30 40 50 60 70 80 90 
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FIGURE 6.2 
Tlie C-terminus of PTEN induces spreading of MDA-MB435 cells. (a) Representative 
examples of sub-confluent U87 cells injected with control GFP (A-C) or Myc-epitope tagged 
cDNAs of PTENACAT (D-F), PTEN-C2 (G-I) and PTENACATAPDZBM (J-L) is shown. 
Cells were fixed and stained with anti-Myc antibody to visualize the injected cells (A, D, G, 
J) and with Rhodamine-conjugated phalloidin to visualize the actin cytoskeleton (13, E, H, K). 
Scale bar 50grm (b) Quantitation of the number of injected cells with the various Myc-epitope 
tagged constructs that exhibit a spread morphology. 
6.3.2 Binding partners for the C-terminus of PTEN 
6.3.2.1 Yeast-two hybrid screen 
The results so far indicate a role for the C-terminus of PTEN both in cell migration 
and cell spreading of glioma cells, however, the mechanisms involved are unclear. 
Therefore a yeast -two hybrid screen was performed in order to identify potential binding 
partners of the PTEN C-terminus that might be involved in mediating these effects. The 
PTENACATAPDZBM was used as bait, firstly, because this region was identified as the 
minimal region required for cell spreading and because it includes the tail region 
(residues 350-398) shown to contain critical residues for the regulation of the C2 function 
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in U373 cells. Secondly, several groups had previously performed yeast-two hybrid 
screens using either full-length PTEN or the entire C-tenninus and all of the proteins 
identified were shown to bind to the PDZ binding motif of PTEN and therefore, to avoid 
pulling out the same proteins, a C-terminal truncation mutant that lacked the PDZ binding 
motif, was used. 
The PTENACATAPDZBM construct was cloned into the yeast expression vector 
pYTH9 and integrated into the yeast strain Y190. To check that the construct was 
suitable as bait in a yeast - two hybrid system, we first investigated the expression of the 
HA-Ga]4BD-PTEN, ACATAPDZBM fusion protein. Total yeast extract of five 
independent Y190 pYTH9:: PTENACAT, ýIPDZBM transformants was prepared, subjected 
to SDS-PAGE and Western analysis using an anti-HA antibody. As shown in figure 6.3, 
transformants #2 and #4 express the fusion protein. Colony #2 was chosen for further 
analysis. Secondly, this construct was tested for whether it was capable of self-activating 
transcription of the HIS3 reporter gene (Figure 6.3). Yeast cells expressing Gal4BD- 
PTENACATAPDZ BM were streaked out on selection medium lacking histidine and 
containing 3AT (SC-T-L-H 3AT). As seen in figure 6.4, Gal4BD-PTENACATAPDZBM 
expressing cells were not growing on SC-T-L-H 3AT plates, while control cells were 
growing. Thus, since Gal4BD-PTENACATAPDZBM did not self-activate transcription, 
it was deemed suitable for the yeast-two hybrid screen. 
1 
. 
FIGURE 6.3 
The PTENACATAPDZBM construct is expressed in yeast. Yeast lysates were prepared as 
described in Materials and Methods and analysed by SDS-PAGE followed by Western 
blotting. An anti-HA antibody was used to detect expression of the construct. Colonies 2 and 
4 express the construct. 
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pYTH9 
APDZBM] 
p ctil p TH9 pActil 
L63RhoA 
pActll-CNK 
3-AT 
FIGURE 6.4 
The PTENACATAPDZBM construct does not self-activate transcription of the IIIS3 gene. 
Y190 pYTH9:: PTENACATAPDZBM strain with empty pACTII as well as Y190 
pYTH9:: L63 RhoA and pACTII:: CNK I as positive control were streaked on SC-T-L and SC- 
T-L-H 3AT plates to check for the absence of growth of Y190 pYTH9:: PTENACATAPDZ 
BM strain on SC-T-L-H 3AT plate. 
The Y190 pYTHP:: PTENACATAPDZBM strain was then transformed with a human 
brain cDNA library cloned into pACTIl, and a total Of 9XI05 colonies were screened 
for growth on SC-T-L-H 3AT medium. After 9 days, 61 growing colonies were 
picked, and re-streaked on SC-T-L-H 3AT plates (see Table 6.1). 30 yeast colonies 
were growing and the library plasmid of each of these was recovered and transformed 
into E. coli. Bacteria colonies from 26 clones were obtained. These were minipreped 
and analyzed by restriction digest. 24 library plasmids contained an insert and were 
grouped according to size and restriction digest pattern, revealing 6 different genes, 
encoding 6 potential PTEN interactors. To verify the interaction in the two-hybrid 
system, these plasmids were re-transformed into the original Y190 
pYTH:: PTENACATAPDZBM strain and analyzed for growth on SC-T-L-H 3AT 
medium as well as for P-galactosidase activity on medium containing x-gal. As seen 
in figure 6.5, transfon-nants of three library plasmids re-grew on SC-T-L-H 3AT 
plates and displayed strong P-galactosidase activity. 
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# of colonies picked form screen 61 
# of colonies that re-grew on SC-T-L-H 3AT plates 30 
# of recovered library plasmids from which bacterial colonies were obtained 26 
# of library plasmids containing an insert 24 
# of different library plasmids grouped according to insert size and further restriction analysis 6 
#r of yeast colonies that re-grew on SC-T-L-H 3AT and showed 
P-galactosidase activity after 3 
retransformation of the library plasmid into yeast 
TABLE 6.1 
The details of the yeast - two hybrid screen are summarized here. 
Clone 9- hVps42 
Va" 
SC- Trp/-Leu SC- Trp/-Leu/-His 
Clone 11 - 
Unknown 
Clone 22 - Ash2 
-ve control 
.4 +ve control (L63RhoA/ CNK) 
P-galactosidase 
assay 
FIGURE 6.5 
Three potential PTEN interactors identified in the yeast-two hybrid screen. (a) Y 190 
pYTH9:: PTENACATAPDZBM strain transformed with library plasmids #9, #11, #22 as well 
as empty pACTII as negative control, and Y190 pYTH9:: L63 RhoA and pACTII:: CNKI as 
positive control were streaked out on SC-T-L, SC-T-L-H 3AT, and SC-T-L Xgal plates. 
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6.3.2.2 PTEN interactors found in the yeast-two hybrid screen 
Sequencing of the DNA inserts of these three library plasmids and Blast analysis of 
the sequences, revealed three different genes encoding for three potential PTEN protein 
interactors: the vesicular protein hVps4, a novel zinc finger containing protein of 
unknown function and the transcription factor ash2. Figure 6.6 shows the predicted 
domain structure of these proteins and the PTEN-interacting region that was pulled out 
from the yeast-two hybrid screen for each of these proteins is indicated with a line. 
hVps4l 
Y2H - interacting 
681 -779 region 
Z -finger domain protein inc 
Y21-1 - interacting 
183-498 region 
s Ash2 
Y2H - interacting 
1 -500 region 
FIGURE 6.6 
Domain structure of the proteins identified by yeast-two hybrid as PTEN interactors. 
Sequence alignments indicate that PTEN interacts with the RING domain of hVps4l, the C- 
terminus of the zinc-finger domain protein and the N-terminus of Ash2- The domain 
structures have been obtained forrn the SMART (Simple Modular Architectural Tool) 
website (Schultz et al., 1998). 
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Sequence alignments of the regions pulled out in the screen with the full-length 
proteins indicate that PTEN most probably interacts with the RING finger domain of 
hVPS41 and the N-terminal of Ash2, which excludes the SPRY domain. In the case of the 
zinc-finger domain protein, PTEN seems to interact with the C-terminal half of the 
protein that includes 7 zinc-finger domains. The interaction of PTEN with these proteins 
is currently being confirmed biochemically and their contribution to PTEN function is 
being investigated. 
6.4 Discussion 
PTEN has previously been shown to be a negative regulator of cell spreading and 
several of its domains, including the phosphatase domain, the C2 domain as well as the 
PDZ binding motif are important for this function. Work in this chapter revealed that a C- 
terminal fragment of PTEN can induce spreading of U87 glioma cells and MDA-MB435 
breast cancer cells and change their morphology from an elongated spindle shape to a 
more flat spread phenotype. To identify potential PTEN binding partners that could 
explain some of the mechanisms of PTEN-induced spreading, as well as PTEN's role in 
cell migration, a yeast-two hybrid screen was performed and three potential novel PTEN 
interacting proteins were identified. 
6.4.1 PTEN and cell spreading 
It has been well established now that PTEN is a negative regulator of cell spreading. 
However the mechanisms involved are still far from being defined. Several studies have 
suggested that the phosphatase activity of PTEN is required for the inhibition of cell 
spreading, but there is still some controversy over whether this involves the protein or the 
lipid phosphatase activity (Gu et al., 1998; Leslie et al., 2001). Work by Leslie et al., has 
shown that the PDZ binding motif of PTEN is required for efficient inhibition of cell 
spreading and PDGF-induced membrane ruffling by PTEN (Leslie et al., 2000). 
The molecules that have so far been proposed to function downstream of PTEN- 
dependent inhibition of cell spreading include the integrin-regulated proteins FAK and 
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Shc. PTEN has been shown to inactivate these proteins by directly binding to them and 
dephosphorylating phospho-Tyr residues (Gu et al., 1998; Tamura et al., 1998). 
Dephosphorylation of Shc by PTEN prevents the recruitment of the adaptor protein Grb2 
and this inhibits subsequent activation of the MAPK pathway. The inhibition of MAPK 
activation by PTEN, however, can also be attributed to downregulation of PI(3,4,5)P3 
levels and the subsequent inhibition of Gabl recruitment to the plasma membrane 
(Rodrigues et al., 2000). Furthermore, the ability of PTEN to dephosphorylate FAK 
appears to be cell-type specific. Studies by Sun et al., have shown that there is no 
difference in the phosphorylation levels of FAK in PTEN4- compared to PTEN+" ES 
cells, and we have not been able to detect any difference in the levels of phosphorylated 
FAK between U373 cells and astrocytes ((Sun et al., 1999) and data not shown). In any 
case, more work is needed in order to delineate the mechanisms of the regulation of cell 
spreading by PTEN. 
Work in this chapter, suggests a novel mechanism by which PTEN can induce cell 
spreading, and this requires the C-terminus, but not the catalytic domain. Introduction of 
a C-terminal fragment of PTEN into U87 or MDA-MB435 cells induced a shape change 
in these cells form an elongated -spindle-like morphology to a more flat and spread 
phenotype. The tail region of PTEN, containing the various phospho-serine and threonine 
residues, was required for this process to occur, while the PDZ binding motif was 
dispensable. How the C-terminal domain of PTEN induces cell spreading and whether 
this is dependent on Shc or FAK remains to be seen. 
In order to explain why data in this chapter implicates PTEN in the induction -rather 
than the inhibition- of cell spreading seen by previous studies, a model is proposed where 
PTEN can act in one of two ways depending on the stimulus (Figure 6.7). In the first 
pathway, a stimulus activates the catalytic activity of PTEN to deplete the pool of 
PI(3,4,5)P3 in the cell and thus downregulate PKB and/or dephosphorylate FAK/Shc and 
thus inhibit cell spreading. In the second pathway, a stimulus leads to the recruitment of a 
protein that probably either relieves an auto-inhibition or stabilises the C-terminus of 
PTEN in an active conformation. The active C-terminus induces cell spreading, probably 
through the recruitment of another protein. 
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FIG( RE 6.7 
Model of PTEN function on cell spreading. Pathway 1, PTEN inhibits cell spreading. 
Pathway 2, PTEN induces cell spreading. See discussion for details. 
6.4.2 Novel, potential binding partners of PTEN 
To further elucidate the mechanism by which PTEN controls spreading and migration, 
a yeast-two hybrid screen was performed and three potential binding partners of the 
PTEN C-ten-ninus were isolated. None of these proteins have been implicated in cell 
spreading or migration as yet, and their role in PTEN function remains to be determined. 
Ash2 is a transcription factor encoded by the absent, small, or homeotic disc 2 (ash2) 
gene, and was identified as being a positive regulator of homeotic genes in Drosophila 
(Adamson and Shearn, 1996). It belongs to the trithothorax group of regulatory genes and 
has been implicated in playing a role early in development in the patterning of the various 
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discs in the fruit-fly, including the imaginal disc. The Ash2 gene is highly conserved 
among species, including yeast (Setl), C elegans and mouse (Ikegawa et al., 1999). The 
yeast orthologue Setl has been shown to play a role in chromatin remodeling by 
modulating histone methylation (Roguev et al., 2003; Roguev et al., 2001). Two splice 
variants of Ash2 have been identified in humans (ASH21, I and ASH2L2), which are 60% 
homologous to the Drosophila gene and implicated in hematopoiesis (Wang et al., 200 1). 
Recent studies have shown that human Ash2 belongs to a steady-state complex 
(ASCOM), which includes the retinoblastoma-binding protein RBQ-3, alpha/beta- 
tubulins and ASC-2, a recently isolated transcriptional coactivator molecule (Goo et al., 
2003). While it is not obvious how a nuclear protein might play a role in cell spreading or 
migration, it is worthwhile to note that PTEN has also been found to exist in the nucleus 
and to specifically activate transcription of p53 (Freeman et al., 2003). Moreover, it has 
been implicated in the up-regulation of cyclin-dependent Idnase inhibitors possibly 
through the Forkhead family of transcription factors, and thus regulate GI arrest (Bruni et 
al., 2000; Cheney et al., 1998; Li et al., 1998). While Ash2 binding to PTEN might not 
regulate cell spreading and migration, it could be important in mediating these nuclear 
functions of PTEN through the specific switching off or on of genes required for cell 
growth or cell cycle arrest and prove to be an important interactor. 
Another PTEN-binding protein, identified in this study, could also be contributing to 
PTEN's role in the nucleus, possibly through the regulation of gene transcription. This 
protein is a novel protein of unknown function that contains multiple zinc-finger domains 
(also present in Ash2), which have been shown to be nucleic acid binding proteins (see 
Figure 6.6). A zinc finger domain is a 25-30 amino acid self-folding domain, which 
contains two conserved cysteine and two conserved histidine residues and one atom of 
Zn. These domains have been shown to bind to both RNA and DNA. A Blast search of 
the amino acid sequence of this protein revealed high homology to the zinc-finger domain 
transcription factor Egr-l. Egr-1 belongs to the family of early growth response genes and 
is upregulated in response to mitogens in various cell types, including glioma cells (Al- 
Sarraj and Thiel, 2002). A direct role for Egr-I regulation of proliferation of primary 
astrocytes has also been proposed and recently it has been shown to directly activate 
expression of PTEN (Virolle et al., 2001). Therefore, FITEN could be acting through zinc- 
finger domain transcription factors in order to regulate cell growth and proliferation. 
The third protein identified by the yeast two-hybrid screen in this study, was the 
human orthologue of the yeast protein Vps4l (vacuolar protein sorting mutant 4 1). Vps4l 
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has been shown to be required in vacuolar assembly in yeast and in the protein sorting of 
vesicles budding from the Golgi (Cowles et al., 1997; Nakamura et al., 1997). 
Subsequently, it was shown to play a role in the formation AP-3 transport vesicles by 
binding to AP-3 through its N-terminus and driving homo-oligomerization through its C- 
tenninal clathrin heavy-chain repeat (CHCR) domain and to facilitate lysosomal vesicle 
docking and fusion (Darsow et al., 2001; Rehling et al., 1999; Stepp et al., 1997). The 
human orthologue of Vps41 contains a RING-142 motif at its C-terminus, which is absent 
in yeast and is responsible for membrane tethering of the protein (McVey Ward et al., 
2001). RING - finger domains, however, have also been shown to be involved in protein- 
protein interactions and this could be the domain interacting with PTEN, as it was 
belonged to the region that was pulled out in the yeast-two hybrid screen. Furthermore, 
various RING domains have been shown to bind to E2-ubiquitin conjugating enzymes 
and the RING domain of c-CbI has intrinsic E3 ubiquitin-ligase activity. Previous studies 
have demonstrated the existence of two PEST sequences on the PTEN tail, which 
modulate protein stability most probably by targeting PTEN to a proteosome-dependent 
degradation pathway (Georgescu et al., 2000; Torres et al., 2003). hVPS41 could 
therefore potentially play a role in the sorting of PTEN to lysosomes and its subsequent 
degradation in the proteosome. 
In summary, while it is not clear if and how these novel PTEN binding partners might 
be involved in the regulation of cell spreading and migration, their interaction with PTEN 
might still play an important contribution to the regulation of other PTEN functions. 
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Discussion 
7.1 Rho GTPases 
Tumour cell migration and invasion are key features of tumour malignancy. The 
mechanisms that drive tumour cell migration, are believed to share similarities with early 
cell migration during development, but are still poorly understood. This thesis examined 
the role of the Rho family of GTPases, which are key regulators of most processes 
involved in cell migration, and explored the role of an important tumour suppressor, 
PTEN, in the control of the aberrant migration of brain tumours; (gliomas). 
Results presented in Chapter 3 demonstrated that both Rac and Cdc42 play an 
essential role in regulating the migration of three gliorna cell lines (U373, U138 and U87) 
and of primary astrocytes. Interestingly, both dominant negative and constitutively active 
forms of Rac and Cdc42 inhibited the migration of U373 cells, suggesting that the precise 
activation in both space and time of these GTPases is crucial for their function. This is 
further supported by pull-down studies that showed that the higher migration rates of the 
gliomas did not correlate with the levels of active Rac or Cdc42 observed. A plausible 
explanation is that Rac and Cdc42 are more efficiently activated precisely at the front of 
the faster migrating U138 and U87 cells compared to U373 cells or astrocytes, something 
which cannot be measured by using pull-down assays. Further investigation into the 
activation levels of the kinases p65PAK and PKC4, downstream effectors'of Rac and 
Cdc42 respectively, revealed that p65PAK was more active in the highly malignant U138 
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and U87 cells, compared to the less aggressive U373 cells. The levels of active PKCý, 
however, remained unchanged. 
In addition to cell migration, the temporal and spatial activation of Rho GTPases is 
essential for the regulation of many other cellular processes, including morphogenesis 
(Etienne-Manneville and Hall, 2002). During S. cerevisiae and C elegans 
morphogenesis, the activation of Cdc42 in the right place is crucial for the establishment 
of the bud site and cellular asymmetry respectively (Gotta et al., 2001; Gotta and 
Ahringer, 200 1; Kay and Hunter, 200 1; Pruyne and Bretscher, 2000). Thus, the aberrant 
glioma migration observed in chapter 3 could be accounted for, in part, by deregulation of 
the spatial and temporal activation of Rac and Cdc42, through, for example the 
upregulation of GEF activity (an effect observed in U87 cells for Rac). 
7.2 PTEN 
Chapters 4 and 5 focused on the controversial role of the lipid and protein phosphatase 
PTEN in the regulation of cell migration. Work in these chapters showed that PTEN 
inhibits cell migration of gliomas through a previously unrecognized activity of its C2 
domain. This effect is dependent on PTEN's protein phosphatase activity and on the 
dephosphorylation specifically at residue Thr383 (Figure 5.12). It is likely that PTEN acts 
autocatalytically to dephosphorylate Thr383, although a more indirect pathway has not 
been formally ruled out. Chapter 6 explored the role of PTEN in cell spreading and 
revealed that, in addition to a previously reported inhibitory role for PTEN of cell 
migration, PTEN can also have a positive effect by inducing cells to spread, a process that 
depends on its C-terminus. Finally, a yeast-two hybrid screen identified three novel 
binding partners for the C-terminus of PTEN and suggested a role for PTEN in the 
nucleus (Figure 7.1). 
The mechanisms that regulate PTEN activation remain unclear, as most studies have 
focused on what inactivates PTEN. It was recently demonstrated that PTEN becomes 
inactivated directly in response to oxidative stress and that this is concomitant with an 
increase of phospho-Akt: levels in the cell (Leslie et al., 2003). The precise mechanism of 
inactivation, however, is unknown. It was shown by several groups that PTEN becomes 
phosphorylated on several serine and threonine residues at its C-terminus and that this 
reduces its lipid phosphatase activity as measured by examining several downstream 
signaling pathways (Birle et al., 2002; Georgescu et al., 1999; Torres and Pulido, 2001). 
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Furthermore it was recently demonstrated that phosphorylation at residues S380 and S385 
protects proteolytic cleavage of PTEN by caspase-3 (Torres et al., 2003). The last 50 
amino acids (tail) of PTEN seem to play a critical role in regulating protein stability. 
Deletion of the PTEN tail or mutation of residues S380, T382 and T383 found in that 
region to alanine, has been reported to reduce the protein half-life and cellular levels of 
PTEN (Vazquez et al., 2000). Dephosphorylated PTEN is degraded at a faster rate in 
what has been proposed to be a proteasome-dependent mechanism (Torres and Pulido, 
2001; Torres et al., 2003). It was also shown that phosphorylation of PTEN at residues 
S380, T382 and T383 reduces its binding affinity to PDZ-domain containing proteins, 
probably through a conformational change that masks the PDZ binding motif 
(Tolkacheva et al., 2001; Vazquez et al., 2001; Vazquez et al., 2000). The binding of 
PDZ-domain proteins to the tail of PTEN might stabilize and protect it from degradation 
(Torres et al., 2003). 
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PTEN regulates a variety of cellular processes. Schematic representation of the PTEN 
functions investigated in this thesis. PTEN regulates spreading, migration, vesicle transport 
and transcription. The isolated Zn-finger protein of unknown function is depicted as Zn-X. 
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The only kinase identified so far as being able to phosphorylate PTEN is CK2. 
Several groups have now shown that both endogenous and exogenous CK2 
phosphorylates PTEN on several residues at its C-terminus, thus enhancing its stability 
and acting as a negative regulator of PTEN activity (Birle et al., 2002; Georgescu et al., 
2000; Torres and Pulido, 2001; Torres et al., 2003). Most intriguing, however, is what 
regulates PTEN activation. Campbell et al. recently demonstrated that PI(4,5)P, 
allosterically activates PTEN. A likely mechanism is that PTEN recruitment to the plasma 
membrane promotes the binding of PTEN's PI(4,5)P, binding motif to PI(4,5)P2 present 
on the membrane, which induces a conformational change and activates the protein 
(Campbell et al., 2003). Data in chapter 4 provide evidence for an intramolecular 
interaction of the N- and C-termini of PTEN. PI(4,5)P, binding could thus out-compete 
the interaction of the C-terminus to the N-terminus and 'open up' the protein to interact 
with its substrate. This 'opening up' and activation of PTEN could be stabilised further 
through the binding of PDZ-domain proteins to the C-terminus of PTEN. No phosphatase 
has been identified so far that can antagonize the action of CK2. Results presented in 
chapter 5, however, suggest a mechanism whereby dephosphorylation specifically at 
Thr383 is directly dependent on the protein phosphatase activity of PTEN. A model for 
PTEN regulation is thus presented in Figure 7.2. 
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Model for the regulation of PTEN. PTEN is constitutively phosphorylated and inactive in the 
cell cytosol. Following stimulation, PTEN gets recruited to the plasma membrane where it 
binds PI(4,5)P2 on its N-terminus. This activates PTEN to mediate dephosphorylation of 
residues on its C-terminus and promotes the binding of PDZ-dornain proteins, which stabilise 
PTEN in an 'open' and active conformation. The C2 domain is then free to interact with 
cellular targets and mediate its role, for example, on cell migration (chapter 4). 
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7.3 Regulation of cell migration 
Results presented in this thesis demonstrate a role for both the Rho GTPases and 
PTEN in the regulation of glioma cell migration. It has been reported that PTEY'* 
fibroblasts have a higher migration rate compared to parental cells and exhibit an increase 
in the activation levels of Rac and Cdc42 (Liliental et al., 2000). The motility and 
activation levels of Rac and Cdc42 were reduced upon re-introduction of a lipid- 
phosphatase active form of PTEN. Even though the same increase in GTP-loading on Rac 
and Cdc42 was not observed in the gliomas (chapter 3) PTEN could still be playing a role 
in their regulation by decreasing the pool of cellular PI(3,4,5)P3. PI 3-kinase and 
PI(3,4,5)P3 have been shown to activate Rac and Cdc42 and this is believed to be 
mediated through the activation of Rho GTPase upstream regulators, namely GEFs 
(Schmidt and Hall, 2002). In chapter 3, an increase in total GEF activity against Rac (and 
CdC42, data not shown) was observed for the highly motile U87 cells, suggesting a 
correlation between the lack of PTEN expression and the activation of these GTPases. 
Furthermore, the absence of PTEN expression and the upregulation of active Rac and 
Cdc42 lead to an increase in the activation of Akt, a known regulator of cell motility 
(Higuchi et al., 2001). 
In summary, PTEN seems to be regulating cell motility through at least two different 
mechanisms. One which is dependent on its lipid phosphatase activity and leads to the 
downregulation of active Akt, Rac and Cdc42 through the reduction of PI(3,4,5)P3, and 
another which is mediated through the C2 domain and is dependent on the protein 
phosphatase activity. The protein phosphatase activity may also affect cell migration 
through inactivation of FAK and Shc, although this is less clear (Figure 7.1). 
In conclusion, it has now been well established that PTEN is a key tumour suppressor, 
found at the center of most major cellular processes. Even though there have been 
significant advances in understanding PTEN function, the mechanisms that precisely 
regulate PTEN activity both spatially and temporally are still poorly understood. The 
challenge for the future will be to answer questions such as, under which circumstances 
does PTEN act as a lipid or as a protein phosphatase and how does a cell control the 
various PTEN functions? PTEN has proven to be an intriguing molecule and future 
research will no doubt add to its complexity before it clarifies it. 
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